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Abstract 
Cell surface display allows peptides or proteins to be expressed on the cell exterior as 
fusions to natural host anchoring motifs. It is a powerful technique with a myriad of applications 
in protein engineering, environmental bioremediation, biocatalysis, as well as vaccine and 
therapeutics development. Compared to intracellular expression, the main advantages of this 
technology include direct access to large target molecules that cannot diffuse into the cell, 
stabilization of enzymes or proteins by attaching them to the cell surface, and elimination of 
time-consuming protein purification steps. This thesis describes our efforts of applying the cell 
surface display technology to address some of the challenges in biomedical research and biofuels 
production. 
Identification of T cell epitopes is a critical, but often difficult step in developing peptide-
based vaccines and T cell immunotherapies. Unlike antibody that recognizes free soluble 
antigens, T cell receptor (TCR) recognizes its epitope bound to major histocompatibility 
complex (MHC) expressed on antigen presenting cells (APCs). In addition, the examination of T 
cell epitope activity requires the use of professional APCs, which are difficult to isolate, expand, 
and maintain. To address these issues, we have developed a facile, accurate, and high-throughput 
method for T cell epitope mapping by displaying pathogen-derived peptide libraries in complex 
with MHC on yeast cell surface. Using human MHC class II protein DR1 and influenza A virus 
as a model system, this method was successfully used to pinpoint a 17-amino-acid-long T cell 
epitope from the entire influenza A virus genome.  
The production of peptide-MHC (pMHC) tetramer, especially class II pMHC tetramer, is 
very time-consuming and labor-intensive and often show low avidity, thus represents another 
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challenge in the biomedical research area. To address these limitations, we sought to engineer 
MHC monomers with high TCR-binding affinity. The wild-type DR2-MBP85-99 complex, which 
is associated with multiple sclerosis, was successfully displayed on insect cell surface and bound 
specific TCR tetramers in an epitope-dependent manner, providing the basis of a high throughput 
screening method to identify DR2 variants with improved affinity by directed evolution. A 
library of DR2 variants in complex with MBP was created and screened using specific TCR 
tetramers. After one round of cell sorting, potential variants with improved TCR-binding affinity 
have been enriched. Further rounds of enrichment are in process. 
Lignocellulosic biofuels represent a sustainable, renewable, and the only foreseeable 
alternative energy source to transportation fossil fuels. The central technological impediment to a 
more widespread utilization of lignocellulose is the absence of low-cost technology to break 
down its major component – cellulose. Consolidated bioprocessing (CBP), which combines 
enzyme production, cellulose hydrolysis, and fermentation in a single step, has been proposed to 
significantly lower the cellulosic ethanol production cost. However, the great potential of CBP 
cannot be realized using microorganisms available today. In an effort to develop a CBP-enabling 
microorganism, we developed an engineering strategy to enable yeast cells to hydrolyze and 
ferment cellulose simultaneously by displaying trifunctional minicellulosomes on the surface. 
The system developed here solved the technical difficulties of displaying multiple proteins and 
represents a useful platform for elucidating principles of cellulosome construction and mode of 
action. Continuing efforts are being directed to improving the hydrolytic efficiency of the surface 
engineered yeast with a focus of increasing the enzyme display levels. 
 iv 
Acknowledgements 
First of all, I would like to thank my advisor, Professor Huimin Zhao. Without his 
guidance and support, this work certainly would not have been possible. His advice has 
contributed greatly to my work as a graduate student and will continuously have a positive 
influence on my academic career in the future. I would also like to thank Professor Richard 
Masel for guiding me through NSF proposal writing and submission process, which has really 
been a valuable experience for me. His insightful suggestions and criticism during numerous 
meetings have greatly helped me to develop as a scientist. I would also like to thank my 
committee members, Professor Paul Kenis and Professor Christopher Rao for their insightful 
input, constructive suggestions, and generous help in preparing me for my future academic career, 
and Professor David Kranz for introducing the insect cell expression system, which later inspired 
my insect cell surface display work. I would also like to thank Professor Jonathan Higdon, 
Professor Mary Kraft, Professor Edmund Seebauer, and Professor Charles Schroeder for their 
helpful discussions and suggestions in pursuing a successful academic career. 
I am also very indebted to every former and current group members of Zhao laboratory 
for their helpful discussions. I am particularly grateful to Dr. Olga Esteban for being a great 
mentor, Jie Sun, Jing Liang, and Tong Si for their assistance with the minicellulosome work, and 
Dr. Zengyi Shao, Dr. Tyler Johannes, Dr. Sheryl Rubin-Pitel, Dr. Ryan P. Sullivan, Dr. Zhilei 
Chen, Jing Du, and Michael Mclachlan for their friendship and assistance. I would also like to 
thank Dr. Ben Montez, Dr. Barbara Pilas, and Dr. Alexander Ulanov for their assistance with cell 
sorting at the Keck Biotechnology Institute and GC-MS analysis at the Carver Metabolomics 
Center, respectively. 
 v 
Last but not least, I would like to thank my family for their continuous support and 
encouragement. My boyfriend Nikhil Nair has my deepest gratitude for also being a friend and a 
colleague. We have been through numerous ups and downs in life and research; his passion, 
humor, and above all, generosity have been, and will always be, the solid and fertile ground for 
our relationship to grow stronger. My parents also deserve special honors for providing 
tremendous educational opportunities that laid solid foundation for me to pursue an academic 
career.  
 
 vi 
Table of Contents 
Chapter 1. Introduction...............................................................................................................1 
1.1. Overview of Cell Surface Display Systems............................................................................1 
1.2. Cell Surface Display and Cellular Immunity Modulation......................................................4 
1.2.1. Major Histocompatibility Complex ...............................................................................5 
1.2.2. T Cell Receptor ..............................................................................................................8 
1.2.3. T Cell Epitope ..............................................................................................................10 
1.2.4. Antigen Presenting Cell ...............................................................................................13 
1.3. Cell Surface Display and Biofuels Production .....................................................................14 
1.3.1. Consolidated Bioprocessing for Cellulosic Biofuels Production.................................16 
1.3.2. Surface Engineered Yeast for Consolidated Bioprocessing ........................................18 
1.4. Project Overview ..................................................................................................................20 
1.5. References.............................................................................................................................22 
Chapter 2. Rapid T Cell Epitope Identification Using Yeast Displaying Single-chain 
Peptide-MHC Complexes as Artificial APCs .......................................................35 
2.1. Introduction...........................................................................................................................35 
2.2. Results and Discussion .........................................................................................................38 
2.2.1. Functional Expression of Single-chain DR1-HA306-318 Complexes on Yeast Cell 
Surface .........................................................................................................................38 
2.2.2. A Positive Correlation between Yeast Surface Expression Level and Peptide-
binding Affinity ...........................................................................................................41 
2.2.3. Functional Analysis of the DR1-HA306-318 Complex Displayed on Yeast Cell 
Surface .........................................................................................................................44 
2.2.4. Use of Yeast Cells Displaying Single-chain Peptide-MHC Complexes as AAPCs....47 
2.2.5. Design of a T Cell Epitope Identification Method.......................................................48 
2.2.6. Epitope Identification from a Single Antigenic Protein - Haemagglutinin .................50 
2.2.7. Epitope Identification from a Pathogenic Organism - Influenza A Virus ...................53 
2.3. Conclusions and Outlook......................................................................................................58 
2.4. Materials and Methods..........................................................................................................61 
2.4.1. Vector Construction .....................................................................................................63 
2.4.2. Yeast Transformation...................................................................................................64 
2.4.3. DNA Sequencing .........................................................................................................64 
2.4.4. Yeast Surface Display..................................................................................................65 
2.4.5. Flow Cytometry Analysis ............................................................................................65 
2.4.6. Extraction of Aga2-DR1-peptide Complexes from Yeast Cell Surface ......................66 
2.4.7. Thermostability Assay .................................................................................................66 
2.4.8. Western Blot ................................................................................................................66 
2.4.9. Library Construction....................................................................................................67 
2.4.10. FACS Analysis of Yeast Library .................................................................................69 
2.4.11. Stimulation of HA1.7 T cell Hybridomas and IL-2 Detection ....................................70 
2.5. References.............................................................................................................................71 
Chapter 3. In vitro Evolution of pMHC Complexes with High Affinity toward TCRs 
Using Cell Surface Display.....................................................................................76 
3.1. Introduction...........................................................................................................................76 
 vii 
3.2. Results and Discussion .........................................................................................................78 
3.2.1. Cloning, Expression, and Purification of DR1-HA-specific TCR...............................78 
3.2.2. Engineering of Folded DR2 Using Yeast Surface Display..........................................81 
3.2.3. Affinity Engineering of DR2-MBP85-99 Complexes Using Yeast Surface Display .....82 
3.2.4. Insect Cell Surface Display of Wild-type DR2-MBP85-99  Complexes ........................83 
3.2.5. Functional Analysis of the DR2-MBP85-99 Complexes Displayed on Insect Cell 
Surface .........................................................................................................................84 
3.2.6. Detection of Insect Cell Surface Displayed DR2-MBP85-99 Complexes with 
Specific TCR Tetramers ..............................................................................................85 
3.2.7. Affinity Engineering of DR2-MBP85-99  Complexes Using Insect Cell Surface 
Display .........................................................................................................................87 
3.3. Conclusions and Outlook......................................................................................................88 
3.4. Materials and Methods..........................................................................................................90 
3.4.1. Cloning and Expression of Single-chain HA1.7 TCR in E. coli .................................92 
3.4.2. Generation of Recombinant Bacmid DNA..................................................................93 
3.4.3. Insect Cell Culture and Protein Expression .................................................................94 
3.4.4. Protein Analyses ..........................................................................................................96 
3.4.5. Yeast Display Library Construction and Screening.....................................................97 
3.4.6. TCR Tetramer Preparation and Staining......................................................................99 
3.4.7. Insect Cell Surface Display Library Creation and Screening ......................................99 
3.4.8. Other Assays ..............................................................................................................100 
3.5. References...........................................................................................................................100 
Chapter 4. Yeast Surface Display of Functional Minicellulosomes for Synergistic 
Hydrolysis of Cellulose .....................................................................................................104 
4.1. Introduction.........................................................................................................................104 
4.2. Results and Discussion .......................................................................................................107 
4.2.1. Design and Construction of Minicellulosomal Components for Yeast Surface 
Display .......................................................................................................................107 
4.2.2. Yeast Surface Assembly of Unifunctional Minicellulosomes ...................................110 
4.2.3. Yeast Surface Assembly of Bifunctional and Trifunctional Minicellulosomes ........113 
4.2.4. Functional Analysis of the Enzyme Components in the Surface Displayed 
Minicellulosomes.......................................................................................................116 
4.2.5. Enhanced Synergy of Bifunctional and Trifunctional Minicellulosomes..................118 
4.2.6. Direct Conversion of Cellulose to Ethanol by Resting Yeast Cells Displaying 
Trifunctional Minicellulosomes.................................................................................122 
4.3. Conclusions and Outlook....................................................................................................123 
4.4. Materials and Methods........................................................................................................126 
4.4.1. Strains, Media, and Reagents.....................................................................................126 
4.4.2. Plasmid Construction.................................................................................................127 
4.4.3. Yeast Surface Display and Flow Cytometry Analysis...............................................131 
4.4.4. Substrate Preparation and Carbohydrate Assays .......................................................132 
4.4.5. Enzyme Activity Assays ............................................................................................134 
4.4.6. Ethanol Production from PASC Using Resting Cells................................................135 
4.5. References...........................................................................................................................136 
 viii 
Chapter 5. Simultaneous Hydrolysis and Fermentation of Cellulose to Ethanol by 
Recombinant Saccharomyces cerevisiae ..............................................................141 
5.1. Introduction.........................................................................................................................141 
5.2. Results and Discussion .......................................................................................................142 
5.2.1. Optimizing the Protein Induction Conditions ............................................................142 
5.2.2. Reducing the Metabolic Burden ................................................................................144 
5.2.3. Alternative Endoglucanases and Exoglucanases .......................................................147 
5.2.4. In vitro Enzyme Loading onto the Yeast Surface Displayed Miniscaffoldin............148 
5.2.5. Development of a Constitutive Yeast Surface Display System.................................151 
5.3. Conclusions and Outlook....................................................................................................154 
5.4. Materials and Methods........................................................................................................156 
5.4.1. Strains, Media, and Reagents.....................................................................................156 
5.4.2. Plasmid Construction.................................................................................................157 
5.4.3. In vitro Loading of Cellulases....................................................................................161 
5.4.4. Cell Growth Analysis on PASC.................................................................................161 
5.4.5. Other Assays ..............................................................................................................162 
5.5. References...........................................................................................................................162 
 
 1 
Chapter 1. Introduction 
1.1. Overview of Cell Surface Display Systems  
Cell surface display is a technique that allows the target protein to be expressed on the 
cell exterior by fusing it to a carrier protein, which is typically a cell membrane-associated 
protein or its subunit [1]. There are several inherent features of the surface display technology 
that make it an effective library screening tool for protein engineering, directed evolution, and 
drug discovery. First of all, the display of a combinatorial protein library on the cell surface 
establishes a physical linkage between the DNA and the protein, allowing fast enrichment of rare 
events using high throughput methods such as fluorescence-activated cell sorting (FACS) in a 
quantitative manner [2]. Second, the target substrates or ligands/receptors are directly accessible 
to proteins displayed on the surface without the need of crossing the cell membrane barrier, thus 
no labor-intensive protein purification steps are required. Third, the cell attachment stabilizes the 
proteins displayed on the surface. Finally, the library screening conditions could be well 
controlled, such as pH, ionic strength, reduction potential, and oxygen content. 
Since its development in the mid-1980s, cell surface display has proved to be a powerful 
tool for basic and applied biomedical, industrial, and environmental research [3-5]. Using this 
technology, a wide range of proteins with improved and/or novel function have been created, 
including peptides, antibodies, cytokines, receptors, and enzymes [6-12]. In the past few decades, 
numerous cell surface display systems have been developed using phage (although phage is not 
considered a living cell, it’s included in this chapter since phage display was developed the 
earliest and has been most often utilized), bacteria, yeast, insect cells, and mammalian cells. 
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Different platforms have advantages and disadvantages that make them more conducive to 
certain protein engineering applications. 
As the first surface display system developed, phage display has been the most 
commonly used technique for combinatorial library screening [13]. In a phage display library, 
the protein variants are expressed on the surface of phage particles as fusions to the phage coat 
protein, such as pIII for low copy display and pVIII for high copy display, and are usually 
screened by panning on a matrix of purified and immobilized molecules, whereby binding 
phages are captured while non-binding phages are washed away [13]. Recent advances have 
enabled screening of phage display libraries in more complex biological systems, such as 
cultured cells and in vivo [14]. Although phage display has been successfully used for epitope 
mapping and engineering of peptides, antibodies, and enzymes [13-16], it is almost impossible to 
develop a generic phage display system for all applications. In addition, its bacterial host has 
limited ability in terms of protein folding and post-translational modifications, therefore the 
phage display has achieved very limited success with more complex mammalian proteins, such 
as major histocompatibility complex (MHC) and T cell receptor (TCR) (see Sections 1.2.1 and 
1.2.2 below).  
Bacterial surface display was developed one year after phage display and addressed some 
of the issues associated with the latter system [4, 5]. A bacterial surface display library is usually 
generated by transforming DNA variants into Escherichia coli cells, which are easier to cultivate, 
quantify, and work with than phage [17, 18]. Depending on the carrier protein used, the protein 
variants are displayed either on the bacterial outer membrane (e.g. Lpp-OmpA [19]) or periplasm 
(e.g. NlpA [20]), which are more suitable for displaying proteins with larger size than phage 
particles [21]. The resulting display library is then screened by FACS, which can analyze and 
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sort up to 100,000 cells per second but is not applicable for phage display due to the small size of 
phage particles [18, 22]. Compared to panning on a matrix, FACS enables fast enrichment of 
positive clones in a more quantitative manner. However, as with phage display, the biggest 
drawback of bacterial surface display is the lack of protein folding and post-translational 
modification machineries found in eukaryotes.  
Yeast surface display has attracted the most attention among all cell surface display 
systems since its development about a decade ago [2, 23]. To display a protein library on yeast 
cell surface, Saccharomyces cerevisiae and the cell-wall-anchored mating protein α/a-agglutinin 
are commonly used as the host and the carrier protein, respectively [24, 25]. As an eukaryotic 
host, yeast has the advantage of possessing post-translational processing pathways, which enable 
folding and glycosylation of complex proteins [2, 24]. Starting with the same library, yeast 
display was shown to sample the immune antibody repertoire considerably more fully than phage 
display, selecting twice as many novel antibodies as phage display [26]. Recent advances in 
glycoengineering have demonstrated the possibility of creating humanized yeast strains that are 
capable of producing proteins with native human glycosylation patterns [27]. In addition to being 
a useful library screening tool, the surface engineered yeast has a wide range of applications in 
vaccine and therapeutics development, environmental bioremediation, and biofuels and 
chemicals production for its generally-regarded-as-safe status and robustness in industrial 
processes ([28-30] and Chapter 2-5). Although yeast is capable of expressing a wider range of 
proteins compared to phage and bacteria, as the protein folds get more complex, it usually 
requires a more sophisticated design or protein engineering to enable a successful surface display 
of the target protein as illustrated by MHC and TCR in Sections 1.2.1 and 1.2.2 below. In such 
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cases, higher eukaryotic insect (see Chapter 3) and mammalian cells could be used as the 
expression hosts.   
While both insect and mammalian cell surface display are well established systems for 
biological and immunological studies [31-34], they have not been widely used for library 
screening probably due to some drawbacks such as high cell culture cost, slow growth rate, lack 
of well-established library creation and screening procedures, and requirement of higher 
experimental expertise compared to microbial systems. Nevertheless, a few recent studies have 
demonstrated the potential of these systems as useful library screening tools for drug discovery 
and protein engineering. By using the major baculovirus envelop protein gp64 or influenza 
haemagglutinin as the carrier protein, peptide libraries have been displayed on the insect cell 
surface for TCR [11] or antibody [35] epitope mapping and engineering, respectively. As proof 
of concept, several antibody libraries have also been displayed on the surface of mammalian 
cells as fusions to various cell membrane proteins [36-38]. Despite the limited examples of 
library screening using insect/mammalian cell surface display, these systems represent 
indispensable alternatives to the phage/microbial display for engineering human enzymes or 
proteins for therapeutic purposes ([39] and Chapter 3). 
1.2. Cell Surface Display and Cellular Immunity Modulation 
Cellular immunity is mediated by T cells, which respond to selected peptides (epitopes) 
in complex with MHC molecules expressed on antigen presentation cells (APCs) through their 
unique surface TCRs. The nature of the induced cellular immunity could be either destructive or 
protective, depending on the nature of this tri-molecular (TCR-peptide-MHC) interaction at the 
interface of T cells and APCs. As a result, all of the three interacting protein members as well as 
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the two immune cells are potential targets for immunotherapy. In the past few decades, various 
cell surface display systems have been applied to engineer the function of these proteins and 
cells with the aim of improving cellular immunity modulation. 
1.2.1. Major Histocompatibility Complex  
Malfunction of the MHC system, consisting of the class I (MHCI) and class II (MHCII) 
MHC proteins, has been implicated in many diseases, such as malaria, rheumatoid arthritis, type-
I diabetes, and graft rejection [40-44]. This has spurred great interests in developing MHC-based 
immunotherapeutics and immunodiagnostics methods. The development of pMHC tetramer, a 
multimeric form of pMHC complexes, has revolutionized the field of T cell research [45]. 
However, there are several limitations associated with the pMHC tetramer technology [46, 47], 
including (1) difficult MHC monomer production using recombinant techniques, (2) time-
consuming and labor-intensive pMHC tetramer preparation that requires enzymatic biotinylation 
and protein purification steps, and (3) low detection sensitivity, especially for CD4+ T cells. 
Therefore, it is highly desirable to engineer MHC molecules with improved solubility or higher 
TCR-binding affinity.  
MHC engineering by phage display is challenging, because MHC molecules are large 
heterodimeric membrane proteins that are highly glycosylated and there are multiple disulfide 
bonds present in the protein. In addition, in the absence of their transmembrane domains, the two 
polypeptide chains are unable to assemble properly and/or tend to aggregate [48]. To date, there 
are only three successful examples of phage display of MHC proteins, with the first one reported 
in 2000 [49]. In this study, a single-chain construct of a murine MHCI protein was displayed on 
the surface of filamentous phage as a fusion with its pIII protein. The displayed complex was 
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functional as judged by binding of conformation-sensitive monoclonal antibodies (mAbs). And a 
small fraction of the phage particles (<0.01%) were bivalent and capable of binding immobilized 
specific TCRs. However, no significant interaction with relevant T cells was detected. Similar 
results were reported later for another murine MHCI and a human MHCI protein [50, 51]: 
although the pMHC complexes were correctly folded [50] and capable of binding specific 
antigenic peptide [51], no T cell interaction was observed [50]. Therefore, it is necessary to 
further optimize and/or develop novel design of the pMHC phage display system for efficient 
and stable T cell recognition. 
Compared to phage display, yeast is a more suitable host for the display of MHC proteins 
and has been used to express both MHCI [52, 53] and MHCII [54-56] proteins. A single-chain 
murine MHCI protein was expressed on yeast cell surface either with or without an N-terminal 
covalently linked peptide [52]. The functional display was evidenced not only by recognition of 
conformation-specific antibodies but also by direct binding of a specific TCR that has been 
engineered to have high affinity (see Section 1.2.2). More significantly, yeast cells displaying 
pMHC complexes upregulated the surface expression level of an early activation marker, CD69, 
on naïve T cells isolated from mice. Although the authors did not rule out the possibility of T cell 
autostimulation as the T cells used in the assay also expressed the same MHCI protein, this study 
clearly suggested that yeast display could be used for MHC engineering. Indeed, the same group 
later successfully isolated stabilized mutants of a murine MHCII protein, which is known to be 
unstable and difficult to work with, from a mutagenesis library displayed on yeast cell surface  
[55]. These mutants revealed the important roles of two residues of the β-chain in stabilizing the 
pMHC complex. In a similar study, mutants of a single-chain human MHCII (DR1) without 
covalently attached peptide were selected from a random mutagenesis library and stably 
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displayed on yeast cell surface [54]. They exhibited specific and fast peptide-binding kinetics, as 
well as high thermostability. By aligning the mutant sequences, three sites were identified to be 
critical for proper folding of DR1. Interestingly, although the single-chain gene construct did not 
include any peptide, the peptide-binding groove of the displayed DR1 mutants was not empty, 
but occupied presumably by yeast endogenous peptides, indicating the importance of binding 
peptides in stabilizing the DR1 display on yeast cell surface.  
Although yeast cell surface display coupled with directed evolution has been shown 
useful in studies of MHC structural stability and peptide-binding, mutations are usually 
introduced to stabilize the protein expression. These mutations, as well as the linkers in the 
single-chain constructs, might affect the conformation and/or peptide-binding kinetics of the 
mutant MHC proteins, and consequently alter their physiological property that is critical for 
pathogenesis studies and therapeutic applications. In an attempt to display non-covalent wild-
type MHC heterodimeric complex, peptide-DR4β-chain was expressed as a fusion to the Aga2p 
(a subunit of yeast a-agglutinin mating receptor), while DR4α-chain was expressed as a soluble 
protein from a separate cassette [56]. The heterodimer surface display was confirmed by mAbs 
that are specific to correctly assembled DR molecules, demonstrating that yeast display could be 
used to express non-covalent multimers. Unfortunately, this non-covalent peptide-DR4 complex 
displayed on yeast cell surface failed to activate T cells. 
Recently, insect cells have also been used for MHC display [11, 57, 58]. Being higher 
eukaryotic cells, insect cells have fewer problems with functional MHC expression. In a 
baculovirus display system, the α- and β-chains of a MHC protein are cloned separately in two 
expression cassettes with the binding peptide attached to the N-terminus of the β-chain, which is 
 8 
in turn fused to the transmembrane and cytosolic domain of gp64. The resulting non-covalent 
pMHC complexes displayed on the insect cell surface were capable of binding specific TCR 
tetramers and activating relevant T cells [57, 58]. To date, the insect cell surface display of MHC 
has only been used to identify T cell epitopes/mimotopes from peptide libraries. Nevertheless, 
the ability of the insect-cell-displayed pMHC complexes to bind specific TCR tetramers makes 
this system a promising platform for pMHC engineering. 
1.2.2. T Cell Receptor 
TCR is a pivotal element in almost every aspect of T lymphocytes, including their 
development, proliferation, differentiation, activity, and specificity. Therefore, researchers have 
been exploring their potential applications as immunotherapeutic or immunodiagnostic reagents 
to specifically target pMHC complexes [59], just as antibodies are used to neutralize or opsonize 
their antigens. However, there are several obstacles impeding therapeutic applications of TCRs. 
First, TCRs are naturally expressed as heterodimeric integral membrane proteins, thus having 
low solubility and tend to aggregate [60]. Second, soluble TCRs are not stable compared to 
antibodies [61]. Third, TCRs have low affinity towards the pMHC complexes, typically in the 
range of 1-100 µM [62]. Therefore, efforts have been devoted to engineering and design of 
soluble, stable and high-affinity TCRs. 
TCR engineering using phage display was not reported until 2005 mainly due to the lack 
of generally applicable method of producing soluble TCRs in bacteria [63]. Many of the initial 
strategies, such as removing exposed hydrophobic residues [60], fusing to antibody constant 
regions [64] or thioredoxin [65], and single-chain TCR constructs [61, 66, 67], worked for very 
limited number of TCRs. Later, the Jun/Fos leucine zipper domains were introduced as fusions 
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to the C-termini of the α/β TCR extracellular domains, respectively [68]. The incorporation of 
leucine zipper domains significantly stabilized the TCR, while maintaining its ligand specificity 
[69]; on the other hand, it raised the potential of immunogenicity. Another generally applicable 
method involves introducing a non-native interchain disulfide bond, predicted by molecular 
modeling based on the TCR crystal structure, into the TCR invariant region [70]. The resulting 
disulfide-stabilized TCR (dsTCR) was highly stable; and compared to the wild-type TCR, the 
sequence/structural change was minimal, reducing the possibility of being immunogenic. More 
importantly, it enabled the engineering of TCRs by phage display. Using the dsTCR format, ten 
different human class I- and class II-restricted TCRs were displayed on phage particles through 
the linkage between the TCR β-chain and the phage pIII coat protein [71]. 
TCRs with the highest affinity ever reported (with picomolar affinities for their specific 
pMHC ligand) were isolated from a phage display library [71]. By using random mutagenesis, 
human TCR mutants with affinities up to 26 pM were isolated, representing more than a million-
fold improvement over the wild-type TCR. And the half-life of binding was also improved by 
approximately 8000-fold to ~1000 minutes at 25 °C. More significantly, these high affinity 
TCRs showed high degree of antigen specificity and no cross-reactivity with endogenous pMHC 
complexes, and, for the first time, they enabled direct visualization of specific pMHC complexes 
on tumor cells [72]. However, when transfected into human T cells, the mutant TCR with highest 
affinity completely lost its antigen specificity, while those expressing TCRs with lower affinity 
(with KD values of 450 nM or 4 µM) responded in an antigen-specific manner [73]. These results 
indicated that genetically engineered T cells with midrange affinity receptors might be more 
effective in immunotherapeutics.  
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Yeast cell surface display has also been applied to engineer soluble TCRs. Using an E. 
coli mutator strain, a TCR library was created and mutants with increased thermal stability and 
secretion efficiency were isolated after FACS screening [61, 74]. Selected mutations were 
combined and resulted in a TCR mutant that was stable for >1 hour at 65 °C, had a solubility of 
>4 mg/mL, and had a shake-flask expression level of 7.5 mg/L [75]. More importantly, although 
mutations were introduced, the resulting TCRs retained their ligand-binding specificity, making 
yeast display an attractive platform for engineering high affinity TCRs [74, 75]. In fact, the first 
example of in vitro affinity engineering of TCR was reported in 2000 using yeast surface display 
[76]. A library of MHCI-restricted single-chain TCR was constructed by mutating the CDR3 
(complementarity-determining region three) of α-chain, and mutants with greater than 100-fold 
higher affinity were identified. Unlike the wild-type TCR, the soluble monomeric form of the 
high-affinity TCR was capable of directly detecting specific pMHC complexes on APCs. In vivo 
studies showed that mouse T cell hybridoma transfected with the high affinity TCR responded to 
a significantly lower concentration of antigenic peptide [77]. In several follow-up studies, it was 
shown that mutations in the CDR1 and CDR2 regions could also contribute to improving the 
affinity of TCRs [78, 79].  
1.2.3. T Cell Epitope 
Peptides recognized by T cells are termed T cell epitopes. The epitopes present in the 
thymus are very important in T cell development. In the thymus, T cells that recognize self-
peptides presented by MHC are eliminated from the immune system; the survived T cells that 
migrate into the peripheral lymph nodes do not undergo proliferation or differentiation, because 
all the pMHC complexes they sample in a healthy individual are self-products. Upon infection, 
protein components derived from the pathogens are processed into small peptides and then 
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loaded onto MHC molecules for surface presentation [80]. Some of these peptides are recognized 
by T cells and activate their effector/helper functions to kill the infected cells and clear the 
infection. Therefore, T cell epitopes in the peripheral serve as flags for T cell targeting. With 
their critical role in T cell development and activation, identification of T cell epitopes is very 
important in studying T cells lineages and phenotypes [81, 82], elucidating self-tolerance 
mechanisms [83], vaccine design and assessment [84, 85], tracking T cells in vivo [86], and etc. 
Great efforts have been devoted to identification of these T cell epitopes in the last two decades 
and some of the commonly used methods are summarized in Table 1.1.  
Table 1.1 Limitations of current T cell epitope identification methods. 
Current T-cell epitope 
identification methods Limitations 
Biochemistry (MS) Limited by the amounts of peptides sample available; labor-intensive and 
time-consuming. 
cDNA library Require the use of professional APCs that are always difficult and time-
consuming to isolate, expand and maintain or engineering of artificial 
APCs. 
Overlapping peptides Require the knowledge of antigenic protein sequence and the use of 
autologous APCs; reagent- and time-consuming. 
Synthetic peptide library Limited by library size; require the knowledge of MHC-binding motif and 
the use of professional APCs. 
Predictive algorithms Require the knowledge of both antigenic protein sequence and MHC-
binding motif, and the use of professional APCs.  
The most straightforward T cell epitope identification method is to use HPLC-MS to 
determine the sequence of the peptides extracted directly from the pMHC complexes on the 
surface of professional APCs [87]. However, this method has met limited success due to the 
limited amount of peptides and representation of antigenic peptides as nested sets with 
heterogeneous lengths. When the antigenic protein sequence is known, the most commonly used 
T cell epitope identification method is to synthesize overlapping peptides covering the entire 
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protein, which are then individually loaded onto the surface of professional APCs (usually 
irradiated PBMC) and tested for their ability of activating specific T cells. If the MHC-binding 
motif is also available, a computational method, TEPITOPE, could be used to predict the 
MHCII-restricted T cell epitopes systematically [88], but may overlook some potential epitope 
candidates due to the complexity of peptide-MHC interaction (see Section 2.2.6). When the 
sequence is unknown, combinatorial synthetic peptide libraries with up to a trillion variants, such 
as positional scanning combinatorial libraries [89] and bead-bound libraries [90], can be used to 
identify T cell epitopes. Synthesis of peptides, however, is expensive. Therefore, expression of a 
DNA library encoding either random peptides or antigens has been employed.  
When the MHC binding motif is known, a random peptide library can be constructed 
using degenerate primers. As with the combinatorial peptide library-based methods described 
above, the library screening usually results in the identification of T cell mimotopes rather than 
epitopes due to the random nature of the peptide library. The mimotopes could be used to 
elucidate the sequence of a biological relevant epitope, however, they could also be very 
different. For example, by co-expressing the peptide library in complex with a restriction murine 
MHCI molecule on the surface of insect cells, a mimotope was successfully isolated and 
subsequently used to identify a self peptide [58]. In contrast, screening of a peptide library 
created in a similar way on the surface of murine fibroblasts resulted in three mimotopes that had 
little resemblance to the epitope [91]. To directly identify T cell epitopes, several expression 
cloning approaches have been developed by either expressing a cDNA library in engineered 
APCs [92] or expressing viral cDNA libraries in E. coli [93] to identify the antigenic protein first, 
so that the epitope could be identified using the method of testing overlapping peptides. In 
addition to their own limitations, most of the T cell epitope identification methods described 
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above suffer from two common limitations: first, they rely on the use of professional APCs that 
are often difficult to isolate, expand and maintain, and second, the screening process is often 
time-consuming, laborious, and reagent-intensive. The development of artificial APC (see 
Section 1.2.4) might overcome these drawbacks. 
1.2.4. Antigen Presenting Cell 
There are three main types of professional APCs: dendritic cells (DCs), macrophages, 
and B cells with DCs being the most potent. There are several features of the DC contributing to 
its proficiency. First, immature DCs circulating in the tissues are equipped with antigen-
capturing machineries, such as phagocytosis [94] and macropinocytosis [95], thus are efficient at 
taking up antigens. Second, DCs are specialized in antigen processing to produce peptides and 
form pMHC complexes, and then transport them onto their cell surface for T cell recognition. 
Third, after being activated, DCs migrate to peripheral lymphoid tissues and undergo maturation 
[96] that is crucial for T cell activation. Matured DCs no longer have antigen-capturing skills; 
instead, they express high levels of MHC proteins, costimulatory molecules CD80/86, as well as 
many other cell adhesion molecules, such as ICAM and LFA. The co-stimulatory molecules are 
required for efficient activation of naïve T cells and the adhesion molecules are important for the 
initial transient interaction between T cells and DCs. Finally, DCs modulate the T cell responses 
(Th1-, Th2-, or Treg- type) by secreting different combinations of cytokines [97] and inform the 
location of the infection site by upregulating specific homing-receptors on primed T cells [98]. 
Because of their crucial role in initiating and modulating the cellular and humoral 
immunity, DCs and other professional APCs have a great potential in clinical applications that 
involve T cells. Studies have shown that, adoptive transfer of T cells is important in elucidating 
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autoimmunity [99, 100], and is effective against infectious diseases [101], cancers [102], 
autoimmune diseases [103], and GVHD [104]. Therefore, it is highly desirable to culture these T 
cells in vitro using professional APCs. However, isolation and expansion of these cells are time- 
and reagent-consuming even with improved methods [105, 106]. Therefore, it would be much 
more convenient if less complex systems could be used as artificial APCs (aAPCs). 
Virtually any surface decorated with pMHC complexes and/or other immune-potentiating 
molecules is a potential aAPC [34]. In the past few decades, several aAPC systems have been 
developed and can be divided into two major groups: cellular and acellular systems. The latter is 
better with respect to that acellular systems do not require cell culture, thus they are clean, 
avoiding potential contamination issues in clinical applications. However, manufacture of such 
systems is relatively difficult. For example, using magnetic beads involves expression and 
purification of MHC [107]; using exosomes requires purification of exosomes from large scale 
of DC culture [108]. Cellular systems that have been exploited so far include Drosophila 
melanogaster cells [34], Spodoptera frugiperda cells [11], mouse fibroblasts [34], a human 
leukemia cell line K32 [34], and a human kidney embryonic cell line [92]. The complexity of 
these systems is significantly reduced compared to that of professional APCs, while some 
features of the professional APCs are retained, such as antigen specificity and antigen processing.  
1.3. Cell Surface Display and Biofuels Production 
In addition to being a useful tool for engineering proteins and immune cells with 
improved cellular immunity modulating function, cell surface display has also been applied to 
address some of the challenges in the production of biofuels as alternatives to fossil fuels. While 
the fossil fuels accounted for 88% of the global energy supply as of year 2007, the oil, natural 
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gas, and coal could only last for approximately 40, 60, and 130 years, respectively, based on 
current fossil fuel reserves-to-production ratios [109]. To alleviate the society’s dependence on 
fossil fuels and reduce greenhouse gas emissions, biofuels are drawing rapidly growing interests 
[110-112]. The first-generation biofuel technologies have been used to produce ethanol from 
corn and sugar cane on a large scale in the United States and Brazil, respectively. However, the 
limited crop supply will not satisfy the ever increasing energy demand; thus, the second-
generation biofuel technologies based on cellulosic biomass are under intense investigation.  
Cellulosic biomass, the fibrous, woody, and generally inedible portions of plant biomass, 
is the only foreseeable sustainable source of transportation fuels [111, 113]. Its major component 
(up to 50%), cellulose (linear chains of glucose linked by β-1,4-glycosidic bonds) is embedded in 
a matrix of polymers formed mainly by hemicellulose and lignin, of which the interaction limits 
the access of hydrolytic enzymes, resulting limited hydrolysis [113, 114]. In addition, cellulose 
forms a distinct crystalline structure, which is so tightly packed that even small molecules, such 
as water, cannot penetrate [115]. What makes cellulose utilization more complicated is the 
diverse architecture of plant cells themselves, and different plant cell types might require 
completely different deconstructing methods [111, 115]. These features protect plants from 
moisture and microbial degradation, but also impede the conversion of plant biomass to value-
added products. To overcome these and many other challenges in enabling the second generation 
biofuel technologies, concerted efforts are required ranging from feedstock construction, 
pretreatment, hydrolysis and fermentation, processing design, product recovery, and marketing 
(comprehensively reviewed in [111]). Among numerous strategies currently undergoing 
development, consolidated bioprocessing (CBP) using yeast S. cerevisiae offers a promising 
solution [116] . 
 16 
1.3.1. Consolidated Bioprocessing for Cellulosic Biofuels Production 
The current processing strategy to overcome the recalcitrance of cellulosic biomass 
consists of multiple steps (Figure 1.1, left panel) [115, 117]: (1) pretreatment of plant biomass to 
attack the matrix structure, making cellulose more accessible for enzymatic hydrolysis and 
releasing hemicellulose, (2) production of cellulose-degrading enzymes − cellulases, (3) 
application of cellulases to hydrolyze pretreated biomass, producing a mixture of fermentable 
sugars, and (4) fermentation of soluble cellulose hydrolysate and/or hemicellulose hydrolysate to 
produce biofuels, such as ethanol using ethanologenic microorganisms (e.g. S. cerevisiae and 
Zymomonas mobilis). These steps are complex, costly, and energy-intensive, making it 
impossible for cellulosic ethanol to compete with gasoline in the market. Great efforts have been 
devoted to improve and simplify the process design [112, 115].  
SSF
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Cellulose 
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Figure 1.1 Simplified processing charts for cellulosic ethanol production. Conventional separate 
hydrolysis and fermentation (SHF) process flow chart is shown on the left. The improved simultaneous 
saccharification and fermentation (SSF) process differs from SHF in the shaded area, where it combines 
two separate steps (cellulose hydrolysis and fermentation) into one. The consolidated bioprocessing 
(CBP) flow chart is shown on the right, which is much more compact than other processes. 
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Prior to the mid-1980s, enzymatic hydrolysis and fermentation were carried out 
separately (separate hydrolysis and fermentation, SHF) (Figure 1.1, left panel). Since the 
development of simultaneous saccharification and fermentation (SSF) by Wright and coworkers 
in 1988 (Figure 1.1, shaded area in left panel) [118], the process have been advancing towards 
more consolidated configurations. In 1996, a highly compact design, later termed consolidated 
bioprocessing (CBP) was proposed by Lynd [119]. It combines enzyme production, pretreated 
biomass hydrolysis, and hydrolysate fermentation into a single step (Figure 1.1, right panel). 
Recent studies have shown that CBP holds great promise to lower the cost of the cellulosic 
ethanol production [112, 116, 120]. However, this great potential cannot be realized by 
organisms available today and requires the development of new and improved organisms that 
can both efficiently break down cellulosic biomass and convert the hydrolysate into ethanol.  
There are two strategies for CBP-enabling organism development: the native cellulolytic 
strategy and the recombinant cellulolytic strategy, both of which have shown great potential and 
have attracted broad attention (comprehensively reviewed in [115]). The native cellulolytic 
strategy aims to engineer naturally occurring cellulolytic microorganisms, such as Clostridia 
[121] with improved biofuels production yield and titer through metabolic engineering. The 
major challenge in applying this strategy is the lack of efficient genetic engineering tools. For 
example, the gene transformation method for C. cellulolyticum and C. thermocellum was not 
available until year 2000 and 2004, respectively, and the latter requires a specialized 
electroporation pulse generator and cuvette [122, 123]. The recombinant cellulolytic strategy 
involves the engineering of microorganisms that are proficient in biofuels production, such as S. 
cerevisiae [116] and Z. mobilis [124] with the ability to utilize cellulose and hemicellulose by 
expressing a heterologous cellulolytic enzyme system. The major challenge in applying this 
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strategy is to express multiple active enzymes at a very high level of ~1-10% of total cellular 
protein [112]. To date, there is no breakthrough advance in the development of cellulosic biofuel 
technology, both strategies merit continuing investigation in the future. 
1.3.2. Surface Engineered Yeast for Consolidated Bioprocessing 
Yeast S. cerevisiae possesses several unique features making it an attractive host for CBP, 
including high ethanol productivity at a close-to-theoretical yield producing 0.51 gram of ethanol 
per gram of glucose consumed, high ethanol tolerance, versatility and robustness in industrial 
fermentation, generally-regarded-as-safe status, and a diverse collection of engineering tools 
available. In the past few decades, yeast has been used as a heterologous host to study and 
engineer dozens of cellulolytic enzymes, either as secreted or surface displayed proteins [115, 
116]. Compared to the secreted version, the β-glucosidase displayed on yeast cell surface as an 
α-agglutinin fusion showed enhanced stability and activity [125], suggesting the advantages of 
displaying hydrolytic enzymes on yeast cell surface. This finding was further supported by the 
fact that the cellulose-enzyme-microbe complexes showed several-fold higher specific 
hydrolysis rates than purified enzymes [126]. In addition, such a cell-bound format is also 
amenable for protein engineering and analysis on insoluble substrates [127]. 
To engineer recombinant yeast strains with the ability to hydrolyze and ferment 
hemicellulose hydrolysate (mainly consists of xylose and arabinose), it is necessary to 
simultaneously display hemicellulases on the cell surface and express xylose- and/or arabinose-
utilization pathway genes intracellularly (metabolic engineering of S. cerevisiae for pentose 
utilization was reviewed in [128, 129]). As an initial step, a xylanase II (XYNII) from 
Trichoderma reesei was displayed on yeast cell surface as a fusion protein to the α-agglutinin 
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receptor and enabled the yeast cell to degrade xylan [130]. In a follow-up study, a second 
xylanolytic enzyme − β-xylosidase (XYLA) from Aspergillus oryzae was co-displayed with 
XYNII on the cell surface, and additional three enzymes (a xylose reductase and a xylitol 
dehydrogenase from Pichia stipitis and a xylulokinase from S. cerevisiae) responsible for xylan-
utilization were expressed intracellularly [131]. The resulting yeast strain produced 7.1 g/L of 
ethanol within 62 hours directly from birchwood xylan. When the same xylose-utilization 
pathway was expressed in a yeast strain displaying a β-glucosidase from Aspergillus aculeatus 
on the surface, it co-fermented xylose and cello-oligosaccharides present in a  sulfuric-acid-
treated woodchip into ethanol with a titer of 30 g/L [132]. Although arabinose-fermenting S. 
cerevisiae strains have been created [129], no enzymes with α-L-arabinofuranosidase activity 
have yet been displayed on yeast cell surface to enable simultaneous release of arabinose from 
cellulosic material and its fermentation. 
Cellulose-fermenting yeast strains have also been created by displaying cellulases on the 
cell surface. Using the α-agglutinin receptor as the carrier protein, a β-glucosidase from A. 
aculeatus was immobilized on the yeast cell surface and enabled cell growth using cello-
oligosaccharides as the sole carbon source [133]. With the same experimental design, an 
endoglucanase II from T. reesei was immobilized on the yeast cell surface and showed 
significantly elevated hydrolytic activity towards barley β-glucan, which is a linear, soluble 
polysaccharide composed of an average of 1200 glucose residues linked by ~70% β-1,4-
glycosidic linkages and ~30% β-1,3-glycosidic linkages [134]. By co-displaying these two 
cellulases on the yeast cell surface, the strain directly fermented barley β-glucan to ethanol with 
a titer of 16.8 g/L and a yield of 0.48 gram of ethanol produced per gram of β-glucan consumed 
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(93.3% of the theoretical yield) [134]. Taking a step further, co-display of a third cellulase – 
cellobiohydrolase II from T. reesei on the same yeast strain enabled simultaneous 
saccharification and fermentation of insoluble amorphous cellulose to ethanol [135]. Although 
this recombinant yeast strain showed relatively low ethanol titer of 3 g/L and no cell growth data 
was reported, it demonstrated the potential of engineering yeast strain as a CBP host.  
1.4. Project Overview 
This thesis focuses on applying the abovementioned cell surface display systems, 
specifically yeast and insect cell surface display, to address some of the challenges in (1) 
biomedical research, including T cell epitope mapping, artificial APC development, and pMHC 
complex affinity engineering, and (2) biofuels production, including displaying complex 
cellulolytic enzyme systems on yeast cell surface, improving cellulose hydrolysis synergy, and 
increasing enzyme expression levels.  
In the second chapter of this thesis, a high throughput and accurate T cell epitope 
identification method was developed [136]. This new approach combined the advantages of 
expression cloning and random peptide library strategies by generating a pathogen-derived 
peptide library. It was demonstrated that yeast cells displaying the pMHC complexes could be 
used as artificial APCs (aAPCs) to activate hybridoma T cells in a peptide-specific manner, 
avoiding the use of professional APCs. Using human MHCII molecule DR1 and influenza A 
virus (X31/A/Aichi/68) as a model system, a high throughput screening method for rapid and 
accurate epitope mapping was established, which was then used to screen a library of all possible 
peptides present in the virus in complex with the wild-type DR1. After as few as two rounds of 
fluorescence-activated cell sorting (FACS), the epitope-containing clones were enriched to ~1%. 
 21 
Following a second screening step using specific T hybridoma cells, the antigenic epitope was 
pinpointed. Although the method was demonstrated by identifying a viral epitope, it could be 
adapted to the identification of T cell epitopes from other systems such as cancer and 
autoimmune diseases. 
The third chapter of this thesis reports the results of pMHC affinity engineering using two 
different cell surface display systems: yeast surface display and insect cell surface display. The 
human MHCII molecule DR2 and a myelin basic protein derived peptide MBP85-99 that have 
been associated with multiple sclerosis were chosen to be our engineering target. Using the yeast 
surface display system, the DR2-MBP complex failed to show any TCR-tetramer-binding, 
indicating that this system was not suitable for engineering pMHC complexes with improved 
TCR-binding affinity. In contrast, the DR2-MBP complex displayed on the insect cell surface 
showed specific and peptide-dependent TCR-tetramer-binding. Coupled with directed evolution 
and FACS, a library of DR2 variants in complex with MBP was created and screened using R-
Phycoerythrin (PE)-labeled TCR tetramers. After one round of cell sorting, potential variants 
with improved TCR-binding affinity have been enriched.  
In the fourth chapter of this thesis, a recombinant cellulolytic and fermentative yeast 
strain was created by displaying a multi-cellulase-containing complex, namely minicellulosome 
on the cell surface [137]. The minicellulosome was formed by co-expressing a miniscaffoldin 
derived from C. thermocellum and three types of cellulases − an endoglucanase, a 
cellobiohydrolase, and a β-glucosidase. The multi-enzyme complex was tethered to the yeast cell 
surface using the a-agglutinin adhesion receptor. Using phosphoric acid swollen cellulose 
(PASC) as a model substrate, the surface displayed minicellulosomes exhibited both enzyme-
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enzyme synergy and enzyme proximity synergy. More importantly, resting cell study showed 
that the recombinant strain displaying the trifunctional minicellulosomes was able to hydrolyze 
and ferment PASC to ethanol, supporting the feasibility of constructing cellulolytic and 
fermentative yeast by displaying recombinant minicellulosomes on the cell surface [110]. 
Furthermore, the display system described in this chapter was shown to be a useful tool for 
producing minicellulosomes with different activities and studying their synergistic cellulolytic 
function. 
The fifth chapter of this thesis reports our continuing efforts to improve the cellulolytic 
efficiency of the yeast strain developed in Chapter 4. Various strategies have been employed 
with a focus of improving the minicellulosomal enzyme display levels. All of the attempts to 
improve the in vivo protein expression failed, including optimization of the protein induction 
conditions, reduction of the plasmid copy number, expression of fewer enzymes, and different 
combinations of alternative endoglucanases (CelG and CelC) and exoglucanases (CelE and 
CelF) isolated from C. cellulolyticum. In contrast, in vitro loading of cellulases onto the 
miniscaffoldin displayed on the yeast cell surface enabled cell doubling over a period of ~8 days, 
confirming that the low enzyme expression level was the limiting step. This result also suggested 
that the minicellulosomes should be continuously synthesized to support a sustained cell culture 
for consolidated bioprocessing. As such, a yeast display system was developed to enable 
constitutive minicellulosome synthesis and assembly on the cell surface. 
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Chapter 2. Rapid T Cell Epitope Identification Using Yeast 
Displaying Single-chain Peptide-MHC Complexes as Artificial APCs 
2.1. Introduction 
Cellular immunity is mediated by T cells, which respond to selected peptides in complex 
with major histocompatibility complex (MHC) expressed on antigen presenting cells (APCs) 
through their unique surface receptors (T cell receptors, TCRs) [1]. Identification of these 
specific antigenic peptides − T cell epitopes − is a critical but often slow and difficult step in 
studying the immune response to tumors, infectious agents, and autoantigens, as well as in 
developing pertinent vaccines and therapeutic strategies [2-4]. As shown in Table 1.1, the 
expression cloning and combinational peptide library based approaches suffer from two common 
limitations: first, they rely on the use of professional APCs that are often difficult to isolate, 
expand and maintain; and second, the screening process is often time-consuming, laborious, and 
reagent-intensive. Therefore, the goal of this project is to develop a facile and high-throughput 
method for T cell epitope identification using an aAPC system that is easier to establish and 
cheaper to manipulate than the existing ones. Between the two types of aAPC systems described 
in Section 1.2.4, acellular and cellular, the latter was chosen to avoid large scale expression and 
purification of MHC molecules, which are required to coat an acellular aAPC surface, such as 
magnetic beads [5].  
A human MHC class II (MHCII) allele, HLA-DR1, was chosen to be the model system. 
While most research efforts to date have focused on MHC class I (MHCI) proteins, recent 
studies have shown that CD8+ T cell immunity is not sufficient on its own to eradicate cancer 
cells [6] or viral infection [7, 8], and a combination of CD4+ and CD8+ T cell responses is 
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necessary to generate an efficient and long-lasting immunity. Therefore identification of CD4+ T 
cell epitope is highly desirable.  
The key step in developing a successful cellular aAPC system is the functional 
expression of the MHC protein on the cell surface. MHC molecules are large heterodimeric 
membrane proteins that are highly glycosylated and contain multiple disulfide bonds. In the 
absence of their transmembrane domains, the two polypeptide chains are unable to assemble 
properly and/or tend to aggregate [9]. Furthermore, it requires the binding of a peptide to 
stabilize the native conformation of MHC molecules [10, 11]. Therefore, soluble expression of 
MHC molecules, especially class II, has been proven to be difficult [12] and represents the first 
challenge of this project.  
Although several cellular aAPC systems that are less complex than professional APC 
have been developed [13, 14], they are still not simple enough and require the use of complex 
culture media and long cell culture time. Our attention was attracted by the two most commonly 
used and well-studied organisms: bacterium Escherichia coli and yeast Saccharomyces 
cerevisiae. Thanks to the development of cell surface display technique [15], both of the 
organisms have the potential to be aAPCs. We sought to use yeast S. cerevisiae for artificial 
antigen presentation. Compared to bacteria display, yeast display is a preferred method for 
expressing complex eukaryotic proteins due to its several advantages, such as the availability of 
posttranslational modifications and protein folding quality control mechanism [16]. Coupled 
with fluorescence activated cell sorting (FACS) using fluorescent labels, target protein displayed 
on yeast surface can be analyzed in a high-throughput and quantitative manner. Since its 
development in 1997 [17], yeast surface display has been successfully used to engineer 
antibodies, MHC molecules,  and TCRs [18]. 
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To date, there are only five successful examples [19-23] of using yeast surface display to 
express MHC proteins, three of which are expression of MHCII molecules [21-23]. In four of the 
examples [19-22], engineering of the MHC molecules was required and mutations were 
introduced to stabilize the surface expression of MHC molecules. These mutations might affect 
the conformation and/or peptide-binding kinetics of the mutant MHC proteins, and consequently 
alter their physiological property that is critical for pathogenesis studies and therapeutic 
applications. Although in one of these four examples, the surface displayed murine MHCI 
molecule was shown to be functional, the observed T cell activation was inconclusive due to 
alternative activation mechanisms [19]. Therefore, none of these mutant MHC proteins were 
shown to activate T cells conclusively. Recently, the wild-type human class II HLA-DR4 
molecules with a covalently attached peptide have been displayed on the yeast surface in their 
native state, but the resulting complex was incapable of stimulating antigen-specific T cells [23]. 
Therefore, the use of yeast cell displaying functional MHCII proteins as an aAPC has yet to be 
demonstrated, thus representing the second challenge of this project. 
The third challenge of this project is to develop a facile and cost-effective T cell epitope 
identification method. In theory, if yeast cells were successfully demonstrated to activate T cells 
in a peptide specific manner, epitopes could be identified readily by analyzing each peptide in an 
expression cloning library individually for their antigenic ability the same way as in the 
conventional methods [24]. However, this procedure has very low throughput. It would be 
convenient if we could use the fluorescence activated cell sorter (FACS) to enrich the potential 
epitopes from the library first, so that epitopes could be identified easily by analyzing only a 
small fraction of the peptide library, such as one hundred clones or even less. Previously, the 
expression level of yeast cell surface display was used as a proxy-screening variable for 
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enhanced thermostability [25]. Therefore, we hypothesized that it might be possible to select 
“good binders” from a peptide library based on the yeast surface expression level of the single-
chain peptide-DR1 complexes.  
In this chapter, each of the three challenges described above is addressed using DR1 and 
its well-defined CD4+ T cell epitope, HA306-318, as a model system [26]. A single-chain construct, 
in which the HA epitope was covalently intercalated between the α- and β-chain of DR1, was 
used to enable the functional display of MHC on yeast cell surface. A positive correlation 
between the yeast surface expression level of the peptide-DR1 complexes and the peptide-
binding affinity was established. For the first time, it was demonstrated that yeast cells 
displaying the DR1-HA complexes can be used as aAPC to activate T hybridoma cells in a 
peptide-specific manner. Based on these findings, a two-step T cell epitope identification method 
was proposed and validated by identifying the HA-derived CD4+ T cell epitope from either a 
single antigenic protein (haemagglutinin) or the entire influenza virus X31/A/Aichi/68 genome.   
2.2. Results and Discussion 
2.2.1. Functional Expression of Single-chain DR1-HA306-318 Complexes on Yeast Cell 
Surface 
Native MHCII molecules are heterodimeric proteins, a single-chain construct is thus 
chosen for yeast surface display of DR1. Other studies have shown that a flexible linker can be 
used to express proteins that are naturally non-covalent heterodimers, including antibodies [27], 
MHCI [28, 29], and MHCII proteins [22]. Previously, Olga Esteban in our group attempted to 
express soluble wild-type single-chain DR1 molecules (scDR1αβ) on the yeast cell surface 
without success [21]. However, directed evolution strategy was successfully applied and enabled 
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yeast surface display of DR1. More specifically, a library of mutant scDR1αβ molecules was 
generated by error-prone PCR and screened by FACS with DR-specific conformation-sensitive 
antibodies, yielding three well-expressed, properly folded scDR1αβ variants displayed on the 
yeast cell surface. The resulting soluble scDR1αβ mutants were shown to specifically bind 
peptide HA306-318. Interestingly, the peptide binding grooves of these mutant proteins were not 
empty, but presumably occupied by yeast endogenous peptides or peptides from the culture 
media [21]. This result indicated that mutations alone were not sufficient for stabilizing the DR1 
molecules although they were necessary; and peptide binding also contributed to the stabilization 
of the native conformation of DR1 molecules displayed on the yeast cell surface, consistent with 
other reports [30, 31]. Therefore, it was hypothesized that the wild type DR1 molecules might be 
possible to be functionally displayed on the yeast cell surface by co-expressing a covalently 
bound peptide, HA306-318.  
To test this hypothesis, a single polypeptide chain, scDR1αHAβ, in which peptide HA306-
318 was covalently intercalated between the C-terminus of DR1α-chain and the N-terminus of 
DR1β-chain through two flexible linkers (Figure 2.1), was constructed, cloned into pYD1 yeast 
display vector, and transformed into EBY100 S. cerevisiae strain [17].  
BstXI XhoI NotI SpeI 
 
DR1α  DR1β stop AGA2 GAL1 P  L L V5  His  Xpress 
 
Figure 2.1 Schematic representation of the single-chain DR1- HA306-318 construct used in yeast display. 
GAL1= yeast GAL1 promoter, AGA2= an adhesion subunit of a-agglutinin of a-yeast-cells [17], 
Xpress=Xpress epitope, L=linker, P= HA306-318 peptide, V5=V5 epitope, His=His6 tag.  
The surface expression level of the scDR1αHAβ protein was analyzed by flow cytometry 
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using two different antibodies: anti-V5 antibody was used to detect the full-length protein; and 
LB3.1, a conformation-sensitive antibody that can only bind correctly assembled DR 
heterodimers [10], was used to detect properly folded protein. As shown in Figure 2.2 (middle 
panel), a positive staining yeast cell population was detected with anti-V5 antibody and the 
relative mean fluorescence units (MFU) of ~100 indicated a high surface expression level of the 
wild type scDR1αHAβ protein. Expression of the properly folded wild type scDR1αHAβ 
protein was also detected as indicated by the LB3.1-positive staining population (Figure 2.2, 
right panel). A comparison of the MFU obtained with anti-V5 and LB3.1 antibody indicated that 
only a fraction of the displayed proteins were in their native conformation, consistent with the 
previous result [21].  Taken together, these data clearly suggested that, with the stabilizing effect 
of the binding peptide HA306-318, the wild type DR1 protein can be displayed on yeast cell surface 
in its native state.  
 
no 1° 
PE 
Anti-DR 
(LB3.1) 
PE 
Anti-V5 
PE 
 
Figure 2.2 Flow cytometric analysis of single-chain DR1-HA expression on yeast cell surface.  Yeast 
cells transformed with pYD1-scDR1αHAβ were stained with anti-V5 antibody to detect full-length 
protein expression, or with LB3.1 (anti-DR) antibody to detect correctly folded complexes. Yeast cells 
stained only with secondary antibody (no 1°) were used as a negative control. 
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2.2.2. A Positive Correlation between Yeast Surface Expression Level and Peptide-binding 
Affinity 
Due to the editing function of non-classical MHC-related molecule HLA-DM on the 
peptide repertoire, only peptides with optimal anchor residue combination and sufficient length 
are able to bind MHC proteins stably for effective antigen presentation [32, 33]. Therefore, 
epitopes should have fairly high binding affinity in order to be loaded onto nascent MHC 
molecules. As such, several T cell epitope identification methods, including “reverse 
immunology” [34] and computational methods [35], have been developed to predict potential 
epitopes based on the MHC binding motif and antigenic protein sequence analysis. However, 
these methods would not be applicable when the underlying molecular mechanism of the 
peptide-MHC interaction or the sequence of the antigen was not available. To develop a more 
generally applicable T cell epitope identification method, we sought to correlate the yeast surface 
display level and peptide binding affinity so that the potential MHC-binding peptides could be 
readily identified from a random peptide library. 
To evaluate whether the yeast-displayed wild type scDR1αHAβ proteins can discriminate 
peptide-binding affinity, a series of scDR1αpepβ constructs containing peptides with different 
affinity towards DR1 molecule was designed (Table 2.1).  
Table 2.1 Sequences and DR1-binding affinity values of peptides used in the scDR1αpepβ constructs.  
Peptide Sequence KD (nM) 
2467 PKYRKMNARKLAT <<14 
M4 GGYRQMSAPTLGG <14 
HA306-318 PKYVKQNTLKLAT 14 
YAK AAYAAAAAAKAAA 118 
CII261-273 AGFKGEQGPKGEP >140 
PKA PKAVKQNTLKLAT 23,000 
L GGGGSGGGGSGGG >>23,000 
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As shown in Figure 2.3, the surface expression level of the scDR1αpepβ complex 
decreases with decreasing DR1-binding affinity of the covalently attached peptide, indicating a 
positive correlation between the peptide binding affinity and the protein surface expression level. 
Therefore, the yeast surface expression level of the scDR1αpepβ protein, as measured by DR-
specific antibody (LB3.1) staining, may be used as a proxy screening variable for high affinity 
peptides, which are candidate CD4+ T cell epitopes. By means of a new expression cloning 
strategy (see Section 2.2.5 below) and FACS, a library of scDR1αpepβ complexes containing up 
to 109 different peptides may be generated within days and examined individually for protein 
surface expression level within hours to enrich the DR1-binding peptides. Single yeast cells of 
interest can also be readily sorted into 96-well plates for further analysis. 
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Figure 2.3 A positive correlation between yeast surface display level of the scDR1αpepβ protein and the 
DR1-binding affinity of the intercalated peptide (Table 2.1). Peptides on the x-axis were ranked in a 
decreasing order of DR1-binding affinity. The expression level of scDR1αβ that has no peptide (no pep) 
in the linker between α chain and β chain was reported previously [21]. MFU = mean fluorescence unit.   
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The yeast surface display level has been previously used as a proxy-screening variable 
for enhanced protein thermostability engineering [25]. Therefore, experiments were also 
conducted to investigate the thermostability of the displayed peptide-DR1 protein complexes. 
After being induced, the yeast cells displaying the complexes were heat-inactivated at various 
temperatures for 10 minutes, and the fraction of active proteins was quantified by binding with 
the LB3.1 antibody. The percentage of maximal binding, which was the LB3.1-binding signal of 
cells without heat-inactivation, was calculated and plotted with respect to the incubation 
temperature to determine T1/2, which was defined as the temperature at which half-maximal 
denaturation occurred.  
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Figure 2.4 Thermostability analysis of the peptide-DR1 complexes displayed on yeast cell surface. The 
irreversible denaturation curves are shown on the left. T1/2 (temperature at which half-maximal 
denaturation occurred after 10 minutes of heat inactivation) is shown in the table on the right. Peptides in 
the table column were ranked in a decreasing order of the peptide-DR1 surface display level. 
As shown in Figure 2.4, the thermostability analysis showed that there was indeed a 
general correlation between the surface display level of peptide-DR1 complex and its 
thermostability. However, compared to the peptide binding affinity towards DR1, the 
thermostability of peptide-DR1 complex did not correlate as well with the protein surface 
expression level. For example, the DR1-M4 complex showed lower T1/2 than those of DR1-HA 
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and DR1-YAK, although it was expressed at a higher level than the latter two constructs (Figure 
2.3). In addition, when the peptide binding affinity dropped below a certain level (>140 nM), no 
difference in the thermostability was observed (compare CII, PKA, and L constructs). 
Nevertheless, the clear difference in the thermostability of DR1 in complex with high-affinity 
peptides (<118 nM) and with low-affinity peptides (>23,000 nM) suggested that the protein 
surface display level could be used as the proxy-screening variable for engineering peptide-MHC 
(pMHC) complexes with improved thermostability.  
2.2.3. Functional Analysis of the DR1-HA306-318 Complex Displayed on Yeast Cell Surface 
Although the DR1-HA complex displayed on yeast cell surface was shown to be in its 
native conformation, the conclusion was made solely based on flow cytometric analysis using a 
conformation-sensitive antibody, LB3.1. The successful binding of LB3.1 does not necessarily 
mean that these complexes are biologically active. The pertinent experiment would be testing 
their ability to activate T cells. In theory, soluble DR-HA protein complex could be expressed 
and purified using the yeast secretion system. However, multiple time-consuming steps, 
including cloning and protein purification are required to switch from the yeast display system to 
the secretion system. It would be more convenient if the protein complexes displayed on yeast 
cells could be directly released from the surface without disrupting their native conformation.   
As shown in Figure 2.5, the peptide-DR1 complex displayed on yeast surface is attached 
to the cell surface through a pair of disulfide bonds formed between Aga1 and Aga2 subunits of 
the yeast a-agglutinin receptor. Therefore, the complex could be released from the cell surface by 
reducing the disulfide bonds. Note that there are also multiple disulfide bonds present in the 
protein complex, thus dithiothreitol (DTT) is not suitable for this task because it would probably 
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disrupt the native structure of the protein. In contrast, tris-(2-carboxyethyl) phosphine (TCEP) is 
a  reducing reagent generally impermeable to cell membranes or to the hydrophobic protein core, 
allowing its use for selective reduction of disulfides that have aqueous exposure [36]. Therefore, 
TCEP was chosen to selectively reduce the disulfide bonds formed between Aga1 and Aga2, 
leaving those buried in the folded scDR1αpepβ protein intact.  
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Figure 2.5 Schematic representation of the single-chain peptide-DR1 complex displayed on yeast surface. 
Adapted from reference [17]. 
After treatment with TCEP, the Aga2-DR1-HA306-318 fusion protein was detected using 
western blot probed with anti-V5 antibody (Figure 2.6).  The fusion protein showed an apparent 
molecular weight of ~90 KDa, consistent with the previous study [21]. To test the biological 
activity of the protein complex released from the yeast cell surface, DR1-HA protein was 
immobilized in a 96-well plate coated with anti-V5 antibody and then incubated with T cells. To 
obviate the need to establish and maintain functional T cell clones, HA1.7 hybridoma cells that 
are specific for DR1-HA or DR4-HA [24] were used in the T cell activation study.   
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Figure 2.6 Western blot analysis of Aga2-DR1-HA fusion protein released from yeast surface using 
TCEP. The molecular weights (KDa) of the protein standards are shown on the left. Lane 1: prestained 
low range protein standards, lane 2: Aga2-DR1L11H-MBP fusion, and lane 3: Aga2-DR1 L11H-HA fusion. 
Note that the mutant proteins were used in the western blot assay because the wild type constructs were 
expressed at a low level (similar to the Aga2-DR1L11H-MBP construct shown in lane 2) and could not be 
detected using western blot. 
As shown in Figure 2.7, the DR1-HA activated the hybridoma T cells and the secretion 
of IL-2 in the supernatant was detected. Taken together, these data suggested that the DR1-HA 
complex can be released from the cell surface using TCEP. More importantly, the TCEP 
treatment did not disrupt the native conformation of the DR1-HA complex and the released 
protein complex activated hybridoma T cells.  
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Figure 2.7 T cell activation assay using immobilized soluble peptide-DR1 complex. 
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2.2.4. Use of Yeast Cells Displaying Single-chain Peptide-MHC Complexes as AAPCs 
To avoid the use of professional APCs, which are required in most CD4+ T cell epitope 
mapping methods, the protein extraction method described in the previous section could be used. 
However, it requires TCEP treatment, dialysis, centrifugal concentration, and the use of 
antibodies to immobilize the protein complex (see Section 2.4.11), making the identification 
process low throughput. To address this issue, the ability of the yeast cells displaying the 
scDR1αpepβ complexes to directly induce antigen-specific T cell activation was examined next. 
Consistent with previous reports [21-23], no IL-2 secretion was detected when HA1.7 hybridoma 
cells were stimulated with yeast cells displaying DR1-HA complexes in suspension. This 
inability to induce T cell activation may be caused by the lack of costimulatory molecules on the 
yeast cell surface. Without the aid of costimulatory molecules, TCR signaling is weak. In 
addition, the spatially restricted MHC-peptide complexes displayed on yeast surface may not 
reach the density threshold that is important for stable interaction with TCRs [37]. Therefore, it 
was postulated that immobilization of yeast cells on a plastic surface might increase the relative 
density of pMHC complexes available for TCR interaction and consequently enable T cell 
activation.   
To test this hypothesis, yeast cells displaying various scDR1αpepβ constructs were first 
immobilized in the wells of a 96-well round-bottom plate and then incubated with HA1.7 
hybridoma cells. As shown in Figure 2.8, the hybridoma cells only responded to yeast 
displaying the scDR1αpepβ construct harboring the HA306-318 peptide, but not to yeast displaying 
scDR1αpepβ construct harboring any other peptide. These data clearly suggested that yeast cells 
displaying the scDR1αpepβ complexes, when immobilized, can activate hybridoma T cells in a 
peptide specific manner, and thus could be used as aAPCs. 
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Figure 2.8 Yeast cells displaying peptide-DR1 complexes acted as aAPCs and activated HA1.7 
hybridoma in an antigen-specific manner. Yeast cells containing empty plasmid pYD1 (EV) were 
cultured, induced, and analyzed in the same way as yeast displaying other constructs. 
2.2.5. Design of a T Cell Epitope Identification Method 
In the previous sections, it has been successfully demonstrated that: (1) yeast cells can be 
engineered to display functional pMHC complexes on the surface, (2) a high throughput 
screening method can be established based on the positive correlation between the peptide 
binding affinity towards MHC and the surface display level of the pMHC complexes, and (3) the 
surface engineered yeast cells can act as aAPCs and activate T cells of interest directly. Based on 
these findings, a new CD4+ T cell epitope identification method was proposed to overcome 
some of the aforementioned issues presented by existing approaches.  
As shown in Figure 2.9, DNA encoding the pathogenic protein(s) is obtained by PCR or 
RT-PCR using sequence-specific primers and random hexamer primers (Figure 2.12) for known 
and unknown antigens, respectively. Unlike professional APCs, yeast does not have antigen 
processing pathways to load antigenic peptides onto MHCII molecules. To address this issue, the 
 49 
advantages of expression cloning and random peptide library were combined to create a 
pathogen-derived peptide library. Specifically, the DNA derived from the pathogen is randomly 
digested into fragments using DNase I. The resulting DNA fragments with size ranging from 30 
to 60 nucleotides that encode all the possible peptides with 10-20 amino acids from the antigens 
(single antigenic proteins or pathogenic organisms such as parasites, tumors, and viruses) is 
purified and fused to the gene encoding the restriction single-chain MHCII molecule in a yeast 
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Figure 2.9 Design of a novel CD4+ T cell epitope identification method. Fragments (~30-60 bp) 
generated from the antigenic DNA material are fused to the single-chain MHCII molecules in a yeast 
display vector (step 1). Following transformation and gene expression (step 2), yeast cells displaying the 
entire library of peptide-MHC complexes are analyzed by FACS (step 3) to identify a small subset of 
yeast cells containing peptides with high affinity toward the restriction MHCII molecule. Plasmids are 
then recovered from these yeast cells (step 4) and analyzed for further enrichment. This enrichment cycle 
is repeated for ~2-4 rounds. Individual clones from the enriched library are then screened for their ability 
to induce antigen-specific T cell activation as indicated by IL-2 production using T cell hybridomas 
transfected with the TCR of interest (step 5). 
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display vector. Following gene expression, yeast cells displaying the entire library of pMHC 
complexes are analyzed by FACS to enrich those containing peptides with high MHC-binding 
affinity based on their surface expression levels. This enrichment cycle is repeated for ~3-4 times 
to obtain a small subset of yeast cells displaying MHC in complex with good binding peptides, 
which are then directly screened for their ability to induce antigen-specific T cell activation using 
T hybridoma cells transfected with the TCR of interest. DNA sequence analysis of the selected 
active clones leads to the identification of antigenic peptides. If necessary, a series of DNA 
fragments encoding overlapping peptide sequences can be used to refine those antigenic peptide 
sequences. To validate the proposed method, a single antigenic protein, haemagglutinin and the 
influenza virus X31/A/Aichi/68 were used as the model antigens. 
2.2.6. Epitope Identification from a Single Antigenic Protein - Haemagglutinin 
Haemagglutinin is an antigenic glycoprotein on the surface of influenza virus and is 
responsible for its entry into host cells through receptor binding and membrane fusion [38]. It 
contains the HA306-318 peptide, thus was used to validate the proposed epitope identification 
method. To create a library of all the possible peptides derived from haemagglutinin, the DNA 
encoding influenza A virus haemagglutinin was obtained by RT-PCR using specific primers and 
randomly digested by DNaseI. The DNA fragments with size ranging from 30 bp to 60 bp 
(corresponding to 10 to 20 amino acids) were purified from the agarose gel after electrophoresis 
and cloned into the yeast display vector using blunt end ligation. To eliminate the possibility that 
the epitope HA306-318 identified from the peptide library is derived from the undigested 
scDR1αHAβ, plasmid scDR1αSTFβ was constructed. The stuffer DNA (STF) is an unrelated 
gene (~1 kb) amplified from the phosphite dehydrogenase gene [39]. A library of 4.6x105 E. coli 
clones was obtained, from which the plasmids were then recovered and transformed into yeast, 
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generating a library of 2.1x106 variants. The haemagglutinin gene is ~1.7 kb in size, thus the 
library created here has ~100% chance of covering all possible ~20-residue-peptides [40]. After 
protein induction, the yeast cells displaying scDR1αpepβ proteins were stained with LB3.1 
antibody and those harboring high affinity binding peptides were enriched by FACS (Figure 
2.10). 
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Figure 2.10 FACS enrichment of potential good binders from the haemagglutinin-derived peptide library. 
LB3.1 antibody was used to stain cells as a measurement of surface expression level of correctly folded 
peptide-DR1 complexes. Comparison between the histogram of the library before enrichment (shade) and 
that after three-rounds of cell sorting (red line) clearly showed that the good binders were greatly 
enriched. 
After three rounds of cell sorting, ten clones were randomly picked from the top 0.05% 
population of the enriched library and evaluated for their protein surface expression levels 
(Figure 2.11a) and the ability to activate HA1.7 T hybridoma cells (Figure 2.11b). All ten 
clones showed higher or comparable expression levels as the yeast displaying the scDR1αHAβ 
complex and five of them (clone 3, 4, 5, 7, and 9), representing 50% of the enriched library, were 
capable of stimulating hybridoma T cells to secret IL-2. DNA sequencing analysis of the five 
active clones revealed that all of them displayed an identical peptide 
PKYVKQNTLKLATGMRNVPEKQT, which contained the HA306-318 epitope underlined.  
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Figure 2.11  Characterization of ten clones randomly picked from the haemagglutinin-derived peptide 
library after three rounds of cell sorting. (a) Surface display levels of folded peptide-DR1 complexes were 
measured using LB3.1 antibody. (b) T cell activation analysis was performed using the ten randomly 
picked clones and five of them (clone 3,4,5,7, and 9) activated T hybridoma cell, HA1.7. 
To probe the reason why the other five peptides were also enriched in the library, the 
peptide-encoding region was sequenced, and the peptide sequence was deduced and analyzed by 
TEPITOPE [35]. Four out of five peptides contained predicted DR1-binding peptides (Table 2.2), 
indicating that 90% of the enriched peptides are, in theory, capable of binding HLA-DR1. Taken 
together, these results suggested that the proposed method can be used efficiently to enrich DR1-
binding peptides and identify T-cell epitopes from a single known antigenic protein. 
Table 2.2 Peptide sequence analysis of the ten clones from the enriched haemagglutinin-derived peptide 
library. The predicted binding 9-residue peptides are shown in blue with red letters corresponding to the 
amino acid residue at position P1.  
Clone Peptide sequence 
1 PLKLATGNVPEKQTL 
2 PASPILSDPSPSETLSDKLQSAL 
3, 4, 5, 7, 9 PKYVKQNTLKLATGMRNVPEKQTL 
6, 10 QWEIEQGNQEDEREIPSL 
8 LKPYQPSII 
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2.2.7. Epitope Identification from a Pathogenic Organism - Influenza A Virus  
To further evaluate whether the described method could be used directly to identify 
CD4+ T cell epitopes from pathogens such as viruses and tumor cells, influenza A virus was 
used as a model antigen. Since the influenza A virus genome consists of eight pieces of anti-
sense RNA [41], cDNA needs to be obtained first for the following fragmentization and ligation 
steps. However, the viral RNA does not have a polyA tail, thus polyT primers cannot be used for 
RT-PCR reaction. To address this issue, random priming was chosen to synthesize the first 
strand cDNA. As shown in Figure 2.12, hexamers randomly anneal to the viral RNA and DNA-
RNA hybrids of different lengths are synthesized using a reverse transcriptase. Following RNase 
H and polymerase I treatment, double-stranded cDNA library is obtained. An additional 
advantage of random priming is that it does not require the knowledge of the genetic sequence, 
allowing the identification of epitopes from any unknown antigenic materials, such as newly 
emerged virus or mRNA from uncharacterized cancer cells.  
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Figure 2.12  A method to generate DNA fragments from the genomic RNA of influenza A virus. 
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Using random priming, a library (3.0×105) of DR1 protein in complex with peptides 
derived from the genome of influenza virus A/Aichi/2/68 was created first in E. coli. Plasmids 
were then recovered and transformed into yeast, generating a library of 2.1×106 variants. After 
four rounds of FACS enrichment (Figure 2.13a), a significant peak shift was observed, 
indicating that yeast cells displaying peptides with high DR1-binding affinity were enriched. 
Twenty clones were randomly picked and analyzed for their surface display level and activity. 
As shown in Figure 2.13b, majority of the twenty clones showed higher expression level than 
scDR1αHAβ. Unfortunately, none of them activated T cells (data not shown). Screening of 
additional five plates still did not reveal any active clones.  
1°library
Sort 1
Sort 2
Sort 3
Sort 4
a
b
0
5
10
15
20
25
30
35
40
45
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 HA
M
FU
 
Figure 2.13 Enrichment of potential good binders from the influenza A/Aichi/2/68 virus genome-derived 
peptide library. (a) Four rounds of FACS analysis of the peptide library using LB3.1 as the primary 
staining antibody. (b) Surface expression levels of 20 clones randomly picked from the enriched library 
after four rounds of cell sorting. 
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The sequencing analysis of the twenty clones (Table 2.3) showed that 17 clones 
contained an identical peptide, KKKKKKKKKKK. The DNA fragment encoding this lysine 
oligomer was not present in the viral genome, but was derived from the carrier RNA that was 
used to extract the viral RNA. In fact, the possibility that the carrier RNA would interfere with 
our screening method was taken into account, and the library was created to have a size that was 
100-fold larger than the required library size. In addition, four rounds of FACS screening were 
conducted instead of three rounds. However, the ability of poly-lysine to stabilize the surface 
display of DR1 protein was unexpected. Note that DNA sequencing analysis also revealed one 
mutation at DR1β26 from leucine to phenylalanine in the DR1-K11 complex. Thus, it was not 
clear whether the improved expression level of DR1-K11 was due to this mutation or the binding 
affinity of poly-lysine peptide. Another interesting finding was that two of the twenty selected 
clones contained no peptide between the α- and β-chain, but expressed well (clone 4 and 17 in 
Figure 2.13b). Further DNA sequencing analysis showed that there was no other mutation 
within the DR1 protein sequence. This experimental result remained inconclusive. Since yeast 
cells displaying the DR1-K11 complex were enriched so much that they accounted for a large 
percentage (85%) of the library after four rounds of cell sorting, there might be a better chance to 
find the HA306-318 epitope in the enriched library from the previous round (third round). Five 
plates from the third round library were collected and analyzed for T cell activation.  However, 
no active clones were identified.  
Table 2.3 Sequencing data of 20 clones randomly picked from the A/Aichi/2/68-derived library after four 
rounds of cell sorting. 
# of clones Peptide sequence 
17 KKKKKKKKKKK 
2 none 
1 HLARLAQHPVSSRLRAFPCLDRAAPDSRVLGRPA                       
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To avoid the carrier RNA contamination, the genomic RNA of the influenza A virus 
strain X31/A/Aichi/68 was purchased and used as the template for random priming. The average 
length of the peptides was determined to be ~14 amino acids. Following the procedures as 
depicted in Figure 2.12, a library of ~1.9x106 yeast clones displaying scDR1αpepβ complexes 
was created. The genome size of influenza A virus is ~12kb, the library size required to have a 
95% chance of being 100% complete is calculated to be ~3x105 [40], thus the library created had 
~100% chance of being 100% complete. To probe the diversity of the peptides in the primary 
library, twenty clones were randomly picked, sequenced, and mapped to the viral genome. There 
was at least one peptide derived from each of the eight pieces of viral genomic RNA displayed in 
either sense or anti-sense orientations (data not shown), indicating a good representation of the 
whole viral genome.  
After two rounds of FACS enrichment (Figure 2.14a, red line), four plates of yeast 
clones (with no more than one cell per well) were collected and screened for their ability to 
activate HA1.7 T cell hybridomas. Four clones (1G6, 2D12, 4H9, 5G9), representing ~1% of the 
enriched library, activated T cell hybridomas (data not shown and Figure 2.14b). Compared to 
yeast displaying scDR1αHAβ, the four identified clones showed comparable surface expression 
level and reduced antigenicity by ~2-3 fold (Figure 2.14b and c). This might be due to the 
reduced binding capacity engendered by the extra amino acids at the N- and/or C- terminus of 
the HA306-318 peptide [42] (Figure 2.14d). Sequence alignment of the four peptides revealed a T 
cell epitope, PKYVKQNTLKLATGMRN with the HA306-318 epitope sequence underlined, and a 
T cell mimotope QYVKQNTLKLATGMRN that differed from the epitope by two residues: 
proline at the P-2 position was absent and the lysine at the P-1 position was replaced with 
glutamine (Figure 2.14d). The presence of the mimotope, not unexpectedly, was a result of an 
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open reading frame fusion at the junction of the vector-encoded and virus-encoded DNA regions 
as described [43]. After two more rounds of FACS screening (top 0.5% population of sort 3, 
Figure 2.14a, blue line), the active clone occurrence frequency was further improved to ~6% 
(data not shown). Taken together, these results clearly suggested that the proposed method was 
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Figure 2.14 Identification of HA306-318 epitope from the influenza X31/A/Aichi/68 virus genome-derived 
peptide library.  (a) FACS enrichment of potential good binders. LB3.1 antibody was used to stain cells as 
a measurement of surface expression level of correctly folded peptide-DR1 complexes. Profiles of the 
peptide library before and after enrichment are shown in black and colored lines, respectively. (b) T-cell 
activation analysis of the four clones identified from the peptide library. (c) The four active clones 
showed comparable surface expression levels as yeast displaying scDR1αHAβ. The relative MFU was 
normalized to HA for direct comparison. (d) The peptide sequences from the four clones were aligned 
with the HA306-318 epitope sequence.  * = fully conserved residues, : = conservation of strong groups. 
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able to rapidly pinpoint a 17-residue CD4+ T cell epitope from the entire influenza A virus 
genome [26], and it can be used to identify T cell epitopes from an unknown antigen.  
2.3. Conclusions and Outlook  
A simple and efficient approach was developed to identify CD4+ T cell epitopes from 
both known and unknown antigens using surface engineered yeast cells for artificial antigen 
presentation. By means of a new expression cloning method, a pathogen-derived peptide library 
was displayed on yeast surface in the context of wild-type single-chain DR1 protein. The ability 
of the recombinant yeast cells to distinguish the peptide binding affinity towards DR1 allowed 
efficient enrichment of DR1-binding peptides using a DR-specific antibody, LB3.1, and the 
epitope occurrence frequency was enriched to ~50% and ~6% of the resulting library for the 
haemagglutinin- and influenza viral genome-derived peptide library, respectively. In the 
subsequent T cell activity screening assay, the recombinant yeast cells can be used directly to 
activate T hybridoma cells in a peptide specific manner, enabling the identification of the epitope. 
This study represents the first demonstration that yeast surface peptide-MHCII display can be 
used to identify T cell epitopes.  
Compared to other existing methods [2], the approach described here is faster, simpler, 
less reagent-intensive, and offers the following advantages. First, unlike other peptide libraries, 
the expression cloning peptide library created in this study consists, in theory, all possible 
peptides derived from a pathogen. Thus it allows direct identification of T cell epitopes, rather 
than mimotopes that are less biological relevant to the natural TCRs. Second, the fragmentation 
of pathogenic protein(s) is carried out at DNA level in vitro and these peptides are genetically 
fused to yeast surface protein, therefore, no complex MHCII peptide processing and presentation 
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pathways are required for artificial antigen presentation, which is the major obstacle for 
conventional expression cloning libraries [14, 43]. Third, the occurring frequency of the epitope 
is greatly increased after enrichment by FACS, thus only a small number of yeast cells (100-200) 
need to be examined for their ability to activate T cells, obviating the brute-force screening. 
Finally, the surface engineered yeast cells can be used directly in the T cell activity assay, thus 
obviating the use of professional APCs.  
To achieve rapid and accurate identification of antigenic CD4+ T-cell epitopes, the two-
step screening method described in this chapter is necessary; because the peptide is covalently 
attached to MHCII protein through flexible linkers, which might enable binding of MHCII 
molecules with peptides that normally do not bind or bind weakly. And these “false-positive” 
binders can be readily eliminated in the secondary screening step using T cells that bear TCRs 
specific for the antigenic peptide. However, this method on its own is not sufficient for more 
complex situations, such as epitope identification from unknown antigens using T cell lines, of 
which the antigen specificity is not well defined. In this case, peptides that do not normally 
activate T cells might also be selected from the library after two steps of screening, because the 
local concentration of covalently attached peptides in the single-chain construct is much higher 
than that found under normal physiological conditions. To address this issue, further examination 
of the isolated peptides should be conducted by using conventional T cell function analysis, 
which involves testing chemically synthesized peptides and using professional APCs. 
Although the CD4+ T cell epitope identification method described above was 
demonstrated with DR1 allele, the generality of this system was partially demonstrated by the 
functional expression of another human MHCII allele, DR4 on yeast cell surface, which also 
activated HA1.7 hybridoma T cells in a peptide specific manner (Figure 2.15).  
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Figure 2.15 Analysis of yeast cells displaying single-chain wild type DR4 in complex with different 
binding peptides. (a) Flow cytometric analysis of single-chain DR4-HA306-318 expression level on yeast 
surface. (b) Yeast displaying DR4-HA activated HA1.7 hybridomas in a peptide-specific manner. 
Compared to DR1-HA complexes, DR4-HA elicited a much weaker response of HA1.7 hybridoma cells. 
Nonetheless, since MHC proteins are highly polygenic and polymorphic, it might be 
difficult to functionally display every target MHCII allele on yeast cell surface. Fortunately, this 
limitation may be overcome by introduction of a few point mutations via directed evolution into 
the target MHC protein [21, 22].  However, there may be concerns about the effect of the 
introduced mutations on the biological activity of MHC molecules. Recently, one of the DR1 
mutants identified earlier, which has a leucine to histidine mutation at position 11 of β-chain, 
was analyzed [21]. It was found that this mutant actually elicited a much stronger T cell response 
than the wild-type DR1 did (data not shown). This was probably a result of the increased surface 
expression level of the mutant, which increased the ligand density for TCR recognition. 
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Therefore, it is possible that mutations could be introduced to only improve the solubility and/or 
expression level of the MHC proteins, and leave their biological function intact. 
Finally, although this method was demonstrated by identifying a viral epitope, it should 
be generally applicable to identification of T cell epitopes from other systems, such as cancers 
and autoimmune diseases. For such applications, the sensitivity of the yeast cells functioning as 
aAPCs needs to be improved so that they could be used to stimulate T cell lines or primary T 
cells, which are much more fastidious in their activation requirements than T hybridoma cells.  
Therefore, the future work would be trying to include the co-stimulatory molecules and 
accessory molecules in yeast, which have been shown to be important for activation of primary T 
cells or T cell lines [13]. It should be noted that this yeast display system is amenable to 
engineering by directed evolution approaches. As such, it provides a technology platform for 
engineering the displayed MHC molecules for the development of various MHC-based reagents 
for basic and applied biomedical research.  
2.4. Materials and Methods 
The sequences of the PCR primers were listed in Table 2.4 and were synthesized by 
Integrated DNA Technologies (Coralville, IA). For PCR amplification, unless otherwise 
specified, the reaction was performed in a 100 µL of mixture (25 µL was used for PCR check, 
such as colony PCR or gene integration verification) consisting of 10 ng of DNA template, 1x 
phusion buffer, 50 pmol of forward primer, 50 pmol of reverse primer, 0.25 mM (each) dNTPs, 
and 2U of phusion DNA polymerase. The typical PCR program consisted of an initial 
denaturation of 2 minutes at 98 °C, followed by 25-30 cycles of denaturation at 98 °C for 30 
seconds, annealing at 55 °C for 30 seconds, and extension at 72 °C for 30 seconds per 1kb long 
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gene, and a final 10-minute elongation at 72 °C. All restriction enzymes were obtained from 
New England Biolabs (Ipswich, MA). Unless otherwise indicated, all chemicals were purchased 
from Sigma (St. Louis, MO). See Fei Wen Notebook 1, pp.18. 
Table 2.4  Primers used in cloning and peptide library creation. 
Name Sequence 
α-5BX 5’GTACCAGGATCCAGTGTGGTGGAAAGGAAAGAAGAACATGTGATC3’ 
β-3XH 5’-CCCTCTAGACTCGAGCTTGCTCTGTGCAGATTCAGAC3’ 
pYD1For 5’-AGTAACGTTTGTCAGTAATTGC3’ 
NotIRev 5’TGCCAACTTCAGGGTGTTTTGCTTAACATACTTGGGGCGGCCGCCTCCTGAGCCTCCACC3’ 
NotIFor 5’GCAAAACACCCTGAAGTTGGCAACAGGTACCGGTGGCTCACTAG3’ 
βRev73-67   5’GGCCCGCCTCTGCTCCAGGA3’ 
StfFor 5’GGAGGCGGCCGCTTT TTG GATGGAGGAATTCATATG3’ 
StfRev 5’CTCACTAGTCGGGAAGACGTACGGGGTATACATGT3’ 
AichiFor 5’ATTCGCGGCCGCATGAAGACCATCATTGCTTTGAGCTACATTTTC3’ 
AichiRev 5’CTAATAACTAGTAATGCAAATGTTGCACCTAATGTTGCCTCTCTG3’ 
2467For 5’GGCCGCCCCAAGTATAGAAAGATGAACGCACGAAAGTTGGCAACAGGTACCGGTGGCTCA3’ 
2467Rev 5’CTAGTGAGCCACCGGTACCTGTTGCCAACTTTCGTGCGTTCATCTTTCTATACTTGGGGC3’ 
M4For 5’GGCCGCGGAGGTTATAGACAGATGTCAGCACCAACTTTGGGAGGCGGTACCGGTGGCTCA 3’ 
M4Rev 5’CTAGTGAGCCACCGGTACCGCCTCCCAAAGTTGGTGCTGACATCTGTCTATAACCTCCGC3’ 
YAKFor 5’GGCCGCGCCGCATATGCCGCAGCGGCTGCCGCAAAGGCTGCCGCAGGTACCGGTGGCTCA3’ 
YAKRev 5’CTAGTGAGCCACCGGTACCTGCGGCAGCCTTTGCGGCAGCCGCTGCGGCATATGCGGCGC3’ 
CIIFor 5’GGCCGCGCTGGGTTTAAGGGGGAACAGGGACCTAAAGGAGAGCCTGGTACCGGTGGCTCA3’ 
CIIRev 5’CTAGTGAGCCACCGGTACCAGGCTCTCCTTTAGGTCCCTGTTCCCCCTTAAACCCAGCGC3’ 
PKAFor 5’GGCCGCCCCAAGGCTGTTAAGCAAAACACCCTGAAGTTGGCAACAGGTACCGGTGGCTCA3’ 
PKARev 5’CTAGTGAGCCACCGGTACCTGTTGCCAACTTCAGGGTGTTTTGCTTAACAGCCTTGGGGC3’ 
LFor 5’GGCCGCGGAGGTGGAGGCTCCGGAGGTGGAGGCTCAGGAGGTGGAGGTACCGGTGGCTCA3’ 
LRev 5’CTAGTGAGCCACCGGTACCTCCACCTCCTGAGCCTCCACCTCCGGAGCCTCCACCTCCGC 3’ 
MBPNotI 5’GGAGGCGGCCGCGAAAACCCGGTTGTTCACTTCTTCAAAAACATCGTTACCCCGCGTGGTACCGGTGGCTCACTAGTGA3’ 
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2.4.1. Vector Construction 
DNA encoding a single-chain polypeptide consisting of the α-chain of DR1, the peptide 
HA306-318, and the β-chain of DR1 (Figure 2.1) was prepared by PCR amplification using primer 
pairs α-5BX and β-3XH and plasmid pJ3/238 (a gift from M. Mage, NIH, Bethesda, MD) as a 
template. The amplification product was cloned into pYD1 (Invitrogen, Carlsbad, CA) via BstXI 
and XhoI to generate pYD1scαHAβ. To facilitate plasmid construction of different peptides, a 
NotI restriction site was introduced by splicing overlapping extension PCR (SOE-PCR) [44]  to 
directly precede HA306-318 using primer pairs pYD1For/NotIRev and NotIFor/βRev73-67. The 
SOE-PCR product was cotransformed with the BstXI/SpeI fragment of pYD1scαHAβ
 
into 
EBY100 strain (Invitrogen) to generate pYD1αHAβ. To eliminate the possibility that the epitope 
HA306-318 identified from the peptide library was the undigested pYD1αHAβ, plasmid 
pYD1αSTFβ was constructed. The stuffer DNA (STF) is an unrelated gene (~1 kb) amplified 
from the phosphite dehydrogenase gene [39] using primers StfFor and StfRev. The PCR product 
was cloned into pYD1 via BstXI and XhoI to generate plasmid pYD1αSTFβ. Plasmids 
pYD1α2467β, pYD1αM4β, pYD1αYAKβ, pYD1αCIIβ, pYD1αPKAβ and pYD1αLβ were 
generated in two steps. First, the double stranded DNA insert encoding the peptide was obtained 
by hybridization of the sense and anti-sense oligonucleotides (Table 2.4) encoding the peptide. 
Second, the resulting DNA insert was phosphorylated by Optikinase (USB, Cleveland, OH), and 
ligated into the same restricted pYD1αSTFβ. Plasmid pYD1αMBPβ was generated in a slightly 
different way: the insert was obtained by annealing, extension and digestion of a self-annealing 
primer MBPNotI. All plasmids were transformed into chemical competent DH5α cells 
(University of Illinois Biochemistry Department’s Media Preparation Facility, Urbana, IL), 
64 
recovered, and confirmed by DNA sequencing. See Fei Wen Notebook 1, pp.22, 26, 46, 80 and 
Notebook 2, pp.16, 109-110. 
2.4.2. Yeast Transformation 
A single colony of EBY100 yeast strain was picked into 3 mL of YPAD (10 g/L yeast 
extract, 20 g/L peptone, 20 g/L glucose) and incubated on a rotary shaker at 250 rpm and 30 °C 
overnight. On the second day, the overnight culture was inoculated into 50 mL YPAD (this is 
enough for 10 transformations, scale down proportionally for less transformations) to a final 
OD600 of 0.2 and incubated at 200 rpm and 30 °C till OD600 reached at least 0.8. The cells were 
washed once with 25 mL of sterile ddH2O, once with 1 mL of 0.1M LiAc, and then resuspended 
in 400 µL of 0.1 M LiAc. 1 mL of ssDNA was boiled in a water bath for 5 min and chilled 
immediately on ice. The transformation mixture was prepared as following: 240 µL of PEG 
(50%w/v), 36 µL of 1 M LiAc, 50 µL of boiled ssDNA, 0.1-10 µg of plasmid DNA and sterile 
ddH2O was add to a final volume of 360 µL. The mixture was mixed extensively by vigorous 
vortexing, incubated at 42 °C for 40-60 minutes. The cells were spun down at 6000 rpm for 30 
seconds and the transformation mixture was carefully removed. The cell pellet was resuspended 
in 1 mL ddH2O gently with pipetting and 50-200 µL of the resuspension was plated on SD-CAA 
(2 % dextrose, 0.67 % yeast nitrogen base, 1 % casamino acids) plate and incubated at 30 °C for 
2-3 days. See Fei Wen Notebook1, pp. 35-38, 62-63. 
2.4.3. DNA Sequencing 
All DNA sequencing reactions were run following the protocols provided by the 
Biotechnology Center Core DNA Sequencing Laboratory at the University of Illinois at Urbana-
Champaign (Urbana, IL). Specifically, ~100-200 ng of plasmid or gel-purified PCR product, 5.2 
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µL of 12.5% glycerol, 2 µL of 2.5 mM primer, 2 µL of 5x sequencing reaction buffer, and 1 µL 
of BigDye V3.1 (Applied Biosystems, Foster City, CA) were added into a PCR tube and the final 
reaction volume was adjusted to 13 µL with ddH2O. The reaction was carried out using MJ 
Research PTC-200 thermocycler (Bio-Rad, Hercules, CA): 96 °C 2 min, 24 cycles of 96 °C 30 
sec, 50 °C 15 sec and 60 °C 4 min. See Fei Wen Notebook 1, pp. 88. 
2.4.4. Yeast Surface Display   
S. cerevisiae EBY100 clones transformed with different plasmid constructs were grown 
in SD-CAA at 30 ºC for ~20 h or till OD600 reached ~5. To induce AGA2 fusion protein 
expression, yeast cells were washed twice (benchtop centrifuge at 6000 rpm for 1 min) with YPG 
medium (10 g/L yeast extract, 20 g/L peptone, 20 g/L galactose), resuspended to an OD600 ~1.0 
in YPG medium supplemented with 50 µg kanamycin in a glass tube and incubated on a rotary 
shaker at 20 ºC and 250 rpm for ~48 hours. The induced yeast cells were stored at 4 ºC up to 4 
months. See Fei Wen Notebook 1, pp. 98-99. 
2.4.5. Flow Cytometry Analysis 
For flow cytometric analysis, ~2.5×106 cells were washed with phosphate buffered saline 
(PBS) containing 0.5% bovine serum albumin (BSA) and incubated for 1 h at 4 ºC with the 
primary antibody staining reagent at a 100-fold dilution rate. The antibodies used were LB3.1 
(American Tissue Culture Collection (ATCC), Manassas, VA) and anti-V5 (Invitrogen). Cells 
were washed with PBS containing 0.5% BSA and incubated for 1 h at 4 ºC with biotinylated 
goat-anti-mouse (GAM) IgG (Rockland, Gilbertsville, PA) followed by streptavidin- 
phycoerythrin (SA-PE) for 30 min at 4 ºC. After washing away unbound SA-PE, labeled yeast 
cells were analyzed on a Coulter Epics XL flow cytometer at the Biotechnology Center of 
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University of Illinois at Urbana-Champaign (Urbana, IL). See Fei Wen Notebook 1, pp. 102. 
2.4.6. Extraction of Aga2-DR1-peptide Complexes from Yeast Cell Surface 
About 2.5 ×108 yeast cells were incubated for 1-2 h with 1 mL of 5 mM TCEP-neutral in 
PBS (EMD Biosciences, Inc. San Diego, CA) at 37 ºC and 200 rpm. The reaction mixture was 
spun down at maximum speed for 5 minutes to remove the cells. The supernatant containing the 
Aga2-DR1-peptide
 
fusion protein was dialyzed against PBS at 4 ºC overnight with gentle mixing 
and used for subsequent analysis. See Fei Wen Notebook 1, pp. 14, 139. 
2.4.7. Thermostability Assay 
The thermostability of the peptide-DR1 variants was monitored directly on the yeast cell 
surface as described elsewhere [21]. Briefly, samples of 4x106 yeast cells were incubated at 
temperatures of 60, 70, 75, 80, 85, or 90 ºC for ten minutes. Immediately after the incubation 
period, the samples were put on ice and protein denaturation was halted with ice-cold PBS 
containing 0.5% BSA. Yeast cells were spun down and the fraction of folded DR1 protein was 
determined by incubation with conformation-sensitive LB3.1 antibodies followed by 
biotinylated-labeled GAM IgG and SA-PE as described in Section 2.4.5. For each construct, 
three individual yeast clones were examined. Thermal denaturation curves were generated and 
the T50 values (temperature at which half-maximal denaturation occurred) were calculated. See 
Fei Wen Notebook 1, pp. 111, 135. 
2.4.8. Western Blot 
Protein standards, Powerpac 300 power supply, Mini-PROTEAN 3 assembly, sodium 
dodecyl sulfate (SDS), and pre-cast 4-20% acrylamide gels were purchased from Bio-Rad 
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(Hercules, CA). 24 µL of concentrated protein sample extracted from yeast surface was mixed 
with 6 µL of SDS-PAGE loading buffer (50% glycerol, 5% SDS, 10 mg bromophenol blue, 0.5 
M Tris-HCl, 5mM EDTA, pH 6.8).  Samples were denatured at 95 ºC for ten minutes, cooled to 
4 ºC, and then loaded onto the gel in a Bio-Rad Mini-PROTEAN 3 assembly. Voltage was 
supplied by a Bio-Rad Powerpac 300 at constant 120 V for 90 minutes.  The proteins were then 
transferred to a polyvinylidene fluoride (PVDF) membrane using the Mini Trans-Blot Cell and a 
voltage of 100V for 1 hour.  The PVDF membrane was then blocked with the blocking buffer 
(3% non-fat milk in PBS) overnight. The primary antibody V5 was added to 15 mL of blocking 
buffer at a 1:2500 dilution and the membrane was incubated at room temperature for ~1.5 hours. 
The membrane was then washed with PBST (PBS with 0.05% TWEEN-20) 3-4 times over a 
period of 10 minutes. A secondary antibody, alkaline phosphatase-conjugated GAM IgG 
(GAMAP), was added at a dilution of 1:4000 in 15 mL blocking buffer and the membrane was 
incubated at room temperature for ~1 hour. The membrane was then washed extensively to 
remove unbound GAMAP IgG over a period of 20 minutes. The western blot substrate buffer was 
added and the membrane to equilibrate for ~1 minute; and subsequently 330 µL of 10 mg/mL 
nitro blue tetrazolium chloride (NBT) in dimethyl formamide and 175 µL of 10 mg/mL 5-bromo-
4-chloro-3’-indolyl-phosphate p-toluidine (BCIP) in dimethyl formamide were added to 10 mL 
of substrate buffer. The membrane was then allowed to develop till the bands appear, after which 
the NBT/BCIP reaction was stopped by rinsing with distilled water several times. See Fei Wen 
Notebook 1, pp. 2, 155. 
2.4.9. Library Construction   
DNA encoding haemagglutinin was obtained by one-step RT-PCR using influenza 
A/Aichi/2/68 viral RNA (a gift from Dr. R. Donis at CDC, Atlanta, GA) as the template and 
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AichiFor and AichiRev as primers. The PCR-amplified DNA encoding haemagglutinin was 
fragmentized using DNaseI (0.075 U/µg DNA for 1 minute) as described elsewhere [45].  DNA 
fragments with size between 30-60 bp were collected and purified from agarose gel, blunt-end 
polished as described [46], and ligated into similarly prepared SpeI and NotI restricted 
DR1αSTFβ vector. The ligation mixture was transformed into ElectroMax DH5α competent 
cells (Invitrogen) and a library of 4.6×105 clones was obtained.  Plasmids were then recovered 
and transformed into EBY100 and a library of 2.1×106 clones was generated.  After two passages 
in the selection media, the library was induced for protein expression using YPG and subjected 
to FACS. The difficulties in cloning small pieces of DNA include: (1) optimization of DNaseI 
digestion step to have majority of the digested DNA fragments within a desired size range; (2) 
intramolecular circularization, which results in high ligation background; (3) occurrence of 
multiple inserts, which result in splicing peptides that are not present in the natural peptide 
repertoire. Accordingly, when constructing the peptide library, it is important to (1) optimize 
DNaseI concentration and digestion time; (2) dephosphorylate the vector and include 15%PEG 
in the ligation mixture to promote intermolecular ligation over intramolecular circularization 
[47]; (3) optimize insert to vector molar ratio. See Fei Wen Notebook 2, pp. 130, 189, 196, 202-
205, 233, 237, 240. 
Genomic RNA purified from influenza virus X31/A/Aichi/68 (Charles River Laboratories, 
Wilmington, MA) was used as the template for cDNA synthesis. First strand cDNA was 
synthesized using a first stand cDNA synthesis kit following the manufacturer’s protocol for 
random priming (Roche, Indianapolis, IN). DNA polymerase I (5 U / 20 µL reaction) and RNase 
H (0.16 U / 20 µL reaction) were then used to synthesize double-stranded cDNA. The cDNA 
encoding the antigenic protein/proteins was fragmented using DNase I (0.075 U/µg DNA for 1 
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minute) as described elsewhere [45]. DNA fragments with size between 30-60 bp were collected 
and purified from agarose gel, blunt-end polished as described [46], and ligated into SpeI and 
NotI restricted pYD1αSTFβ vector that was similarly blunt-end polished. The ligation mixture 
was transformed into ElectroMax DH5α competent cells (Invitrogen, Carlsbad, CA) and a 
library of 1.9×106 clones was obtained. Plasmids were then recovered and transformed into 
EBY100 and a library of 6.6×106 clones was generated. After two passages in selection media, 
the library was induced for protein expression using YPG and subjected to FACS. See Fei Wen 
Notebook 3, pp. 76-78, 86, 89-90, 112, 119, 121. 
2.4.10. FACS Analysis of Yeast Library 
The library of yeast clones displaying DR1 in complex with different peptides derived 
from haemagglutinin was enriched through three cycles of FACS. An aliquot of induced library 
culture containing 7.4x106 yeast cells was stained with LB3.1 followed by treatment with biotin-
conjugated GAM IgG and SA-PE as described in Section 2.4.5 and sorted by a Coulter 753 
bench FACS (Flow Cytometry Facility, University of Illinois at Urbana-Champaign). About 
1.3% of the population with the highest fluorescence was collected and recovered for the next 
round of cell sorting. During the second and third round screening, the top 0.5% of the 
population was collected from the previous sorted library. Cells from the top 0.05% population 
of the enriched library were sorted into a 96-well plate. Ten of these cells were randomly picked 
and analyzed individually for their ability to stimulate T cell hybridoma. DNA sequencing was 
carried out to determine the sequence of the peptide insert. See Fei Wen Notebook 2, pp. 242-246, 
249. 
The library of yeast clones displaying DR1 in complex with different peptides derived 
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from the influenza A virus genome was enriched through two cycles of FACS.  An aliquot of 
induced library culture containing 108 yeast cells was stained with LB3.1 followed by treatment 
with biotin-conjugated GAM IgG and SA-PE as described in Section 2.4.5 and sorted by a 
Coulter 753 bench FACS at the Biotechnology Center of the University of Illinois (Urbana, IL). 
About 1.5% of the population with the highest fluorescence was collected and recovered in the 
first round of cell sorting. In the second round of cell sorting, cells from the top 0.5% of the 
population were sorted into four 96-well plates and analyzed individually for their ability to 
stimulate T-cell hybridoma. Two more rounds were carried out in the same manner. See Fei Wen 
Notebook 3, pp. 122-130. 
2.4.11. Stimulation of HA1.7 T Cell Hybridomas and IL-2 Detection   
The HA1.7 hybridoma T cells [24] were used as an indicator cell line for productive 
MHC-peptide-TCR interactions that produce IL-2 upon receptor engagement. They were 
maintained in IMDM (Invitrogen) with 10% fetal bovine serum (FBS) at 37 ºC with 5% CO2.  
About 106 yeast cells were washed once with 300 µL PBS, resuspended in 300 µL PBS and 
loaded into each well of a 96-well tissue-culture plate. After incubation at 4 ºC overnight, 
unattached yeast were washed off three times with 350 µL PBS.  HA1.7 hybridoma cells were 
added to wells (105 cells per well) and incubated for ~24 h at 37 ºC with 5% CO2. The 
supernatant was tested for IL-2 production using a murine IL-2 ELISA kit (eBiosciences, San 
Diego, CA). See Fei Wen Notebook 1, pp. 136-137,143.   
In some experiments, soluble Aga2-DR1-peptide complexes released from yeast cell 
surface were added into wells pre-coated with rabbit anti-V5 polyclonal antibodies and incubated 
overnight at 4 ºC. The peptide-DR1 protein was immobilized onto the plate by binding to anti-
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V5 antibodies adsorbed to the wells. 105 HA1.7 hybridoma cells in 300 µL of IMDM medium 
were added into the each well and incubated for ~24 h at 37ºC with 5% CO2. The amount of 
interleukin-2 (IL-2) produced by the hybridoma was quantified using a murine IL-2 detection 
sandwich enzyme-linked immunosorbent assay kit (eBiosciences, San Diego, CA). See Fei Wen 
Notebook 1, pp. 142-143.   
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Chapter 3. In vitro Evolution of pMHC Complexes with High 
Affinity toward TCRs Using Cell Surface Display 
3.1. Introduction 
Identification and quantitative analysis of antigen-specific T cell populations is important 
in studying T cell behavior, cellular immune responses, and immune memory development [1-3]. 
Until recently, these analyses were possible only based on T cell functions, such as proliferation, 
cytotoxicity, and cytokine secretion [1]. These function-based assays have several limitations. 
First, they require in vitro stimulation of T cells, thus significantly alter the T cell differentiation 
status making them not suitable for downstream experiments [4]. Second, they generate varying 
results between experimental runs, and probably underestimate the true number of antigen-
specific T cells [1]. Third, they are carried out in vitro, thus not applicable for studying T cell 
behavior in the native environment. To address these issues, a structure-based assay, in which T 
cells are directly identified by virtue of their antigen-binding specificity, has been developed 
− pMHC tetramer staining.  
Due to the natural low affinity (typically in a range of 1-100 µM) between TCR and its 
pMHC ligand [5], a pMHC monomer cannot be used as a staining reagent to detect antigen-
specific T cells. The pMHC tetramer staining technology overcame this obstacle by using 
multimerized pMHC molecules (normally in the form of tetramers), which bind T cells stably as 
a result of multivalent interactions [6]. More importantly, multimerization of biotinylated pMHC 
monomers using fluorescently labeled streptavidin allows the use of high throughput flow 
cytometry for fast and accurate T cell isolation and phenotype analysis. Since the development 
in 1996, the use of pMHC tetramers has enabled direct detection [6] and identification [7] of 
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antigen-specific T cells, modulation of T cell responses in vivo to treat graft rejection [8] and 
autoimmune diseases [9], and detailed monitoring of cellular immune responses induced by 
immunotherapy, which is critical for a better understanding of tumor immunology and 
improving immune-based therapies [10]. 
Although the development of the pMHC tetramer staining technology has revolutionized 
the field of T cell research, it has some drawbacks. First, it has been reported that the binding 
avidity of the pMHC tetramer is directly proportional to the binding affinity of the pMHC 
monomer [11], therefore, there exists a lower limit of the TCR affinity that can be detected by 
using pMHC tetramers. In addition, compared to MHCI restricted CD8+ T cells, MHCII 
restricted CD4+ T cells occur at a much lower frequency and bind pMHCII tetramers with a 
lower avidity, making the detection of CD4+ T cells even more difficult [12]. Second, the 
production of MHC monomers using recombinant techniques has been proven to be difficult, 
especially in the case of MHCII proteins [12]. Third, the preparation of the pMHC tetramer 
involves multiple protein purification and modification steps, making the process time-
consuming and labor-intensive. To address the limitations associated with the pMHC tetramer 
staining technology, the goal of this project is to engineer pMHC monomers with high TCR-
binding affinity so that the resulting pMHC mutants can be used directly for T cell staining 
without being tetramerized. In addition, the pMHC tetramer made of the resulting mutants 
should in theory exhibit higher avidity for target TCRs, thus improve the T cell detection 
sensitivity. 
In this chapter, we report the results of pMHC affinity engineering using two different 
cell surface display systems: yeast surface display (Section 3.2.1-3.2.3) and insect cell surface 
display (Section 3.2.4-3.2.7). Using the yeast surface display system, the pMHC complexes 
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failed to show any TCR-tetramer-binding, indicating that this system was not suitable for 
engineering pMHC with improved TCR-binding affinity. In contrast, pMHC complexes 
displayed on insect cell surface showed specific and peptide-dependent TCR-tetramer-binding. 
Coupled with directed evolution and fluorescence-activated cell sorting (FACS), a library of 
pMHC complexes was created and screened using R-Phycoerythrin (PE)-labeled TCR tetramers. 
After one round of cell sorting, potential variants with improved TCR-binding affinity have been 
enriched.  
3.2. Results and Discussion 
3.2.1. Cloning, Expression, and Purification of DR1-HA-specific TCR 
To engineer pMHC complexes with high TCR-binding affinity, their specific TCR 
tetramers are required for library screening due to the unstable interaction between pMHC and 
TCR monomers as described above. With the successful functional display of single-chain wild-
type DR1-HA306-318 protein on yeast surface, we sought to produce the HA1.7 TCR specific for 
DR1-HA complex. An initial attempt to produce single-chain HA1.7 TCR with a C-terminal 
fusion of a human constant kappa domain (huCκ) and co-expression of a chaperon skp [13] did 
not yield any soluble TCR expression in E. coli. This result indicated the limited applicability of 
the reported expression system. Therefore, the baculovirus-insect expression system was chosen 
next since it has been successfully used to produce a wide range of complex proteins, including 
TCRs [14-17]. 
HA1.7 TCR extracellular α- and β-chain encoding genes [18] with a BirA tag fused to 
the C-terminus of β-chain were expressed under the control of ph and p10 promoters, 
respectively. TCR protein expression using baculovirus infected Sf9 insect cells was analyzed by 
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ELISA. A set of four monoclonal antibodies (mAbs) raised against different epitopes of the 
natural membrane-anchored receptor was used: H28-710 and ADO-304 that are specific for two 
different epitopes in murine constant α-chain [15, 19], H57-597 that specifically binds the FG-
loop of murine constant β-chain [20], and a clonotypic mAb specific to the variable region of 
human β3 TCR [21]. As shown in Figure 3.1, the soluble TCR reacted with all four mAbs, 
indicating a successful expression of HA1.7 TCR.  
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Figure 3.1 ELISA analysis of HA1.7 TCR expression. Four monoclonal antibodies, H28-710, ADO-304, 
H57-597, and anti-Vβ3.1 were used in the assay. The supernatant absorbance of insect cells infected with 
baculovirus containing empty bacmid was normalized to zero.   
After optimizing the infection and protein expression conditions, the HA1.7 TCR was 
purified from 1 L of cell culture supernatant using H57-597-coupled sepharose beads. 
Unfortunately, the TCR expression level was too low to be detected by SDS-PAGE and resulted 
in contamination of H57-597 mAb in the eluate (data not shown). To further improve the protein 
expression level, a different insect cell line High Five, which has been reported to have ~5-10 
fold higher secreted expression level than Sf9 cells [22], was used. By using a lower expression 
temperature of 19 °C, the TCR expression level was improved by ~7-fold (data not shown), but 
it still required a large scale protein expression to obtain enough TCR for tetramer preparation. 
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Fortunately, another TCR – Ob.1A12 specific for DR2-MBP85-99 complex (a kind gift from K.W. 
Wucherpfennig, Harvard Medical School) became available, thus we decided to engineer DR2 
variants with high Ob.1A12 TCR-binding affinity.  
DR2 is a human MHCII protein and has been associated with susceptibility to multiple 
sclerosis (MS) [23]. The peptide MBP85-99 (residues 85-99 of myelin basic protein, MBP) is a 
candidate antigenic epitope and T cells specific for the DR2-MBP85-99 complex have been shown 
to be reactive to myelin [24]. To display the wild-type DR2-MBP complex on yeast cell surface 
for affinity engineering, the single-chain strategy was employed as described in Section 2.2.1 
(see Figure 2.1 and Figure 3.2b). In contrast to the results as seen for DR1-HA306-318, co-
expression of a covalently attached binding peptide did not enable the display of correctly folded 
wild-type DR2 (data not shown), thus directed evolution experiment was conducted next to 
improve its surface expression level. 
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Figure 3.2. Engineering of correctly folded DR2 using directed evolution and yeast surface display. (a) 
FACS enrichment of DR2-MBP variants with improved surface display level as indicated by increased 
staining intensity of LB3.1 antibody. (b) Sequence alignment of the evolved variants with the wild-type 
DR2-MBP. The number of independent isolates of each clone is shown in parentheses. P=MBP85-99 
peptide 
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3.2.2. Engineering of Folded DR2 Using Yeast Surface Display 
A library of DR2-MBP variants was created by error-prone PCR (EP-PCR) and screened 
by FACS using the conformation sensitive antibody, LB3.1. As shown in Figure 3.2a, after two 
rounds of cell sorting, there was a modest enrichment of variants with improved expression level, 
and a distinct positive population was observed after the third round. Twelve clones were 
randomly selected and sequenced. The alignment with the wild-type DR2-MBP
 
sequence 
revealed two interesting mutations (Figure 3.2b): the first one was a proline to histidine 
mutation at β11 position (Pβ11H was present in seven of the twelve isolated clones), which was 
also found to be important in the proper folding of DR1 as shown in a previous study [25]; the 
second one was a phenylalanine to tyrosine mutation at the P4 position of the MBP peptide 
(MBPF4Y), which was shown to favor aromatic as well as aliphatic residues [24, 26].  
To minimize the number of introduced mutations thus their potential of altering TCR 
interaction, three single mutants were constructed: DR2
 Pβ11H-MBP, DR2 Pβ11R-MBP (our earlier 
experiments showed that Pβ11R mutation was able to improve the DR1 expression level), and 
DR2
 
-MBPF4Y. As shown in Figure 3.3, Pβ11H substitution significantly improved the
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Figure 3.3 Surface expression levels of correctly folded DR2-MBP variants with single mutations. 
Monoclonal LB3.1 antibody was used for staining. P1 indicates the positive staining region. 
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expression level of folded DR2 protein, while Pβ11R and MBPF4Y mutations only had a modest 
effect. With the success of displaying properly folded DR2 protein on yeast cell surface, further 
affinity engineering experiment was carried out next using DR2
 Pβ11H-MBP as the template. 
3.2.3. Affinity Engineering of DR2-MBP85-99 Complexes Using Yeast Surface Display 
Although the directed evolution experiment yielded a mutant DR2
 Pβ11H-MBP that 
strongly reacted with a conformation sensitive antibody, yeast cells displaying this mutant 
complex failed to activate DR2-MBP-specific O7678 T hybridoma cell or to bind the Ob.1A12 
TCR tetramer (data not shown). To exclude the possibility that the
 
Pβ11H mutation might have 
abolished the pMHC-TCR interaction, additional three mutants DR2-MBPV1I, DR2-MBPF4W, and 
DR2-MBPV1I-F4W, which contain peptides with better DR2-binding affinity than the wild-type 
MBP (H. Zhao and K.W. Wucherpfennig personal communication), were created. However, all 
of them showed similar expression levels as DR2-MBPF4Y (data not shown).  
Since the goal was to engineer DR2 variants with improved TCR-binding affinity, one 
round of directed evolution was carried out to test if any positive mutants could be obtained. A 
library of ~2.7×105 DR2-MBP variants was created and screened using the Ob.1A12 TCR 
tetramer. After three rounds of enrichment, no improvement of the fluorescence signal was 
observed (data not shown). These results indicated that the yeast surface display was not suitable 
for engineering DR2 variants with improved TCR-binding affinity, probably due to the low 
binding affinity between DR2-MBP and Ob.1A12 TCR [27]. Recent studies have shown that 
pMHC complexes displayed on insect cell surface could activate T cells and bind TCR tetramers 
stably [28]. Therefore, we sought to use insect cell surface display system to engineer DR2 
variants with improved TCR-binding affinity. 
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3.2.4. Insect Cell Surface Display of Wild-type DR2-MBP85-99  Complexes 
Two different types of anchors, gp64 and VSVG, are commonly used for displaying 
proteins on insect cell surface [29, 30]. Using the single-chain strategy, both of the scDR1-HA-
gp64 and scDR1-HA-VSVG polypeptides were successfully displayed as indicated by LB3.1 
antibody staining (Figure 3.4a). Although the surface expression levels of both constructs were 
similar, the scDR1-HA-VSVG construct activated HA1.7 T hybridoma cell more potently than 
scDR1-HA-gp64 (data not shown). Therefore, VSVG was used as the anchor protein in the 
display constructs described henceforward. Consistent with the results of yeast surface display 
system, the scDR2-MBP-VSVG construct showed a much lower surface expression level than 
scDR1-HA-VSVG (Figure 3.4a). Nevertheless, the ability of insect cells to express the wild-
type scDR2-MBP without introducing any mutations suggested that this higher eukaryotic 
system was more suitable for expressing MHC proteins. 
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Figure 3.4 Insect cell surface display of pMHC constructs. (a) Histogram overlay of scDR1-HA-gp64 
(red), scDR1-HA-VSVG (blue), scDR2-MBP-VSVG (lime), and empty bacmid (black). The 
conformation sensitive antibody LB3.1 was used as the primary staining reagent to detect correctly folded 
DR proteins. (b) Expression level comparison of non-covalent heterodimeric and single-chain DR2 
constructs: LZ=leucine zipper dimerization motifs, sc=single-chain, w/ (w/o) = co-expression with 
(without) a covalently attached MBP peptide, PFB = empty bacmid.  
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To improve the surface expression level of the DR2-MBP complex, the leucine zipper 
dimerization motifs from transcription factors Fos and Jun [31] were fused to the C-terminus of 
DR2α- and DR2β-chain, respectively. The DR2α-Fos and DR2β-Jun-VSVG (with or without a 
MBP85-99 peptide covalently attached to the N-terminus of DR2β−chain) constructs were co-
expressed in insect cells under the control of ph and p10 promoters, respectively. As shown in 
Figure 3.4b, the leucine zipper dimerization motifs significantly improved the surface display 
level of properly assembled DR2 heterodimers compared to single-chain constructs. In addition, 
the presence of a covalently attached MBP85-99 peptide further increased the DR2 heterodimer 
expression, consistent with the stabilizing effect of a binding peptide observed in our previous 
study ([25, 32] and Chapter 2).  
3.2.5. Functional Analysis of the DR2-MBP85-99 Complexes Displayed on Insect Cell 
Surface 
To test the function of the insect cell surface displayed DR2 protein, T cell activation 
analysis using DR2-MBP-specific O7678 T hybridoma cells was conducted by incubating insect 
cells directly with hybridomas. As shown in Figure 3.5, the empty DR2 (LZ-DR2) heterodimer 
was capable of binding MBP85-99 peptide and induced IL-2 secretion by O7678 cells in a peptide-
dependent manner. The DR2 heterodimer with a covalently linked MBP85-99 peptide (LZ-DR2-
MBP) also activated O7678 cells, but to a lesser extent. Surprisingly, although the expression 
levels of the leucine zipper DR2 constructs were much higher than those of single-chain DR2 
constructs, their IL-2 induction levels were only ~2-fold higher than those induced by single-
chain constructs (data not shown). This result may indicate that the T cell activation threshold 
that provides maximal sensitivity is at low antigen levels [33]. Taken together, these data clearly 
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suggested that both the empty DR2 and DR2-MBP complex displayed on the insect cell surface 
were functional. To avoid in vitro peptide loading, the LZ-DR2-MBP construct was used in the 
following TCR staining assay and affinity engineering. 
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Figure 3.5 Functional analysis of insect cell surface displayed non-covalent DR2 heterodimers. The DR2-
MBP-specific O7678 T hybridoma cells were incubated with Sf9 insect cells displaying DR2 with LZ-
DR2-MBP or without LZ-DR2)-MBP85-99 peptide covalently attached. The activation was indicated by IL-
2 secretion in the supernatant monitored using ELISA at 650 nm.  
3.2.6. Detection of Insect Cell Surface Displayed DR2-MBP85-99 Complexes with Specific 
TCR Tetramers 
With the success of displaying a functional wild-type DR2-MBP85-99 complex on insect 
cell surface, its ability to bind the specific Ob.1A12 TCR tetramer was tested next. Insect cells 
displaying single-chain DR1-HA306-318 complexes (scDR1-HA) and empty DR2 heterodimers 
(LZ-DR2), both of which showed similar DR display levels as LZ-DR2-MBP (Figure 3.6a), 
were used as negative controls. As shown in Figure 3.6b, PE-labeled Ob.1A12 TCR tetramers 
bound to insect cells displaying LZ-DR2-MBP, but not to the negative control cells. The 
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fluorescent staining signal-to-noise ratio was ~4 (Figure 3.6c). Such low level of staining was 
expected based on the reported Biacore study with purified Ob.1A12 TCR and DR2-MBP [27]. 
After optimizing the staining conditions, the signal-to-noise ratio was improved to ~12 (data not 
shown) using 25 µg/mL TCR tetramer and incubation temperature of 27 °C. These results 
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Figure 3.6 Detection of insect cell surface displayed DR2-MBP complex with Ob.1A12 TCR tetramers. 
(a) Histogram overlay of cells expressing scDR1-HA, LZ-DR2, LZ-DR2-MBP, and empty bacmid (PFB) 
stained with LB3.1 antibody. (b) Dot plots of TCR tetramer staining of insect cells displaying three 
different constructs. Positive staining events were shown in the red box. (c) A bar diagram of the TCR 
tetramer staining results. The fluorescence staining intensity was measured as mean fluorescence units 
(MFU) from (b).  
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suggested that the DR2-MBP complex displayed on the insect cell surface was capable of 
binding specific TCR tetramers in an epitope-dependent manner. Coupled with directed 
evolution and FACS, DR2 variants with improved TCR-binding affinity could be readily 
identified from a mutagenesis library in a high throughput manner.  
3.2.7. Affinity Engineering of DR2-MBP85-99  Complexes Using Insect Cell Surface Display  
A random mutagenesis library of DR2 was created using the Bac-to-Bac baculovirus 
expression system [34]. To minimize the possibility of altering peptide specificity and maintain 
the function of leucine zipper dimerization motifs, mutations were introduced into the DR2α- 
and DR2β-encoding regions using EP-PCR. A library of 3.1x106 DH5α clones was created, from 
which the plasmids were recovered and transformed into DH10Bac. Following blue-and-white 
screening, ~7000 transformants containing recombinant bacmids were selected, pooled together, 
and grown overnight. The recombinant bacmid DNA was then isolated and used to transfect 
insect cells, generating a display library of DR2 variants in complex with the MBP85-99 
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Figure 3.7 Affinity engineering of DR2 variants with improved TCR-binding affinity. (a) Surface 
expression level of correctly folded DR2 variants in the primary library. (b) FACS enrichment of DR2 
variants with improved TCR-binding affinity. Ob.1A12 TCR tetramer was used to stain the library. 
Comparison between the histogram of the library before enrichment (black) and that after one round of 
cell sorting (red) indicated that potential DR2 variants with improved TCR-binding affinity were 
enriched. 
88 
peptide. The expression levels of correctly folded DR2 variants (Figure 3.7a) were comparable 
to that of the wild-type DR2-MBP (Figure 3.6a), suggesting that the mutation rate (~2 amino 
acid change per gene) was well tolerated for DR2 protein folding. The DR2-MBP-specific 
Ob.1A12 TCR tetramer was used as the staining reagent for sorting the library, and one round of 
enrichment has been completed. As shown in Figure 3.7b, the fluorescence peak shift indicated 
that potential DR2 variants with improved TCR-binding affinity were successfully enriched. 
Further rounds of enrichment are in process. 
3.3. Conclusions and Outlook  
The pMHC tetramer staining technology has overcome the major limitations associated 
with function-based T cell assays and enabled in vivo T cell analyses. However, pMHC tetramers 
are very time-consuming and labor-intensive to prepare and often show low avidity. To address 
these limitations, we sought to engineer pMHC monomers with high TCR-binding affinity. 
Using the DR2-MBP85-99 complex implicated in multiple sclerosis as the engineering target, a 
random mutagenesis library was created and screened using two different cell surface display 
systems − yeast surface display and insect cell surface display. The former system failed to 
express functional wild-type DR2-MBP complex. Although a folded mutant DR2
 Pβ11H-MBP was 
identified through directed evolution, it failed to activate DR2-MBP-specific T hybridoma cell or 
to bind the Ob.1A12 TCR tetramer. Using the DR2
 Pβ11H-MBP as the template for EP-PCR 
library creation and the Ob.1A12 TCR tetramer as the staining reagent for library screening, no 
positive mutants were isolated. Therefore, yeast surface display was not a suitable system for 
engineering DR2-MBP with improved TCR-binding affinity. 
89 
In contrast, the wild-type DR2-MBP complex was successfully displayed on insect cell 
surface and was capable of activating specific T hybridoma cell. More importantly, the surface 
displayed DR2-MBP complex bound the Ob.1A12 TCR tetramers in an epitope-dependent and 
specific manner, providing us a high throughput screening method for directed evolution 
experiments. After one round of cell sorting, potential DR2 variants with improved TCR-binding 
affinity have been successfully enriched from a random mutagenesis library. Currently, further 
enrichment is in process. 
Once a distinct fluorescence peak shift is observed (typically require another 2-3 rounds 
of cell sorting), the future work should focus on further improvement and characterization of the 
isolated mutants. Specifically, individual mutants will be isolated and analyzed to identify the 
“hot spots” affecting the pMHC-TCR binding, which could then serve as the target sites for 
saturation mutagenesis study. Alternatively, DR2 residues that form direct contact with the TCR 
could be identified from the solved crystal structure (PDB accession code: 1YMM) and 
mutagenized to further improve the TCR-binding affinity. The resulting mutants will then be 
examined for their antigen-binding specificity, TCR-binding affinity and kinetics, and T cell 
staining and function.  
Since the library creation and screening using insect cell surface display is quite time-
consuming compared to yeast surface display, the resulting mutants isolated from the studies 
described above should be tested using the latter system to check if it is feasible to be used to 
conduct further engineering work. In theory, TCR tetramer staining should be observable if the 
pMHC exhibits affinity above a certain threshold [33]. Using the yeast surface display system, 
the affinity engineering study could be significantly accelerated. If successful, such engineered 
high affinity pMHC complexes may provide a new class of diagnostic reagents capable of 
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monitoring disease progression and T cell therapy efficacies. In addition, they may be used as 
novel reagents to treat infectious diseases and prevent autoimmunity, and the engineered MHC in 
complex with antagonist might be used as an immune suppressor to treat established 
autoimmunity. 
3.4. Materials and Methods 
The primer sequences are listed in Table 3.1. All restriction enzymes were purchased 
from New England Biolabs (Ipswich, MA). Unless otherwise indicated, all chemicals were 
purchased from Sigma (St. Louis, MO). 
Table 3.1 Primers used in this study. 
Name Sequences 5’→3’ 
TAFor TATAAGGCCCAGCCGGCCATGCTCCTGCTGCTCGTCCCAGTG 
TARev GGAGCCTCCACCTCCTGAGCCTCCACCTCCGGAGCCTCCACCTCCTGAGCCTCCACCTCCTATGATGGTGAGTCTTGTTCCAGT 
TBFor GGAGGTGGAGGCTCAGGAGGTGGAGGCTCCGGAGGTGGAGGCTCAGGAGGTGGAGGCTCCATGGGAATCAGGCTCCTCTGTCGT 
TBRev GAATTCGGCCCCCGAGGCCCCCTCTACAACGGTTAACCTGGTCCC 
BamHIalphaFor CGCGGATCCATGCTCCTCCTGCTCGTCCC 
EcoRIalphaRev TTTGAATTCTTAAACTGACAGGTTTTGAAAG 
BamHIbetaFor CGCGGATCCATGGGAATCAGGCTCCTCTGTCG 
EcoRIbetaRev TTTGAATTCTCAGTCCCGCAGCTCCATCTTCAT 
M13For GTTTTCCCAGTCACGAC 
M13Rev CAGGAAACAGCTATGAC 
NotICIIFor AGAGACGGCGGCCGCATCGCTGGCTTTAAAGGCGAGCAGGG 
DR4betaXhoIRev TCCACCCTCGAGAGCAGATTCAGACCGTGCTCTCC 
SpeIDR2betaFor GGCTCACTAGTGCCACGGGGCTCTGGAGGAGGTGGGTCCGGGGACACCCGACCACGTTTCCTGTGGCAGCCTAAGAGGGAGTGTCATTTCTTCAATGGG 
DR4betaXhoIRev TCCACCCTCGAGAGCAGATTCAGACCGTGCTCTCC 
pYD1For AGTAACGTTTGTCAGTAATTGC 
pYD1Rev GTCGATTTTGTTACATCTACAC 
P11RRev CCCATTGAAGAAATGACACTCCCTCTTGCGCTGCCACAGGAAACGTGGTCGGG 
P11HRev CCCATTGAAGAAATGACACTCCCTCTTATGCTGCCACAGGAAACGTGGTCGGG 
MBPF4YFor 
 
GGCTCAGGAGGCGGCCGCGAAAACCCGGTTGTTCACTTCTACAAAAACATCGT
TACCCCGCGTGGTACC 
DR2-XhoIRev TCTAGACTCGAGCTTGCTCTGTGCAGATTCAGACCGTGCTCTCCATTCC  
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Table 3.1 continued  
Name Sequences 5’→3’ 
MBPF4WFor GGCTCAGGAGGCGGCCGCGAAAACCCGGTTGTTCACTTCTGGAAAAACAT
CGTTACCCCGCGTGGTACC 
MBPV1IFor GGCTCAGGAGGCGGCCGCGAAAACCCGGTTATCCACTTCTTCAAAAACAT
CGTTACCCCGCGTGGTACC 
MBP1I-4WFor GGCTCAGGAGGCGGCCGCGAAAACCCGGTTATCCACTTCTGGAAAAACAT
CGTTACCCCGCGTGGTACC 
gp64SFor GGGCGCGGATCCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCG
GCGGCGCATTCTGCCTTTGCGAAAGAAGAACATGTGATCATCCAGGCCG 
gp64TMRev GCCTTTGAATTCTTAATATTGTCTATTACGGTTTCTAATCATACAGTACAAA
AATAAAATCACAATTAATATAATTACAAAGTTAACTACATGACCAAACAT
GAAGAAGGGCCCTCTAGACTCGAGCTTGCTCTGTGCAGATTCAGATCG 
VSVG1Rev GATTAACCCTATGATAAAGAAAAAAGAGGCAATAGAGCTGAAGGGCCCTC
TAGACTCGAG 
VSVG2 GCCTCTTTTTTCTTTATCATAGGGTTAATCATTGGACTATTCTTGGTTCTCC
GAGTTGG 
VSVG3 CTTGGTGTGCTTTAATTTAATGCAAAGATGGATACCAACTCGGAGAACCA
AGAATAG 
VSVG4 CATTAAATTAAAGCACACCAAGAAAAGACAGATTTATACAGACATAGAGA
TGAACCGAC 
VSVG5 GCCTTTGAATTCTTACTTTCCAAGTCGGTTCATCTCTATGTCTG 
NcoI-DRaFor CTCGAGCCATGGCCATAAGTGGAGTCCCTGTGCTAGGATTTTTCATCATAG
CTGTGCTGATGAGCGCTCAGGAATCATGGGCTATCAAAGAAGAACATGTG
ATCATCCAGGCCG 
SphI-FosRev GGTACCGCATGCTCAATGGGCGGCCAGG 
BamHI-MBP1 GGCGCGGATCCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCGG
CGGCGC 
BamHI-MBP2 GAAGAAGTGAACAACCGGGTTTTCCGCAAAGGCAGAATGCGCCGCCGCCG
CCAAAAGCAC  
BamHI-MBP3 GCGGAAAACCCGGTTGTTCACTTCTTCAAAAACATCGTTACCCCGCGTGGA
GGTGGAGGC 
BamHI-MBP4 GAGCCCCGTGGCACTAGTGATCCACCGCCACCTGAGCCTCCACCTCCACGC
GGGGTAACG  
BamHI-MBP5 GGCGGTGGATCACTAGTGCCACGGGGCTCTGGAGGAGGTGGGTCCGGGGA
CACCCGACC 
BamHI-MBP6 CCCTCTTAGGCTGCCACAGGAAACGTGGTCGGGTGTCCCCGGACCCACCTC
CTCC 
DR2b1-7 GGGGACACCCGACCACGTTTCC 
JunVSVGRev GATTAACCCTATGATAAAGAAAAAAGAGGCAATAGAGCTACCGCCACCTC
CAGAATGGTTCATGACTTTCTGTTTAAGCTGTGCC  
VSVGEcoRIRev GGCCTTTGAATTCCTACTTTCCAAGTCGGTTCATCTCTATGTCTG 
w/oMBPFor GGCGCGGATCCATGGTAAGCGCTATTGTTTTATATGTGCTTTTGGCGGCGG
CGGCGCATTCTGCCTTTGCGGGGGACACCCGACCACGTTTCCTGTGGCAGC
CTAAGAGGG 
SphI-VSVGRevRV GGTACCGCATGCTTACTTTCCAAGTCGGTTCATCTCTATGTCTG 
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Table 3.1 continued 
3.4.1. Cloning and Expression of Single-chain HA1.7 TCR in E. coli 
Total RNA was purified from HA1.7 hybridoma cells using RNeasy Midi kit (Qiagen, 
Valencia, CA) and used as the template for TCR cloning. One-step RT-PCR was performed to 
generate TCRα and TCRβ genes using primer pairs TAFor/TARev and TBFor/TBRev, 
respectively. The PCR products were spliced using SOE-PCR [35] and amplified with the two 
end primers TAFor/TBRev, yielding scTCR PCR product, which was then ligated into SfiI 
digested pMoPac54 (a kind gift from J. Maynard, University of Texas at Austin). The ligation 
product was transformed into chemical competent DH5α cells (Media Preparation Facility, 
Department of Biochemistry, University of Illinois, Urbana, IL), recovered, and sequence 
confirmed. For scTCR expression, two E. coli hosts, DH5α and BL21(DE3), were tested. 100 µL 
of overnight culture was inoculated into fresh 4 mL LB media in a Falcon culture tube and 
shaken at 250 rpm and 30 °C for 2 hours. Protein expression was then induced with IPTG at a 
final concentration of 0.5 mM. 1 mL of sample was taken at 6h, 8h, and 21h for SDS-PAGE 
analysis. See Fei Wen Notebook 3, pp. 17-21, and Notebook 9, pp. 14. 
Name Sequences 5’→3’ 
AE-SphI-FosRev GGTACCGCATGCTCAATGGGCGGCCAGGATGAAC 
AE-FosFor TTAACTGATACACTCCAAGCGGAGACAGATC 
AE-aEPRev GATCTGTCTCCGCTTGGAGTGTATCAGTTAA 
AE-aEPFor GCTGTGCTGATGAGCGCTCAGGAATCATGGGCT 
AE-SaRev AGCCCATGATTCCTGAGCGCTCATCAGCACAGC 
AE-MBPRev ACGCGGGGTAACGATGTTTTTGAAGAAGTGAACAACCGGGTTTTC 
AE-bEPFor GAAAACCCGGTTGTTCACTTCTTCAAAAACATCGTTACCCCGCGT 
AE-bEPRev GGTTTTCACTTTTTCCTCGAGCCGGGCGATGCG 
AE-JunFor CGCATCGCCCGGCTCGAGGAAAAAGTGAAAACC 
AE-EcoRI-VSVGRev GGCCTTTGAATTCCTACTTTCCAAGTCGGTTCATC 
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3.4.2. Generation of Recombinant Bacmid DNA  
3.4.2.1. HA1.7 TCRα and TCRβ Constructs  
Plasmid pBACp10ph encoding HA1.7 TCR (a kind gift from E. Boder, University of 
Tennessee) was used as the PCR template, and TCRα and TCRβ genes were obtained by PCR 
using primer pairs BamHIalphaFor/EcoRIalphaRev and BamHIbetaFor/EcoRIbetaRev, 
respectively. The PCR products were BamHI/EcoRI digested and ligated into pFastBac vector 
(Invitrogen), yielding two donor plasmids, which were then transformed into DH5α cells, 
recovered, and sequence confirmed. The recombinant bacmid DNA encoding TCRα/TCRβ gene 
was obtained by transforming the corresponding donor plasmid into DH10Bac (Invitrogen, 
Carlsbad, California) and blue-and-white screening. Bacmid DNA from 4 white colonies of each 
construct was purified using HiPure plasmid miniprep kit (Invitrogen, Carlsbad, California) and 
analyzed by PCR using M13For/M13Rev primers. After verifying the transposition, recombinant 
bacmid DNA was used to transfect Sf9 cells for virus production (see Section 3.4.3). See Fei 
Wen Notebook 9, pp. 18-21, 23-24. 
3.4.2.2. Single-chain and Non-covalent pMHC Constructs 
The scDR1-HA-gp64 donor plasmid was created by ligating the PCR product, which was 
obtained by using pYD1αHAβ encoding single-chain DR1-HA (see Section 2.4.1) as the 
template and gp64SFor/gp64TMRev as the primer pair, into BamHI/EcoRI digested pFastBac 
plasmid. The gene encoding the VSVG transmembrane domain was obtained by splicing 
VSVG2-5 together. The resulting PCR fragment was spliced with another fragment obtained by 
using pYD1αHAβ as the template and gp64SFor/VSVG1Rev as the primer pair, and then ligated 
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into BamHI/EcoRI digested pFastBac plasmid, yielding the scDR1-HA-VSVG donor plasmid. 
The DR2α-Fos-encoding gene was obtained by PCR using pPIC-DR2α (a kind gift from K.W. 
Wucherpfennig, Harvard Medical School) as the template and NcoI-DRaFor/SphI-FosRev as the 
primer pair, and then ligated into NcoI/SphI digested pFastBacDual vector (Invitrogen), yielding 
pFastBacDual-DR2α. The DR2β-MBP-Jun-VSVG-encoding gene was obtained by splicing 
three PCR products: product 1 was obtained by splicing BamHI-MBP1-6, product 2 was 
obtained by PCR using pPIC-DR2β (K.W. Wucherpfennig) as the template and DR2b1-
7/JunVSVGRev as the primer pair, and product 3 was obtained by splicing VSVG2-4 and 
VSVGEcoRIRev. The spliced PCR product was then ligated into BamHI/EcoRI digested 
pFastBacDual-DR2α to generate LZ-DR2-MBP donor plasmid. The DR2β-Jun-VSVG-encoding 
gene was obtained by splicing two PCR products: product 1 was obtained by PCR using pPIC-
DR2β as the template and w/oMBPFor /JunVSVGRev as the primer pair, and product 2 was by 
splicing VSVG2-4 and VSVGEcoRIRev. The spliced PCR product was then ligated into 
BamHI/EcoRI digested pFastBacDual-DR2α to generate LZ-DR2 donor plasmid. The single-
chain scDR2(-MBP)-VSVG donor plasmid was created by ligating the PCR product, which was 
obtained by using the LZ-DR2(-MBP) donor plasmid as the template and gp64SForS/SphI-
VSVGRevRV as the primer pair, into BamHI/SphI digested pFastBac plasmid. The recombinant 
bacmid DNA was obtained by transforming the corresponding donor plasmid into DH10Bac as 
described in Section 3.4.2.1. See Fei Wen Notebook 8, pp. 60-62, 69-70, 74, 77. 
3.4.3. Insect Cell Culture and Protein Expression 
To initiate an insect cell culture, a frozen stock was removed from liquid nitrogen, placed 
in a 37 °C water bath, and thawed rapidly with gentle agitation until the cells were almost 
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thawed (leaving cells at 37 °C after they have thawed will result in cell death). The cells were 
then transferred into a 25 cm2 flask pre-wet with 4 mL of complete medium (Sf-900 II SFM 
medium supplemented with 10% heat inactivated fetal bovine serum and 100 µg/mL penicillin-
streptomycin, Invitrogen). After incubation for ~40 minutes at 27 °C, the medium was removed 
and replaced with 5 mL of fresh complete medium. After another 24 hours, the medium was 
changed again and the cells were grown to confluency. The cells were then subcultured until they 
doubled every 18-24 hours and were 95% viable before they could be used for bacmid 
transfection or viral infection. Once a stable cell culture was established, a frozen stock could be 
made by resuspending 107 insect cells (>90% viable and ~80-90% confluent) in 1 mL of freezing 
medium (60% Sf-900 II SFM Medium, 30% FBS, and 10% DMSO). 
Recombinant baculovirus was obtained by transfecting insect cells with recombinant 
bacmid DNA following manufacturer’s protocol (Bac-to-Bac, Invitrogen). Briefly, 106 cells were 
seeded in each well of a 6-well plate and allowed to attach for at least 1 hour at 27 °C.  5 µL of 
bacmid DNA, 6 µL of CellFECTIN (Invitrogen), and 189 µL of Sf-900 II SFM medium were 
mixed gently, incubated at room temperature for 45 minutes, and then 800 µL of Sf-900 II SFM 
medium was added. The cells were washed three times with 2 mL of Sf-900 II SFM medium and 
the 1 mL transfection mixture was added to each well. The resulting plate was incubated at 27 °C 
for 5 hours and the transfection mixture was replaced with 2 mL of complete medium. The virus 
was harvested after 72 hours by centrifugation at 500×g for 5 minutes and stored at 4 °C. To 
amplify the virus, 1.2×107 cells were seeded in a 75 cm2 flask and allowed to attach for at least 1 
hour at 27 °C. 500 µL of the viral stock from the initial transfection step was added into the flask 
and mixed gently. The virus was harvested after 48 hours by centrifugation at 500×g for 5 
minutes and stored at 4 °C. The virus amplification was carried out twice to bring up the virus 
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titer to ~108 pfu/mL before it was used for protein expression. For long term storage, a 1 mL 
aliquot of the amplified virus stock was stored at -80 °C. 
For protein expression in insect cells, 8×106 cells were seeded in a tissue culture plate 
(Corning Inc., Corning, NY) and allowed to attach for at least 1 hour at 27 °C. The infection 
conditions including multiplicity of infection (MOI), expression temperature, and infection time 
were optimized for expressing different proteins. For example, the optimal condition for HA1.7 
TCR expression was determined to be 5 µL virus stock (MOI ~ 1), 19 °C for 6 days. See Fei 
Wen Notebook 9, pp. 24-25, 31-32, 37, 46. 
3.4.4. Protein Analyses 
3.4.4.1. Native PAGE and Western Blot  
Protein standards, Powerpac 300 power supply, Mini-PROTEAN 3 assembly, Mini 
Trans-Blot Cell, and pre-cast 4-20% acrylamide gels were purchased from Bio-Rad (Hercules, 
CA). All steps were carried out at 4 ºC. 15 µL of protein sample was mixed with 15 µL of 
native-PAGE loading buffer (62.5 mM Tris-HCl, pH 6.8, 40% glycerol, 0.01% Bromophenol 
Blue). Samples were loaded onto the gel in a Bio-Rad Mini-PROTEAN 3 assembly and ran in 
native electrophoresis buffer (25 mM Tris, pH 8.3, 192 mM glycine) at a current of 100 V for 
120 minutes. For native PAGE, the gel was stained with Coomassie Blue followed by destaining 
with a destaining solution (40% methanol, 10% glacial acetic acid). For native western blot, the 
proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane using the Mini 
Trans-Blot Cell and a voltage of 100V for 1 hour. The PVDF membrane was then developed as 
described in Section 2.4.8 except that the primary antibody used was H28-710 at a 1:2500 
dilution. See Fei Wen Notebook 8, pp. 79, and Notebook 9, pp. 32-35. 
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3.4.4.2. ELISA 
90 µL of protein sample was mixed with 10 µL of 1× coating buffer (eBiosciences, San 
Diego, CA) and loaded into the Immuno 96-MicroWell plate (Thermo Fisher Scientific, 
Rochester, NY). After incubation at 4 °C overnight, each well was washed three times with 400 
µL PBST (phosphate buffered saline (PBS) supplemented with 0.05% Tween-20) and then 
blocked with 200 µL 1× assay diluent (eBiosciences) for 2 hours at room temperature. Wells 
were then washed with 400 µL PBST three time and incubated with detection antibody, 
biotinylated H57-597 (BD Bioscience, San Jose, CA) at a 1:200 dilution for ~3 hours at room 
temperature, followed by avidin-HRP (eBiosciences) for 30 min at room temperature.  After 
washing away unbound avidin-HRP, substrate solution was added and the absorbance at 650 nm 
was measured after 15 min using a SpectraMax microplate reader (Molecular Devices, 
Sunnyvale, CA). See Fei Wen Notebook 9, pp. 32-35. 
3.4.5. Yeast Display Library Construction and Screening  
3.4.5.1. Engineering of Folded DR2 Variants in Yeast 
Plasmid pYD1-DR2-MBP was generated by replacing the DR1β gene in DR1αMBPβ 
(see Section 2.4.1) with DR2β gene through SpeI/XhoI digestion and ligation. DR2β gene was 
obtained by PCR using pPIC-DR2β as template and primer pair SpeIDR2betaFor/ 
DR4betaXhoIRev. Using pYD1-DR2-MBP as template and pYD1For/pYD1Rev as primers, EP-
PCR was carried out with 0.15mM MnCl2. The mutation rate was determined to be ~3 amino 
acid changes per gene. The EP-PCR product was then digested with BstXI and SpeI and ligated 
into DR1αSTFβ (see Section 2.4.1). The ligation mixture was transformed into ElectroMax 
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DH5α competent cells (Invitrogen) and a library of 1.7×106 clones was obtained. Plasmids were 
recovered and transformed into EBY100 and a library of 1.8×106 clones was generated. After 
two passages in the selection media SD-CAA (2% dextrose, 0.67% yeast nitrogen base, 1% 
casamino acids), the library was induced for protein expression using YPG (1% yeast extract, 2% 
peptone, 2% galactose) and subjected to FACS. The FACS analysis was carried out in the same 
way as described in Section 2.4.10 except that after the third round of enrichment, full-length 
DR2 variants were selected using anti-V5 antibody (Invitrogen) in the primary staining step. 
Twenty clones were randomly picked and analyzed individually for their surface display levels. 
DNA sequencing was carried out to determine the mutations and DR2 variants with single 
mutation were created as the following: DR2Pβ11H-MBP was created by co-transforming a PCR 
product (obtained by using pYD1-DR2-MBP as template and primer pair pYD1For/P11HRev) 
and BstXI/SpeI digested pYD1-DR2-MBP into EBY100. DR2Pβ11R-MBP was created in the 
same way except that P11RRev was used in the PCR reaction in place of P11HRev. DR2-
MBPF4Y was created by ligating a PCR product (obtained by using pYD1-DR2-MBP as template 
and primer pair MBPF4YFor/DR2-XhoIRev) into NotI/XhoI digested pYD1-DR2-MBP
. 
DR2-
MBPV1I, DR2-MBPF4W, and DR2-MBPV1I-F4W were created similarly except that primers 
MBPF4WFor, MBPV1IFor, and MBP1I-4WFor were used in PCR reaction in place of 
MBPF4YFor, respectively. See Fei Wen Notebook 4, pp. 1-4, 28, 35-36, and Notebook 5, pp. 
10-12. 
3.4.5.2. Affinity Engineering of DR2 Variants in Yeast 
An EP-PCR library was created in the same way as described above except that plasmid 
pYD1-DR2Pβ11H-MBP was used as the template. The mutation rate was determined to be ~2-3 
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amino acid changes per gene and the yeast library size was 2×106. The cells were stained with 
the Ob.1A12 TCR tetramer (described in Section 3.4.6) and subjected to FACS. ~1% and ~ 
0.5% of the population with the highest fluorescence was collected in the first and second round 
of sorting, respectively, and recovered for further enrichment. In the third round, cells from top 
0.1% population were sorted into a 96-well plate and individual clones were analyzed for 
tetramer staining and sequencing. See Fei Wen Notebook 5, pp. 11-15. 
3.4.6. TCR Tetramer Preparation and Staining 
The volume of streptavidin-PE conjugate required to give a 1:1 molar ratio of 
biotinylated TCR to biotin binding sites was calculated and tested using native PAGE (see 
Section 3.4.4.1). The streptavidin-PE conjugate was then slowly added to the biotinylated TCR 
solution stepwise in 1/10 volume aliquots every 5 minutes. This step was performed at room 
temperature and away from light. The resulting tetramer solution was then diluted to 100 µg/mL 
for yeast cell staining and 50 µg/mL for insect cell staining. The staining was carried out at 30 °C 
(yeast cell) or 27 °C (insect cell) for 2 hours and unbound TCR tetramer was washed away three 
times using PBS. See Fei Wen Notebook 5, pp. 13, 32, 41-42, and Notebook 8, pp. 79. 
3.4.7. Insect Cell Surface Display Library Creation and Screening 
The LZ-DR2-MBP donor plasmid was used as template to amplify five DNA fragments 
with primer pairs AE-SphI-FosRev/AE-FosFor, AE-aEPRev/AE-aEPFor, AE-SaRev/AE-
MBPRev, AE-bEPFor/AE-bEPRev, and AE-JunFor/AE-EcoRI-VSVGRev for fragments 1 
through 5, respectively. High fidelity PCR condition was used for amplifying fragments 1, 3, and 
5, while EP-PCR condition (0.15mM MnCl2) was used for amplifying fragment 2 and 4. After 
splicing the five fragments, the resulting product was SphI/EcoRI digested and ligated into 
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pFastBacDual vector. The ligation mixture was then transformed into DH5α, generating a donor 
plasmid library with a size of ~3.1x106. The donor plasmids were then recovered and 
transformed into DH10Bac. After blue-and-white screening, 7000 white colonies were picked 
and pooled to generate a recombinant bacmid library, which was then used to transfect insect 
cells to create a recombinant baculovirus library encoding DR2 variants in complex with MBP85-
99 peptide. The insect cells infected with the recombinant baculovirus library were stained with 
the Ob.1A12 TCR tetramer (described in Section 3.4.6) and subjected to FACS. ~15% and ~ 
0.5% of the population with the highest fluorescence was collected in the first and second round 
of sorting, respectively, and recovered for further enrichment. See Fei Wen Notebook 5, pp. 31-
38. 
3.4.8. Other Assays 
Please refer to Section 2.4.2 for yeast transformation, Section 2.4.3 for DNA sequencing, 
Section 2.4.4 for yeast surface display, Section 2.4.5 for flow cytometry analysis, Section 2.4.8 
for SDS-PAGE, and Section 2.4.11 for T cell hybridoma activation and IL-2 detection.  
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Chapter 4. Yeast Surface Display of Functional Minicellulosomes 
for Synergistic Hydrolysis of Cellulose  
4.1. Introduction 
The development of alternatives to fossil fuels has attracted intense political and 
academic attention due to the increasing concerns about energy security, sustainability, and 
global climate change [1-4]. Among all forms of renewable energy sources, lignocellulosic 
biofuels, such as ethanol, have been widely regarded as a promising and the only foreseeable 
alternative to petroleum products for transportation, and cellulosic ethanol is expected to replace 
at least 30% of current US petroleum consumption by 2030 [3, 5, 6]. Currently, the central 
technological impediment to lignocellulosic biofuel production is the absence of a low-cost 
technology to break down its major component – cellulose [5, 7]. Cellulose (a linear 
homopolymer of glucose linked by β-1,4-glycosidic bonds) is insoluble, forms a distinct 
crystalline structure, and is protected by a complex plant cell wall structural matrix [8, 9]. As a 
result, a separate processing step is required to produce large amounts of cellulases for the 
hydrolysis of cellulose into fermentable glucose (shown in Figure 1.1), making cellulosic 
ethanol too expensive to compete with gasoline. To address this issue, consolidated 
bioprocessing (CBP), which combines cellulase production, cellulose hydrolysis, and 
hydrolysate fermentation in a single step, has been proposed to significantly lower the cost of 
cellulosic ethanol production [1, 10]. However, the great potential of CBP cannot be realized 
using microorganisms available today and requires the development of new and improved 
organisms that can both efficiently hydrolyze cellulose and convert the hydrolysate (glucose) 
into ethanol.  
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Between the two strategies for CBP-enabling organism development: native cellulolytic 
strategy (engineer naturally occurring cellulolytic microorganisms to improve their ethanol 
production) and recombinant cellulolytic strategy (engineer non-cellulolytic microorganisms that 
are proficient in ethanol production to utilize cellulose, see Section 1.3.1), the latter approach 
was chosen considering the difficulties in engineering native cellulolytic microorganisms. In 
contrast, yeast Saccharomyces cerevisiae is easy to manipulate with a large collection of genetic 
engineering tools available. Additionally, yeast is widely known for its high ethanol tolerance, 
high ethanol productivity (close-to-theoretical yield of 0.51 g ethanol /g glucose), and robustness 
in industrial fermentation processes. Therefore, the goal of this project is to engineer yeast S. 
cerevisiae with the ability to hydrolyze cellulose by heterologously expressing a functional 
cellulolytic system.  
Nature has provided us two ways of designing cellulolytic systems: (i) noncomplexed 
cellulase systems, in which free enzymes are secreted and act discretely, and (ii) complexed 
cellulase systems, namely cellulosomes, in which enzymes with complementary activities are 
held together by a non-catalytic scaffoldin protein through high affinity interactions between 
cohesins and enzyme-borne dockerins [1]. By mimicking the noncomplexed cellulase system, 
several groups have successfully constructed cellulolytic S. cerevisiae strains that directly 
convert amorphous cellulose to ethanol, although the titer and yield were relatively low [11-13]. 
Compared to the noncomplexed cellulase systems, the cellulosome exhibits much greater 
degradative potential as a result of its highly ordered structural organization that enables enzyme 
proximity synergy and enzyme-substrate-microbe complex synergy [14-17], and could provide a 
“quantum leap” in the biomass-to-biofuels technology development [18]. Therefore, we sought 
to display cellulosome on yeast cell surface. The format of cell surface display was chosen over 
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secretory proteins to potentially incorporate the cellulose-enzyme-microbe complex synergy 
unique to native cellulolytic microorganisms [14]. In addition, coupled with flow cytometry, 
yeast surface display provides us a more convenient engineering platform, avoiding labor-
intensive protein purification steps. Such cell-bound format is also amenable for enzyme activity 
analysis on insoluble substrates [19].  
To date, in vivo production of recombinant cellulosomes has been limited to 
unifunctional complexes containing only one type of cellulolytic enzyme [20-22]. Since 
complete enzymatic hydrolysis of cellulose to glucose requires synergistic action of three types 
of cellulases: endoglucanases (EC 3.2.1.4), exoglucanases (including cellodextrinases, EC 
3.2.1.74 and cellobiohydrolases, EC 3.2.1.91), and β-glucosidases (EC 3.2.1.21) [1], 
cellulosomes with higher complexity are necessary to be synthesized and assembled on yeast cell 
surface to enable its cellulose utilization. Recent studies have revealed a modular nature of 
cellulosome assembly: by simply appending a dockerin domain, up to three enzymes (either 
cellulosomal or noncellulosomal) with different origins could be incorporated into a chimeric 
miniscaffoldin consisting of divergent cohesin domains to form a minicellulosome in vitro. The 
chimeric miniscaffoldin was in the form of either purified [23-25] or yeast surface displayed 
protein [26]. In both cases, the resulting recombinant minicellulosomes showed enhanced 
hydrolytic activity towards cellulose. These results indicate that the high affinity cohesin-
dockerin interactions are sufficient to dictate the assembly of a functional cellulosome. Therefore, 
we hypothesized that the same results could also be achieved in vivo by co-expressing the 
cellulosomal components in yeast.  
In this chapter, we describe the design and development of a yeast display system that 
enabled the first successful surface assembly of a series of unifunctional, bifunctional, and 
107 
trifunctional minicellulosomes. Using phosphoric acid swollen cellulose (PASC) as a model 
substrate, the surface displayed minicellulosomes exhibited both enzyme-enzyme synergy and 
enzyme proximity synergy. More importantly, resting cell study showed that the recombinant 
strain displaying the trifunctional minicellulosomes was able to hydrolyze and ferment PASC to 
ethanol, supporting the feasibility of constructing cellulolytic and fermentative yeast by 
displaying recombinant minicellulosomes on the cell surface. Furthermore, we demonstrated that 
the display system described here can be a useful tool for producing minicellulosomes with 
different activities and studying their synergic cellulolytic function. The following experiments 
were designed by Fei Wen and carried out by Fei Wen with Jie Sun’s assistance. 
4.2. Results and Discussion 
4.2.1. Design and Construction of Minicellulosomal Components for Yeast Surface 
Display  
Complete and efficient enzymatic hydrolysis of cellulose requires synergistic action of at 
least three types of cellulases. Therefore, a trifunctional minicellulosome, which consists of a 
miniscaffoldin, an endoglucanase (EG), a cellobiohydrolase (CBH), and a β-glucosidase (BGL), 
Yeast cell wall
CipA3-EGII-CBHII-BGL1
Coh1 Coh2 Coh3
CBD
EGII BGL1CBHII
Aga1-Aga2
 
Figure 4.1 Design of a yeast surface display system for assembly of minicellulosomes. CipA3 (Coh1-
Coh2-CBD-Coh3) enables display of cellulosomes with up to three enzymatic activities. The cohesin 
domains are numbered as described elsewhere [27]. CBD = cellulose binding domain, Coh = cohesin. 
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is the minimum requirement for cellulose utilization by yeast (Figure 4.1). The miniscaffoldin 
CipA3 used in this study was designed based on the well-characterized scaffoldin protein CipA 
from Clostridium thermocellum [28]. It contains a cellulose binding domain (CBD) and three 
cohesin modules (Coh1-Coh2-CBD-Coh3), and allows the surface assembly of minicellulosomes 
with up to three enzymatic activities. By fusing the gene encoding CipA3 to the C-terminus of 
AGA2 protein in the yeast pYD1 display vector (Figure 4.2), the miniscaffoldin was expected to 
be tethered to the yeast a-agglutinin mating adhesion receptor [29], thus displayed on the cell 
surface. 
pRS425-CBHII-BGL1
GAL1 GAL10
ss1 CBHIIFLAGc-MycBGL1 ss2docA docS
pYD1-CipA3-EGII
GAL10 GAL1
Aga2 V5HisEGII ss1docS CipA3
TADH1TADH2TMTαTADH1
 
Figure 4.2 Plasmids used for constructing strain CipA3-EGII-CBHII-BGL1 (Table 4.1) displaying 
trifunctional minicellulosomes. ss1 = synthetic prepro signal peptide [30], ss2 = α-factor signal peptide 
with AG dipeptide spacer [31], T = terminator. V5 (GKPIPNPLLGLDST), His (HHHHHH), FLAG 
(DYKDDDDK), and c-Myc (EQKLISEEDL) are epitope tags used for detection of minicellulosomal 
components on yeast cell surface.  
The enzyme components used in this study were of fungal origin, including EGII and 
CBHII isolated from Trichoderma reesei and BGL1 isolated from Aspergillus aculeatus, all of 
which had been functionally expressed in S. cerevisiae [11]. The non-cellulosomal enzymes were 
chosen to demonstrate the feasibility of using yeast to produce designer cellulosomes [18]. To 
enable the surface assembly of minicellulosomes, three expression cassettes each consisting of a 
promoter, a secretion signal peptide, an epitope tag, a cellulase, a dockerin module, and a 
terminator were assembled in two plasmids (pYD1 and pRS425) in different combinations 
(Figure 4.2 and Table 4.1): GAL10-(prepro signal peptide)-His-EGII-docS-ADH1, GAL10-
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(prepro signal peptide)-FLAG-CBHII-docS-ADH1, and GAL1-(α-factor signal peptide)-(c-
Myc)-BGL1-docA-ADH2. The dockerin modules, docS and docA, were obtained from the two 
major cellulosomal cellulases of C. thermocellum, CelS [32] and CelA [33], respectively. To 
simultaneously produce more than two proteins (e.g. bifunctional or trifunctional 
minicellulosomes) at high and balanced expression levels in yeast, a bi-directional GAL1-10 
promoter [34] was used. Upon galactose induction, chimeric enzymes His-EGII-docS, FLAG- 
CBHII-docS, and/or c-Myc-BGL1-docA were expected to be secreted and bind the cohesin
Table 4.1 Recombinant S. cerevisiae EBY100 strains constructed in this study. 
 
Straina Plasmid Phenotype 
HZ1901 pYD1ctrl & pRS425 No surface display (negative control) 
HZ1859  
(CipA3-EGII) 
pYD1-CipA3-EGII Displays unifunctional minicellulosome 
with EGII activity 
HZ1890  
(CipA3-CBHII) 
pYD1-CipA3 & 
pRS425-CBHII 
Displays unifunctional minicellulosome 
with CBHII activity 
HZ1900  
(CipA3-BGL1) 
pYD1-CipA3 & 
pRS425-BGL1 
Displays unifunctional minicellulosome 
with BGL1 activity 
HZ1892  
(CipA3-EGII-CBHII) 
pYD1-CipA3-EGII & 
pRS425-CBHII 
Displays bifunctional minicellulosome 
with EGII and CBHII activityb 
HZ1886  
(CipA3-EGII-CBHII-BGL1) 
pYD1-CipA3-EGII & 
pRS425-CBHII-BGL1 
Displays trifunctional minicellulosome 
with EGII, CBHII, and BGL1 activityb 
HZ1891  
(CipA1-EGII-CBHII) 
pYD1-CipA1-EGII & 
pRS425-CBHII 
Displays two types of unifunctional 
minicellulosomes with EGII or CBHII 
activity, respectively  
HZ1885  
(CipA1-EGII-CBHII-BGL1) 
pYD1-CipA1-EGII & 
pRS425-CBHII-BGL1 
Displays three types of unifunctional 
minicellulosomes with EGII, CBHII, and 
BGL1 activity, respectively 
a
  For the purpose of clarity, the strains will be referred by their names in the parentheses. 
b
 The phenotype listed in the table assumes that all minicellulosome components are expressed at an 
equal molar ratio. However, due to the relative low enzyme expression level, our results showed a 
heterogeneous population of cells displaying uni-, bi-, and/or trifunctional minicellulosomes when two 
or three enzymes were co-expressed with CipA3 (see Section 4.2.3 below). 
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domains of the miniscaffoldin on the cell surface, forming a minicellulosome structure (Figure 
4.1). The N-terminal epitope tags are included to allow the detection of successful assembly of 
minicellulosomes using flow cytometry. 
4.2.2. Yeast Surface Assembly of Unifunctional Minicellulosomes   
Yeast surface display of the miniscaffoldin CipA3 is pivotal to the minicellulosome 
assembly since it serves as the anchor for the secreted enzymes. To verify the surface 
immobilization of CipA3, yeast cells transformed with pYD1-CipA3 were stained with 
monoclonal anti-V5 antibody and analyzed by flow cytometry. As shown in Figure 4.3, a 
positive staining population was detected, indicating that the CipA3 was successfully displayed 
in full length on yeast cell surface. The peak observed for the strain transformed with plasmid 
pYD1ctrl was the background fluorescence typical for yeast cells. By using calibration 
microsphere standards coated with a known amount of fluorochrome molecules, the surface 
display efficiency of CipA3 was determined to be approximately 1.8×104 copies per cell. 
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Figure 4.3 Flow cytometric analysis of yeast cells displaying miniscaffoldin CipA3. The miniscaffoldins 
CipA3 was successfully displayed on the yeast cell surface as indicated by V5-epitope detection. Yeast 
cells transformed with empty plasmid pYD1ctrl was used as a negative control. 
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To test whether minicellulosomes with the simplest structure - unifunctional 
minicellulosomes could be assembled on the yeast cell surface, plasmid pRS425 encoding one of 
the three chimeric enzyme expression cassettes was transformed into yeast cells with or without 
plasmid pYD1-CipA3. The surface display of each enzyme was monitored by measuring the 
expression of the corresponding N-terminal epitope tag using flow cytometry. As shown in 
Figure 4.4, the chimeric enzyme was detected on the cell surface only when the miniscaffoldin 
CipA3 was co-expressed. In the absence of the miniscaffoldin, the enzyme expression was
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Figure 4.4 Flow cytometric analysis of yeast cells displaying unifunctional minicellulosomes. Chimeric 
enzyme display was dependent on the presence of the miniscaffoldin on the cell surface. With CipA3 on 
the surface (top row), enzymes were detected. In contrast, without CipA3 on the surface (bottom row), no 
enzymes were detected on the surface. This CipA3-dependence indicated the successful assembly of 
unifunctional minicellulosomes. The results were representative of three independent experiments using 
three individual clones. 
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detected in the supernatant (data not shown), but not on the cell surface, and the recombinant 
yeast cells only showed background fluorescence (Figure 4.4, bottom row).  
Compared to EGII or CBHII, co-expression of BGL1 did not result in a significant 
fluorescence peak shift (Figure 4.4, top right panel), indicating a low surface display level of 
BGL1. To exclude the possibility that the fusion of BGL1 affected the binding of docA to CipA3, 
the supernatant of strain CipA3-BGL1 (Table 4.1) was analyzed by SDS-PAGE (Figure 4.5) 
and Western blotting (data not shown). Even after concentrating the supernatant by ~75 fold, no 
free BGL1 was detected using either method. To analyze the cell pellet fraction, ~1.5x107 yeast 
cells were boiled to release the surface displayed proteins. While a very faint band of CipA3 was 
observed (indicated by arrows in Figure 4.5), no BGL1 was detected. Note that CipA3 was 
expressed at a much higher level (~180-fold) than BGL1 (Figure 4.6). These data suggested that
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Figure 4.5 SDS-PAGE analysis of cellulosomal component expression by strain CipA3-BGL1. The 
molecular weights (KDa) of the protein standards are shown on the left. Lane 1: prestained protein 
standards, lane 2(5): supernatant of the CipA3-BGL1 (negative control) induction culture concentrated by 
75-fold, lane 3(6) & 4(7): cell-associated protein fraction from ~0.75×107 & 1.5×107 CipA3-BGL1 
(negative control) cells, respectively. The bands of CipA3 protein are indicated by arrows. 
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the majority, if not all, of the secreted BGL1 bound to the cell surface. Therefore, the low surface 
display level of BGL1 was a result of low expression level of chimeric BGL1. Taken together, 
these results indicated that unifunctional cellulosomes were successfully assembled on the yeast 
cell surface through the interaction between the dockerin domain of the secreted chimeric 
enzyme and the cohesin module of miniscaffoldin CipA3. 
4.2.3. Yeast Surface Assembly of Bifunctional and Trifunctional Minicellulosomes   
With the success of unifunctional minicellulosome assembly, the ability of yeast cells to 
display more complex minicellulosomes on the surface was examined next. Two yeast strains, 
CipA3-EGII-CBHII and CipA3-EGII-CBHII-BGL1, were constructed to test the assembly of 
bifunctional and trifunctional minicellulosomes, respectively. As shown in Figure 4.6, 
CipA3-EGII CipA3-CBHII CipA3-BGL1 CipA3-EGII-CBHII    CipA3-EGII-CBHII-BGL1 negative
10
100
1000
10000
Re
la
tiv
e
 
m
e
an
 
flu
or
e
sc
en
ce
 
u
n
its
 CipA3
 EGII
 CBHII
 BGL1
 
Figure 4.6 Display levels of all CipA3-based minicellulosomal components on the yeast cell surface. 
Refer to Table 4.1 for the phenotype of each yeast strain. The results were obtained from three 
independent experiments using three individual clones, and the average and standard deviation were 
plotted. 
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compared to yeast strains displaying unifunctional minicellulosomes (CipA3-EGII, CipA3-
CBHII, and CipA3-BGL1), coexpression of two chimeric enzymes in strain CipA3-EGII-CBHII 
caused a noticeable but not significant decrease in the display levels of all three minicellulosomal 
components. However, the expression of a third enzyme in strain CipA3-EGII-CBHII-BGL1 
caused a dramatic decrease in the display level of CBHII with a more than 160-fold drop in mean 
fluorescence units (MFU), which might be a result of the metabolic burden imposed on the cells 
by trying to produce all four proteins simultaneously. Alternatively, it might be a result of the 
“balancing function” of the bi-directional GAL1-10 promoter used for protein expression [34].  
The significant lower expression levels of CBHII and BGL1 compared to CipA3 and 
EGII also suggested an imbalanced molar ratio of the four minicellulosome components, which 
could in theory lead to three populations of yeast cells each displaying uni-, bi-, or trifunctional 
minicellulosomes within the induced CipA3-EGII-CBHII-BGL1 culture. To test this hypothesis 
and measure the percentage of each population, multi-antibody-staining analysis was conducted. 
Compared to single-antibody-staining, multi-antibody-staining showed a significantly lower 
efficiency, resulting in a ~22-, ~85-, and ~3.5-fold reduction in the percentage of positive-
staining population for EGII (Figure 4.7, left panel), CBHII, and BGL1 (data not shown), 
respectively. This reduction in antibody staining signal was expected since three enzymatic 
minicellulosomal components were in close proximity to each other, creating steric hindrance for 
simultaneous access of three bulky antibody-fluorochrome conjugates. Nevertheless, both 
double-positive (EGII+-CBHII+ in the lower-right quadrant and EGII+-BGL1+ in the upper left 
quadrant of Figure 4.7, right panel, respectively) and triple-positive (EGII+-CBHII+-BGL1+ in 
the upper right quadrant of Figure 4.7, right panel) populations were detected for strain CipA3-
EGII-CBHII-BGL1, indicating that a fraction of the cells displayed bifunctional (~0.3%) and 
115 
trifunctional (~0.07%) minicellulosomes. However, it should be noted that the percentage values 
of double- and triple-positive populations presented in Figure 4.7 do not represent, and probably 
significantly underestimate the true fraction size of each population due to the much lower 
efficiency of multi-antibody staining.  
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Figure 4.7 Multi-antibody staining analysis of strain CipA3-EGII-CBHII-BGL1. The multi-antibody-
staining showed significantly lower efficiency compared to single-antibody staining (left panel). The right 
panel was gated on EGII+ population shown by the R1 region in the left panel. The percentage of each 
population was shown and the corresponding percentage values of the negative control were shown in 
parentheses. 
Similar results were also obtained for strain CipA3-EGII-CBHII displaying bifunctional 
minicellulosomes. Based on the relative expression levels of all three cellulosomal components 
as shown in Figure 4.6, the fraction of cells displaying bifunctional minicellulosomes should be 
~40%. However the multi-antibody-staining analysis showed that only ~8.1% of the cells 
displayed bifunctional minicellulosomes on the surface (upper right quadrant of Figure 4.8). 
Taken together, these data clearly suggested that the surface displayed miniscaffoldin 
CipA3 and enzyme-bound dockerins (docS and docA) were all correctly folded, and their high 
affinity interactions were sufficient to direct the assembly of a series of bi- and trifunctional
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Figure 4.8 Multi-antibody staining analysis of strain CipA3-EGII-CBHII. No gate was set and the 
percentage of each population was shown. The corresponding percentage values of the negative control 
were shown in parentheses. 
minicellulosomes on the yeast cell surface, although a fraction of the cells also displayed 
minicellulosomes with a lesser complexity. The cell-associated recombinant minicellulosomes 
were found to be highly stable, with a half-life of approximately two months at 4 °C (data not 
shown). 
4.2.4. Functional Analysis of the Enzyme Components in the Surface Displayed 
Minicellulosomes 
To examine whether the chimeric enzymes in the surface displayed minicellulosomes 
were functional, three recombinant strains CipA3-EGII, CipA3-CBHII, and CipA3-EGII-CBHII-
BGL1 (Table 4.1) were tested for their ability to hydrolyze amorphous cellulose - PASC. As 
shown in Figure 4.9A, both of the strains CipA3-EGII and CipA3-CBHII released soluble 
reducing sugars from PASC, indicating that both EGII and CBHII in the recombinant 
minicellulosomes were functional. HPLC analysis of the hydrolysis products showed that 
CipA3-EGII released cellobiose and cellotriose as its main products, while only cellobiose was 
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detected in the hydrolysis reaction mixture of strain CipA3-CBHII (data not shown). Although 
no reducing sugar was detected in the hydrolysis reaction mixture of strain CipA3-EGII-CBHII-
BGL1, a significant reduction of the residual insoluble PASC was observed (Figure 4.9B), 
indicating that BGL1 was active.  
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Figure 4.9 Functional analysis of surface displayed minicellulosomes. Cells displaying different 
minicellulosomes were tested for their ability to hydrolyze PASC. The concentrations of (A) released 
reducing sugars and (B) residual PASC were plotted over time. All data points were obtained from 
triplicate experiments, and the average and standard deviation were plotted. 
The activity of BGL1 was further analyzed using cellobiose as substrate. The traditional 
p-nitrophenyl-β-glucopyransoside-based BGL1 activity assay was not used because cellobiose is 
the authentic substrate in the context of direct fermentation of PASC to ethanol. In addition, 
efficient cellobiose utilization is a prerequisite to a successful development of a cellulolytic yeast 
strain. As shown in Figure 4.10, the growth of strain CipA3-EGII-CBHII-BGL1 using 
cellobiose as the sole carbon source indicated that the BGL1 was active. In addition, the inability 
of strain CipA3-EGII-CBHII to grow on cellobiose excluded the possibility of yeast endogenous 
BGL activity. These data clearly suggested that BGL1 was highly active, and the soluble 
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oligosaccharides were quickly hydrolyzed by BGL1 to glucose, which was then immediately 
assimilated by yeast cells. Both HPLC analysis (data not shown) and phenol-sulfuric acid assay 
(Figure 4.9) showed that no PASC was hydrolyzed by the negative control strain. Taken 
together, these results demonstrated that all three chimeric enzymes in the minicellulosomes 
were active. The continuous degradation of PASC indicated that the surface displayed 
cellulosomes were also highly stable at 30 °C (Figure 4.9), and the hydrolysis reached 
completion after ~6 days for strain CipA3-EGII-CBHII-BGL1 (data not shown). 
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Figure 4.10 Time courses of the cell growth using cellobiose as the sole carbon source. Samples were 
taken at indicated time points and the optical density was measured at the wavelength of 600 nm using a 
UV-Vis spectrometer. All data points were obtained from triplicate experiments, and the average and 
standard deviation were plotted. 
4.2.5. Enhanced Synergy of Bifunctional and Trifunctional Minicellulosomes 
The recombinant yeast strains were tested for their ability to hydrolyze amorphous 
cellulose PASC at 30°C. The number-average degree of polymerization of PASC and Avicel was 
determined to be 190 and 192, respectively, suggesting that the phosphoric acid treatment 
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process disrupted the supramolecular structure of Avicel without any significant acid hydrolysis. 
Compared to yeast displaying unifunctional minicellulosomes (i.e. CipA3-EGII, CipA3-CBHII), 
strain CipA3-EGII-CBHII displaying bifunctional minicellulosomes showed an increased 
hydrolysis rate towards PASC (Figure 4.9A). Despite the dramatic decrease in CBHII display 
level, the addition of a third enzyme, BGL1, in strain CipA3-EGII-CBHII-BGL1 further 
enhanced the hydrolysis efficiency as indicated by lesser amount of residual PASC (Figure 
4.9B). The level of the observed activity enhancement reached a maximum of ~8.8 fold after ~24 
hours (Figure 4.9B and Figure 4.12),  then decreased to ~2 fold and remained steady until the 
completion of hydrolysis after ~144 hours (data not shown).  
To further examine whether the enhanced hydrolytic activity of bi- and trifunctional 
minicellulosomes was simply a result of enzyme-enzyme synergy or a combination of enzyme-
enzyme synergy and enzyme proximity synergy - a characteristic feature of cellulosomes - two 
more recombinant yeast strains, CipA1-EGII-CBHII and CipA1-EGII-CBHII-BGL1, were 
constructed (Table 4.1). In these two strains, a different miniscaffoldin CipA1 consisting of a 
CBD and a single cohesin module (CBD-Coh3) was used to enable simultaneous display of two 
or three types of unifunctional minicellulosomes (Figure 4.11A). Similar to the results of CipA3, 
the CipA1 miniscaffoldin protein showed a high surface display level (Figure 4.11B) with 
approximately 3×104 copies per cell. In addition, CipA1-dependent display of enzymes was also 
observed (Figure 4.11C), indicating successful assembly of unifunctional minicellulosomes on 
the yeast cell surface. Compared to the CipA3-based unifunctional minicellulosomes (Figure 
4.4), the CipA1-based complexes showed slightly higher display levels (Figure 4.11C), 
presumably due to a lighter metabolic burden for expressing a smaller miniscaffoldin protein. 
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Figure 4.11 Characterization of CipA1-based minicellulosomes on yeast cell surface. (A) Schematic 
representation of CipA1-based minicellulosome display, which enables codisplay of three unifunctional 
minicellulosomes that are spatially distributed. The miniscaffoldin CipA1 (CBD-Coh3) was expressed at 
a high level (B) and served as an anchor for surface assembly of unifunctional minicellulosomes (C). 
Because the a-agglutinin receptor is incapable of two dimensional diffusion [35], the 
unifunctional CipA1-based minicellulosomes are spatially distributed on the yeast cell surface 
(Figure 4.11A) and should exhibit little, if not any, enzyme proximity synergy. As a result, the 
comparison between the CipA1- and CipA3-based minicellulosomes allows us to dissect the 
contributions of the two different synergisms. As shown in Figure 4.12, both strain CipA1-EGII-
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CBHII and CipA1-EGII-CBHII-BGL1 clearly showed enzyme-enzyme synergy and resulted in a 
~5.5-fold higher activity than CipA3-EGII and CipA3-CBHII after 24 hours. When the chimeric 
enzymes were brought in proximity on the miniscaffoldin CipA3, strain CipA3-EGII-CBHII and 
CipA3-EGII-CBHII-BGL1 showed another ~1.3- and 1.6-fold higher activity than their 
corresponding CipA1-strains, respectively. These results strongly suggested that the enhanced 
hydrolytic activity of the bi- and tri-functional minicellulosomes displayed on yeast cell surface 
was a combined result of enzyme-enzyme synergy and enzyme proximity synergy. More 
specifically, the enzyme-enzyme synergy and enzyme proximity synergy accounted for ~63% 
and ~37% of the overall enhanced activity of the trifunctional minicellulosome, respectively.  
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Figure 4.12 Enhanced synergy of bifunctional and trifunctional minicellulosomes. The PASC conversion 
percentages of six surface engineered yeast strains were compared after 24 and 73 hours. The differences 
between the CipA1-based minicellulosomes and the unifunctional minicellulosomes reflect the enzyme-
enzyme synergy, while those between the CipA3- and CipA1-based minicellulosomes reflect the enzyme-
proximity synergy. 
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Notably, the synergistic effect of BGL1 was more profound when it was in close 
proximity with EGII and CBHII, indicating a higher local cellobiose concentration near the 
surface of the PASC reacting site that inhibited the activity of EGII and/or CBHII. As a result, 
although strain CipA3-EGII-CBHII-BGL1 showed much lower CBHII display level than strain 
CipA3-EGII-CBHII, the former maintained higher hydrolytic activity even after ~144 hours 
(data not shown), while the opposite result was obtained for the CipA1-based strains (Figure 
4.12). 
4.2.6. Direct Conversion of Cellulose to Ethanol by Resting Yeast Cells Displaying 
Trifunctional Minicellulosomes 
Direct production of ethanol from PASC was carried out anaerobically in a serum bottle 
using strain CipA3-EGII-CBHII-BGL1 displaying trifunctional minicellulosomes. Since this 
strain did not show sustained growth on PASC (data not shown), cells were precultured, induced, 
and then resuspended in fermentation medium to an OD600 of 50. As shown in Figure 4.13, 
PASC consumption by strain CipA3-EGII-CBHII-BGL1 started without a time lag, and within 
the first 6 hours of fermentation, the ethanol titer quickly reached ~1 g/L. Afterwards, the ethanol 
production rate slowed down and the titer reached ~1.8 g/L after 70 hours. The decrease in the 
ethanol production rate was probably due to the pH increase of the fermentation medium to ~7, 
at which the enzyme activity was not optimal. The yield was 0.31 grams of ethanol produced per 
gram of PASC consumed, which corresponded to ~62% of the theoretical yield. Ethanol 
produced by the negative control strain was not a result of PASC but YP medium fermentation 
since the same amount of ethanol was also observed using un-supplemented YP medium (Figure 
4.13B and data not shown). 
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Figure 4.13 Direct fermentation of PASC to ethanol by the resting yeast cells (CipA3-EGII-CBHII-
BGL1) displaying trifunctional minicellulosomes. The concentration of (A) ethanol and (B) residual 
PASC is plotted over time. Yeast strain HZ1901 (Table 4.1) was used as a negative control. 
4.3. Conclusions and Outlook 
CBP is one of the most promising processing scenarios for cost-effective cellulosic 
ethanol production, and the development of a whole-cell biocatalyst that can efficiently ferment 
cellulosic biomass to ethanol is the key to its success [1, 10, 18]. Much effort has been devoted 
to engineering of S. cerevisiae for CBP because S. cerevisiae has many superior traits, including 
high ethanol productivity, yield, and tolerance; robustness in industrial fermentation; a wide 
variety of genetic engineering tools; and generally-regarded-as-safe status [36]. One of the key 
challenges of using S. cerevisiae as a CBP host is to confer the ability to degrade cellulose 
rapidly into glucose. In nature, cellulolytic anaerobes have evolved an intricate multi-enzyme 
complex – cellulosome – to efficiently break down plant cell wall. Its degradative potential has 
sparked great interest in producing and engineering recombinant or designer cellulosomes for 
biotechnological and bioenergy applications [18, 37]. In this chapter, we report the successful 
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display of two miniscaffoldins, CipA3 and CipA1, on the yeast cell surface, which served as 
anchor proteins to assemble a series of uni-, bi-, and tri-functional minicellulosomes. All of the 
recombinant minicellulosomes were very stable and showed hydrolytic activity towards 
amorphous cellulose PASC. This study represents the first successful report of producing 
functional multi-enzyme-containing minicellulosomes in vivo. More importantly, the 
recombinant yeast cells displaying trifunctional minicellulosomes on the surface synergistically 
hydrolyzed amorphous cellulose to glucose and directly converted it to ethanol with a titer of 
~1.8 g/L. These results demonstrated the feasibility of combining designer cellulosomes and 
CBP, two of the most promising technologies in future biorefinery.  
A recent study has shown that synergistic hydrolysis of amorphous cellulose could be 
achieved by simply codisplaying three cellulases on yeast cell surface as individual fusion 
proteins with the C-terminal-half region of α-agglutinin [11]. Their experimental design 
resembles the CipA1-strains created in this study, in which the enzymes are spatially distributed 
on the yeast cell surface and thus no enzyme-proximity synergy could be incorporated using their 
display system. In addition, the C-terminal fusion of the α-agglutinin impaired enzyme activity 
since CBHII-fusion showed no activity towards PASC and no EGII activity was detected within 
the first 10 hours of reaction [11]. In contrast, when CBHII or EGII were displayed on cell 
surface through cohesin-dockerin interactions, both showed higher activity towards PASC 
(Figure 4.9). Bringing the two enzymes in close proximity on a miniscaffoldin, CipA3 further 
enhanced the activity: 1.9 mM (this study) vs. 1.3 mM [11] of reducing sugars was released from 
PASC after ~72 hours. These results clearly showed the advantage of engineering cellulolytic 
yeast strains through surface display of minicellulosomes to incorporate their synergistic 
hydrolytic activity.  
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Another study published when the work described in this chapter [38] was under review 
also successfully displayed a functional miniscaffoldin on yeast cell surface [26]. While both that 
study and the work reported here showed synergistic hydrolysis and direct conversion of PASC 
to ethanol, there is a significant difference between the engineered yeast strains with respect to 
consolidated bioprocessing. Tsai et al. [26] did not demonstrate that the yeast cells were capable 
of synthesizing functional minicellulosomes. In fact, the recombinant yeast strain in their study 
was not truly cellulolytic and required in vitro loading of the enzyme components, which were 
produced in E. coli, onto the scaffoldin. In contrast, we have shown that, by co-expressing a 
miniscaffoldin and three types of cellulases, yeast cells could be rendered cellulolytic - a critical 
requirement for using yeast cells in consolidated bioprocessing [1]. Therefore, we believe that 
the yeast strain described in this study represents a better engineering platform for CBP-enabling 
microorganism development. In addition, the recombinant yeast cell developed in this study 
could also be a useful tool for studying and engineering the synergism of cellulosomes. The 
mechanisms responsible for the enhanced activity of cellulosomes were poorly understood until 
recently, when precise control of cellulosomal composition and arrangement was made possible 
by constructing designer cellulosome chimeras in vitro [15, 23]. In theory, such chimeras can be 
readily assembled on the yeast cell surface by replacing the miniscaffoldin CipA3 used in this 
study with a chimeric scaffoldin containing divergent cohesin modules and the dockerin domains 
with those of cognate specificity. Since the display method described here allows production of 
all cellulosomal components in vivo, it avoids the labor-intensive protein purification step. In 
addition, any of the cellulosomal components could be easily swapped with those of interest 
using the DNA assembler method, which allows fast assembly of DNA fragments into a large 
molecule in a single transformation step [39]. Therefore, the in vivo method described here 
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represents a convenient and robust means of producing and studying cellulosomes for 
biotechnological and industrial applications. As an example, we have shown in this chapter that 
the display system can be used as a simple and useful tool to dissect the contributions of enzyme-
enzyme synergy and enzyme proximity synergy to the overall enhanced hydrolytic activity of the 
trifunctional minicellulosomes.  
Finally, we have successfully demonstrated the direct conversion of amorphous cellulose 
to ethanol using resting yeast cells displaying trifunctional minicellulosomes. However, the 
direct conversion of crystalline cellulose to ethanol remains a challenging task. In theory, the 
trifunctional minicellulosomes constructed in this study should meet the minimum requirement 
for crystalline cellulose fermentation. Indeed, when we tested strain CipA3-EGII-CBHII-BGL1 
for its ability to ferment Avicel, it did produce ethanol, but at an extremely low level with a titer 
of ~0.4 g/L after about 5 days (data not shown). Such slow catalysis and low fermentation 
efficiency could be potentially improved by increasing the enzyme display levels and/or activity. 
Concomitantly, cellulosomes with higher levels of complexity could be assembled to further 
boost synergy. Although these studies are still in progress (see Chapter 5), the results presented 
in this chapter clearly underscores the potential of engineering yeast as a CBP platform organism 
using the strategy of surface display of cellulosomes.  
4.4. Materials and Methods 
4.4.1. Strains, Media, and Reagents  
S cerevisiae EBY100 (Invitrogen, Carlsbad, CA) was used for the yeast cell surface 
display, and the recombinant yeast strains are summarized in Table 4.1. Escherichia coli DH5α 
(Cell media facility, University of Illinois at Urbana-Champaign, Urbana, IL) was used for 
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recombinant DNA manipulation. Clostridium thermocellum (DSM1237), Trichoderma reesei 
(DSM769), and Aspergillus aculeatus (DSM2344) were purchased from DSMZ (Braunschweig, 
Germany). S. cerevisiae EBY100 transformants were selected and maintained on SC-Trp, SC-
Leu, or SC-Trp-Leu plates (0.167% yeast nitrogen base without amino acids and ammonium 
sulfate [Difco laboratories, Detroit, MI], 0.5% ammonium sulfate, 2% glucose, 1.5% agar, and 
appropriate supplements) and induced in YPG (1% yeast extract, 2% peptone, 2% galactose). E. 
coli was cultured in LB medium (Fisher, Pittsburgh, PA). C. thermocellum was cultured 
anaerobically in Reinforced Clostridial Medium (Difco) supplemented with 0.6% cellobiose. The 
anaerobic medium was prepared by dissolving the mixed powder in anaerobic ddH2O in an 
anaerobic chamber, followed by autoclave in rubber-stoppered serum bottles. T. reesei and A. 
aculeatus were grown on YPAD plates (1% yeast extract, 2% peptone, 2% glucose, 0.01% 
adenine hemisulphate, 1.5% agar). All restriction enzymes were obtained from New England 
Biolabs (Ipswich, MA). Unless otherwise indicated, all chemicals were purchased from Sigma 
(St. Louis, MO).  
4.4.2. Plasmid Construction  
The sequences of all PCR primers used are listed in Table 4.2. Primers were synthesized 
by Integrated DNA Technologies (Coralville, IA). The PCR reaction condition used is described 
in the first paragraph of Section 2.4 unless otherwise specified. Plasmid pYD1ctrl was created by 
co-transforming hybridized RemoveFor/RemoveRev double-stranded DNA (dsDNA) and 
XhoI/PmeI digested pYD1 (Invitrogen) to EBY100. Genes encoding miniscaffoldin CipA1 and 
CipA3 were obtained by PCR using primer pairs CipA1For/CipA1Rev and CipA3For/CipA3Rev, 
respectively, with C. thermocellum genomic DNA as a template. Plasmids pYD1-CipA1 and 
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pYD1-CipA3 were constructed by co-transforming the CipA1 or CipA3 PCR products and 
XhoI/PmeI digested pYD1 to EBY100. See Fei Wen Notebook 6, pp. 6-8, 11. 
Table 4.2 Primers used for cloning. 
Name Sequence 5’→3’ 
RemoveFor GCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCTTCGAATGAGT
TTAAACCCGCTGATCTGATAACAACAGTGTAGATG 
RemoveRev CATCTACACTGTTGTTATCAGATCAGCGGGTTTAAACTCATTCGAAGGGCCCTCTA
GACTCGAGCGGCCGCCACTGTGCTGGATATCTGC 
CipA1For CGGCCGCTCGAGAATGCAACACCGACCAAGGGAGC 
CipA3Rev GCGGGTTTAAACTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTT
ACCTTCGAAGGGCCCATTCGAATCATCTGTCGGTGTTGTTACAGG 
CipA3For CGGCCGCTCGAGGTATCGGCGGCCACAATGACAGTCGAG 
egl2For2  GAGAGAAGCTCATCATCACCATCACCATGGTCAGCAGACTGTCTGGGGCCA 
egl2Rev2 GTAGAGGACCCACCTCCTCCAGATCCCCATGGCTTTCTTGCGAGACACG 
cbh2For GCAGAAGGCTCTTTGGACAAGAGAGAAGCTCGGCCGGATTATAAAGATGACGAT
GACAAACAAGCTTGCTCAAGCGTCTGGGGCCAATG 
cbh2Rev GTAGAGGACCCACCTCCTCCAGATCCCCATGGCAGGAACGATGGGTTTGCGTTTG
TGAGAAGC 
bgl1For3 GTTTTATTCGCAGCATCCTCCGCATTAGCTGCAGGTGAACAAAAACTCATCTCAG
AAGAGGATCTGGATGAACTGGCGTTCTCTCCTCCATTCTATCCC 
bgl1Rev3 CGTCGCCATTTACATCACCGTAAACAACCTGAGGAGAACCTCCACCGCCACTACC
CCCGGGTTGCACCTTCGGGAGCGCTGCGTGAAGGGGC 
BsaXIFor GACCACACCTCTACCGGCATGACTAGCCAGCTTTTGTTCCCT  
BsaXIRevRV GGAGAGCGCACGAGGGAGCT 
GAL10For  CTGATTAATTACCCCAGAAATAAGGCTAAAAAACTAATCGCATTATCATC 
GAL10RevRV CAAGACAATCAAAACCTTCATTTATATTGAATTTTCAAAAATTCTTACTTTTTTTTT
GG 
PreproForRV CCAAAAAAAAAGTAAGAATTTTTGAAAATTCAATATAAATGAAGGTTTTGATTGT
CTTG 
PreproRev CCTAGGTACGTATTTGTCATCGTCATCTTTATAATCCGGCCGAGCTTCTCTCTTGT
CC 
DR1For GATTATAAAGATGACGATGACAAATACGTACCTAGGAAAGAAGAACATGTGATC
ATCCAGGCCG 
DR1Rev CCATATGGGACCCACCTCCTCCAGATCCGAGCTCCTTGCTCTGTGCAGATTCAGAT
CG 
C-mycFor GAGCTCGGATCTGGAGGAGGTGGGTCCCATATGGAACAAAAACTCATCTCAGAA
GAGGATCTGTGATGGACTTCTTCGCCAGAGGTTTGGTCAAGTCTC 
ADH1Rev AGGGAACAAAAGCTGGCTAGTCATGCCGGTAGAGGTGTGGTC 
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Table 4.2 continued 
Name Sequence 5’→3’ 
AGA2For GGCAGTAACCTGGCCCCACAAACCTTCAAATGAACG 
pYD1Rev GTCGATTTTGTTACATCTACAC 
9E-docStFor CCATGGGGATCTGGAGGAGGTGGGTCCTCTACTAAATTATACGGCGACGTC 
9E-docStRev GACTTGACCAAACCTCTGGCGAAGAAGTCCATTAGTTCTTGTACGGCAATGT 
G1A2For1 GCGATTAGTTTTTTAGCCTTATTTCTGGGG 
G1A2Rev1 ACCTGCAGCTAATGCGGAGGATGCTGCGAATAAAACTGCAGTAAAAATTGAAGG
AAATCTCATGGTTTTTTCTCCTTGACGTTAAAGTATAGAGG 
G1A2For2 CCTCAGGTTGTTTACGGTGATGTAAATGGCGACG  
G1A2Rev2 GAGATCCGCTTATTTAGAAGTGTCGAATTCCTAATAAGGTAGGTGGGGTATGCTC
TTTATC 
G1A2For3 GAATTCGACACTTCTAAATAAGCGGATCTC  
G1A2Rev3 GTAATACGACTCACTATAGGGCGAATTGGGCTCGAGGGCATGCGAAGGAAAATG 
G10A1For1 GTACAGATCCCGACCCATTTGC 
G10A1Rev1 CGCTTAACTGCTCATTGCTATATTGAAGTACGGATTAGAAGCCGCCGAGCGGGTG
ACAGC 
G10A1For2 GTACTTCAATATAGCAATGAGCAGTTAAGCG 
G10A1Rev2 ACCATGGTGATGGTGATGATGAGCTTCTCTCTTGTCCAAAGAGCC 
G10A1For3 CCATGGGGATCTGGAGGAGGTGGG  
G10A1Rev3 CTAAAGGGAACAAAAGCTGGCTAGTCATGCCGGTAGAGGTGTGGTC 
G10A1For4 GACCACACCTCTACCGGCATGACTAGCCAGCTTTTGTTCCCTTTAG  
G10A1Rev4 CCTGGTATCTTTATAGTCCTG 
BGL1-ctrl-For GGGCCCCCCCTCGAGGTCGACGGTATCGATACGGATTAGAAGCCGCCGAGCGGG
TGACAG 
BGL1-ctrl-Rev CAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTCCTCGAGGGCATGCGAA
GGAAAATGAGAAATATCG 
EGII-ctrl-For GGGCCCCCCCTCGAGGTCGACGGTATCGATATCGCTTCGCTGATTAATTACCCCA
G 
EGII-ctrl-Rev CAATTAACCCTCACTAAAGGGAACAAAAGCTGGAGCTCCATGCCGGTAGAGGTG
TGGTCAATAAGAGC 
The construction of all other plasmids involved either the use of the DNA assembler 
method as described elsewhere [39] or the conventional homologous recombination method, 
which splices multiple DNA fragments into a larger molecule using PCR [40] followed by co-
transformation with a linearized vector into yeast. Both methods require preparation of several 
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PCR fragments, and the templates, primer pairs, and PCR products used for each assembly are 
summarized in Table 4.3. PCR fragments F0-F5 were spliced and ligated into BsaXI/EcoRI 
digested pYD1 to assemble a GAL1-10-prepro-ADH1 expression cassette (G10A1), which was
Table 4.3  PCR fragment sets for plasmid construction using the DNA assembler method [39] 
then transferred into pRS425 (New England Biolabs, Beverly, MA) between SacI and HindIII 
sites for protein expression. The fungal cDNA was prepared as the following: ~0.2 g of fungi 
grown on appropriate plate (the recipe is detailed in Section 4.4.1) was scraped off using a 
spatula, frozen with liquid nitrogen in a mortar, and ground thoroughly with a pestle. Liquid 
nitrogen was added continuously to avoid thawing. The frozen powder was then transferred into 
Template Primer pairs (forward/reverse) PCR product 
pYD1 BsaXIFor/BsaXIRevRevised F0 
Yeast genomic DNA GAL10For/GAL10RevRevised F1 
pRSGAL PreproForRevised/PreproRev F2 
NW1 DR1For/DR1Rev F3 
Yeast genomic DNA C-mycFor/ADH1Rev F4 
pYD1 AGA2For/pYD1Rev F5 
T. reesei cDNA cbh2For/cbh2Rev FLAG-CBHII  
C. thermocellum genomic DNA 9E-docStFor/9E-docStRev docS 
pYD1 G1A2For1/G1A2Rev1 G1A2-HR1 
A. aculeatus  cDNA bgl1For3 / bgl1Rev3 c-Myc-BGL1 
C. thermocellum  genomic DNA G1A2For2/G1A2Rev2 docAt 
Yeast  genomic DNA G1A2For3/G1A2Rev3 ADH2 
pYD1 G10A1For1/ G10A1Rev1 G10A1-HR1  
pRS425-CBHII G10A1For2/ G10A1Rev2 G10A1-HR2 
pRS425-CBHII G10A1For3/ G10A1Rev3 G10A1-HR3 
pYD1 G10A1For4/ G10A1Rev4 G10A1-HR4 
T. reesei cDNA egl2For2/ egl2Rev2 HisG-EGII 
pRS425-CBHII-BGL1 BGL1-ctrl-For/BGL1-ctrl-Rev BGL1-ctrl 
pYD1-R1-EGII EGII-ctrl-For/EGII-ctrl-Rev EGII-ctrl 
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an eppendorf tube quickly and treated using the RNeasy plant kit (Qiagen, Valencia, CA) 
following the manual for filamentous fungi. The on-column DNase digestion was performed 
using the RNase-Free DNase set (Qiagen) following manufacturer's protocol. The isolated total 
RNA was used as template to synthesize the cDNA library immediately using the transcriptor 
first strand cDNA synthesis kit (Roche, Indianapolis, IN) with oligo (dT)18 primer. Plasmid 
pRS425-CBHII was obtained by co-transforming FLAG-CBHII, docS, and EagI/NdeI digested 
pRS425-G10A1 into EBY100. Plasmids pRS425-EGII and pRS425-BGL1 were obtained by co-
transforming EGII-ctrl and BGL1-ctrl, respectively, with HindIII/SacI digested pRS425 into 
EBY100. Plasmid pRS425-CBHII-BGL1 was obtained by co-transforming G1A2-HR1, c-Myc-
BGL1, docAt, ADH2, and ApaI digested pRS425-CBHII. Plasmid pYD1-CipA1(3)-EGII was 
obtained by co-transforming G10A1-HR1, G10A1-HR2, G10A1-HR3, G10A1-HR4, HisG-EGII, 
and DrdI/NheI digested pYD1-CipA1(3) into EBY100. All plasmids were purified from S. 
cerevisiae and transformed into DH5α, recovered, and confirmed by DNA sequencing. See Fei 
Wen Notebook 4, pp. 37-40, and Notebook 6, pp. 4-5, 13, 19, 25. 
4.4.3. Yeast Surface Display and Flow Cytometry Analysis  
S. cerevisiae EBY100 clones transformed with different plasmid constructs were cultured, 
induced for 48 hours or 72 hours, and analyzed using flow cytometry as described elsewhere [41] 
except that only 2.5x106 cells were used in each staining assay (see Section 2.4.5 for more 
details). 48-hour induction was used for strains CipA3-EGII-CBHII-BGL1 and CipA1-EGII-
CBHII-BGL1 to get higher enzyme display levels, while 72-hour induction was used for all other 
strains to get higher cell density. 24-hour induction was also tested, but it did not reach full level 
of protein expression. Primary mouse monoclonal antibodies used in the assay were anti-V5 
(Invitrogen), anti-His (Sigma), anti-FLAG (Sigma), and anti-c-Myc (Invitrogen) with a 100-fold 
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dilution rate. Quantification of the surface expression level of the miniscaffoldin was carried out 
using the Quantum FITC MESF microsphere kit (Bangs Laboratories, Inc., Fishers, IN) and anti-
V5-FITC monoclonal antibody (Invitrogen) following manufacturer’s protocol. Since the clonal 
variation of enzyme expression level was small (Figure 4.6), a single clone was analyzed in 
triplicate in the enzyme activity assay and resting cell study. See Fei Wen Notebook 6, pp. 14, 
19-20, 23. 
4.4.4. Substrate Preparation and Carbohydrate Assays 
PASC was generated from Avicel PH-101 crystalline cellulose as described elsewhere 
[42]. Briefly, 10 g of Avicel was slowly added into 30 mL ddH2O with stirring at 4 °C, forming 
a homogeneous solid white paste. A total volume of 500 mL of 85% phosphoric acid was then 
added into the Avicel paste at 4 °C with the first 250 mL added very slowly. The resulting 
transparent solution was left at 4 °C overnight with gentle stirring. The cellulose was precipitated 
by addition of 4×500 mL of cold ddH2O with vigorous mixing between each addition, followed 
by extensive wash with cold ddH2O until pH reached ~6. The residual phosphoric acid was 
neutralized by washing the cellulose with 1% NaHCO3 three times and then with cold ddH2O 
until pH reached ~5-7. For long-term storage, 5 mM sodium azide was added to prevent bacterial 
growth. Before enzyme activity assay or resting cell study, the PASC was washed at least ten 
times to remove sodium azide and/or soluble sugars.  
The concentration and number-average degree of polymerization of the insoluble 
substrates (PASC and Avicel) were determined using the phenol-sulfuric acid method and the 
modified 2,2'-bicinchoninate (BCA) method as described elsewhere [43, 44]. The phenol-sulfuric 
acid method was used to measure the total sugar concentration. Briefly, 1 mL of diluted sample 
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(0.001%-0.01% glucose equivalent) was mixed with 1 mL of 5% cold phenol, followed by 
addition of 5 mL of 98% sulfuric acid. The mixture was immediately mixed by inverting the tube 
three times and then cooled down to room temperature before measuring the absorbance at 490 
nm. Caution is needed in this step since the mixing generates a lot of heat. The modified BCA 
method was used to measure the reducing sugar concentration. Briefly, 1 mL of diluted sample 
(0.0001%-0.001% glucose equivalent) was mixed with 1 mL of BCA working solution (made 
fresh by mixing equal volumes of solution A containing 0.942% disodium 2,2’-bicinchoninate, 
5.428% Na2CO3, and 2.42% NaHCO3, and solution B containing 1.248% CuSO4•5H2O and 
1.262% L-serine). The mixture was shaken at 75 °C, 250 rpm for 30 minutes and then cooled 
down to room temperature. For soluble sugars, the absorbance of the mixture was measured at 
560 nm directly; for insoluble sugars, the reaction mixture was spun down and the absorbance of 
the supernatant was measured at 560 nm.  
When analyzing the hydrolytic activity of cell surface displayed minicellulosomes, the 
Somogyi-Nelson method was used to measure the reducing sugar concentration as described 
elsewhere [43]. Briefly, the Somogyi working solution was prepared fresh by mixing 800 µL of 
Somogyi reagent I containing 18% Na2SO4, 1.5% Rochelle, 3% Na2CO3, and 2% NaHCO3 with 
200 µL of Somogyi reagent II containing 18% Na2SO4 and 2% CuSO4•5H2O. 1 mL of diluted 
sample (0.001%-0.01% glucose equivalent) was then mixed with 1 mL of Somogy working 
solution, boiled for 15 minutes, cooled down to room temperature, and 1 mL of Nelson reagent 
(5% ammonium molybdate, 4.2% H2SO4, and 0.6% sodium arsenate) was added and mixed 
vigorously by vortexing. Caution is needed in this step since the mixing generates a lot of gas, 
and the assay should be carried out in a 15 mL tube. The BCA assay should not be used when 
there are cells in the reaction even with SDS precipitation and ethanol washing. The 
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dinitrosalicylic (DNS) colorimetric assay did not work well for reducing sugar measurement, 
giving non-linear and irreproducible standard curves. See Fei Wen Notebook 6, pp. 16, 29-30, 
32-33. 
4.4.5. Enzyme Activity Assays 
Yeast transformants displaying different minicellulosomes on the cell surface were 
analyzed for their ability to hydrolyze PASC and Avicel. After induction in YPG, cells were 
washed twice with hydrolysis buffer (50 mM sodium acetate, pH 5.0) to prevent media carry 
over and then resuspended in hydrolysis buffer supplemented with 0.1% PASC or Avicel to 
OD600~10. The induced cells could be stored at 4 °C for up to two weeks without significant loss 
of hydrolytic activity. Hydrolysis reactions were carried out in serum bottles at 30 °C with 100 
rpm agitation and 2 mL of reaction sample was drawn at time intervals as indicated. The amount 
of reducing sugar released from the insoluble substrates was measured using the Somogyi-
Nelson method, and the concentrations of total sugar, total soluble sugar, and cell derived sugar 
were quantified using the phenol-sulfuric acid method. The concentration of residual insoluble 
sugar was obtained by subtracting total soluble sugar and cell derived sugar from total sugar. All 
sugar concentrations were determined as glucose equivalent. The supernatant was analyzed for 
the hydrolysis products using high performance liquid chromatography (HPLC) equipped with a 
low temperature evaporative light scattering detector (Shimadzu, Columbia, MD). Separation 
was carried out using a Prevail carbohydrate ES column (Alltech Associates, Inc., Deerfield, IL) 
at 32 °C using a gradient mobile phase (80-65% acetonitrile in water in 50 min, v/v) at a flow 
rate of 1 mL/min.  
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The activity of BGL1 was analyzed by cell growth using cellobiose as the only carbon 
source. Induced yeast trains (CipA3-EGII-CBHII-BGL1, CipA3-EGII-CBHII, and negative 
control) were washed twice with corresponding synthetic drop-out media supplemented with 1% 
of cellobiose and then resuspended to OD600~0.1. Samples were drawn at time intervals as 
indicated and the cell density was plotted over time. The cell growth on PASC was also 
examined. The induced yeast cells were washed twice with YPA medium and the PASC was 
washed extensively (at least 5-10 times) with YPA (1% yeast extract, 2% peptone, 2% glucose, 
0.01% adenine hemisulphate) to remove sodium azide and soluble sugars. Then the cells and 
PASC were combined and resuspended in YPA to final OD600~1 and 0.5%, respectively. The 
cell density was determined using a hemacytometer (Hausser Scientific, Horsham, PA). See Fei 
Wen Notebook 6, pp. 18-19, 27, 31-37. 
4.4.6. Ethanol Production from PASC Using Resting Cells 
After induction in YPG, yeast strain CipA3-EGII-CBHII-BGL1 was washed twice with 
YP medium (1% yeast extract, 2% peptone) and resuspended to OD600~50 in YP medium 
supplemented with 0.001% ergosterol, 0.042% Tween 80, and 1% PASC/Avicel. All reagents 
were prepared anaerobically and the experiment was carried out in an anaerobic chamber. 
Ergosterol was prepared as a 500× stock solution in dimethylformamide. The yeast strain 
HZ1901 was used as a negative control and analyzed the same way as strain CipA3-EGII-
CBHII-BGL1. The fermentation was carried out anaerobically in serum bottles at 30 °C with 250 
rpm agitation and 1 mL of sample was taken at time intervals as indicated. Residual total sugar 
concentration was determined by subtracting cell derived sugar from total sugar. Ethanol 
concentration was determined by gas chromatography using an Agilent 7890A (Agilent Inc., 
Palo Alto, CA) equipped with an Agilent 5975C mass selective detector and an HP-INNOWAX 
136 
column (Agilent Inc.) with helium as the carrier gas (1 mL/min flow rate). 1-propanol was used 
as the internal standard. The temperature program used for compound separation was 80 °C for 2 
min, 5 °C/min to 150 °C, 25 °C/min to 260 °C for 2 min. See Fei Wen Notebook 6, pp. 33, 36-37. 
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Chapter 5. Simultaneous Hydrolysis and Fermentation of Cellulose 
to Ethanol by Recombinant Saccharomyces cerevisiae 
5.1. Introduction 
As stated in Chapter 4, consolidated bioprocessing (CBP), which features cellulase 
production, cellulose hydrolysis, and hydrolysate fermentation in a single step, has a great 
potential to significantly lower the cost of cellulosic ethanol production than other process 
configurations [1-5]. The key challenge in realizing such potential is to develop a recombinant 
microorganism that is capable of efficiently hydrolyzing cellulose and fermenting the 
hydrolysate (glucose) into ethanol. In an effort to develop a CBP-enabling microorganism, we 
have engineered a cellulolytic yeast strain by displaying trifunctional minicellulosomes on the 
cell surface ([6] and Chapter 4). The trifunctional minicellulosome was assembled by co-
expressing a mini-scaffoldin derived from Clostridium thermocellum and three types of 
cellulases − an endoglucanase and a cellobiohydrolase isolated from Trichoderma reesei, and a 
β-glucosidase isolated from Aspergillus aculeatus. It showed both enzyme-enzyme synergy and 
enzyme proximity synergy, and was stable at 4 °C for at least two months. The yeast strain 
displaying the trifunctional minicellulosome was able to directly ferment amorphous phosphoric 
acid swollen cellulose (PASC) to ethanol, demonstrating the feasibility of engineering yeast 
Saccharomyces cerevisiae as a platform microorganism for CBP. 
Although the results were promising, the cellulose degradation capability of the yeast 
strain reported in Chapter 4 was still limited and it was unable to grow using PASC as the sole 
carbon source. As a result, yeast cells had to be pregrown in glucose and resuspended at a high 
cell density (OD600~50) before PASC conversion to ethanol was possible, introducing additional 
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steps into a cellulosic ethanol production process. In addition, even at such a high cell density, 
the surface engineered yeast strain could not efficiently hydrolyze and ferment crystalline 
cellulose Avicel to ethanol. Therefore, the goal of this project is to improve the cellulose 
hydrolytic efficiency of yeast S. cerevisiae to enable its growth on cellulose and one-step 
conversion of cellulose to ethanol.  
In this chapter, we report the preliminary results of engineering the minicellulosome 
yeast display system for improved cellulolytic efficiency. Various strategies have been attempted, 
including (1) improving the cellulosomal enzyme display level through optimizing the protein 
induction conditions, reducing the cell metabolic burden, expressing alternative endoglucanases 
and exoglucanases, and in vitro cellulase loading, and (2) developing a constitutive yeast display 
system. Among these strategies, cell growth was only observed when cellulases were loaded in 
vitro onto the miniscaffoldin, indicating that the enzyme expression level was the limiting step. 
Future work will focus on improving the cellulase expression level with concomitant enzymatic 
activity engineering using the constitutive yeast display system. The following experiments were 
designed by Fei Wen and carried out by Fei Wen with Jie Sun’s assistance.  
5.2. Results and Discussion 
5.2.1. Optimizing the Protein Induction Conditions 
As shown in Figure 4.6, the surface display level of CBHII dropped significantly in 
strain CipA3-EGII-CBHII-BGL1 compared to other strains. Since the protein induction 
condition (20 °C in 3 mL of induction medium for 48 hours) used for minicellulosome surface 
display was designed based on that optimized for MHC display, it may not be optimal for 
minicellulosome expression. To improve the cellulosomal component display level, the protein 
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induction time was optimized first. After 24 hours and 48 hours of induction, samples were taken 
and the surface display level was measured using flow cytometry. As shown in Figure 5.1, 
although both CBHII and BGL1 showed a decreased (~10%) display level after 48 hours, the 
expression level of EGII was improved by almost 3-fold. Since the EGII activity was shown to 
be important for amorphous cellulose hydrolysis [7], 48-hour-induction was chosen. Interestingly, 
when the protein expression was scaled up from 3 mL to 50 mL, all cellulosomal components 
showed decreased display levels albeit to a different extent (Figure 5.1). Extending the induction 
time to 72 hours further decreased the expression levels of CBHII and BGL1, thus 48-hour-
induction was also used for 50 mL induction volume to have more balanced expression levels of 
the three cellulosomal enzymes. 
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Figure 5.1 Surface display levels of minicellulosomal components using different protein induction time 
(24, 48, and 72 hours) and different induction volume (3 mL vs. 50 mL). MFU=mean fluorescence unit.  
Induction temperature was also an important parameter for protein expression and was 
optimized next. Since the EGII, CBHII, and BGL1 enzymes were quite stable with optimal 
activity observed at 55 °C, 60 °C and 50 °C, respectively [8-10], their expression in yeast at 
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30 °C was tested. The flow cytometric results showed that increasing the temperature reduced 
the surface display level of all minicellulosomal components after 48 hours of induction, and 
shortening the induction time to 24 hours did not help (data not shown, see Fei Wen Notebook 6, 
pp. 17-18). Taken together, these date suggested that the induction condition used in Chapter 4 
was optimal for minicellulosome surface display.  
5.2.2. Reducing the Metabolic Burden 
To test the hypothesis that the low display level of CBHII was due to the metabolic 
burden imposed on the cell by expressing four proteins simultaneously (see Section 4.2.3), two 
strategies were employed next with the aim of reducing the metabolic burden. The first strategy 
was to express the CBHII and BGL1 enzymes using a single-copy CEN plasmid pRS415 instead 
of the multi-copy 2µ plasmid pRS425 with the assumption that the former would require less 
resource to maintain. As shown in Figure 5.2, switching the 2µ origin of replication to the 
CEN/ARS sequence did not improve the expression level of CBHII, but significantly decreased 
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Figure 5.2 Relative surface display levels of minicellulosomal components of strain 415-CipA3-EGII-
CBHII-BGL1 (Table 5.1) to those of strain CipA3-EGII-CBHII-BGL1. The MFU of strain CipA3-EGII-
CBHII-BGL1 minicellulosomal components was normalized to 1. 
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the expression level of both CipA3 and EGII, hence the total protein expression level, since 
CipA3 and EGII expressed at a level of >100-fold higher than CBHII and BGL1. The reason 
why replacing pRS425-CBHII-BGL1 with pRS415-CBHII-BGL1 did not affect the expression 
of CBHII or BGL1 as much as that of CipA3 and EGII, both of which were encoded in a 
different plasmid, was unknown. These data indicated that reducing the plasmid copy number 
did not seem to reduce the metabolic burden of cells, and on the contrary, it resulted in a reduced 
total protein expression level. 
Table 5.1 Recombinant S. cerevisiae EBY100 yeast strains constructed in this study. 
Strain namea Database number Plasmid 
CipA3-EGII-BGL1 HZ1883b + HZ1896b pYD1-CipA3-EGII & pRS425-BGL1 
CipA3-CBHII-BGL1 HZ1845b + HZ1868b pYD1-CipA3 & pRS425-CBHII-BGL1 
415-CipA3-EGII-CBHII-
BGL1 
HZ1911 pYD1-CipA3-EGII & pRS415-CBHII-BGL1 
CipA1-CelG-CelF-BGL1 HZ1854b + HZ1867b pYD1-CipA1-CelG & pRS425-CelF-BGL1 
CipA3-CelG-CelE-BGL1 HZ1857b + HZ1893b pYD1-CipA3-CelG & pRS425-CelE-BGL1 
CipA3-CelC-CelF-BGL1 HZ1866b + HZ1867b pYD1-CipA3-CelC & pRS425-CelF-BGL1 
CipA3-CelC-CelE-BGL1 HZ1866b + HZ1893b pYD1-CipA3-CelC & pRS425-CelE-BGL1 
CipA3-EGII-CelF-BGL1 HZ1888 pYD1-CipA3-EGII & pRS425-CelF-BGL1 
CipA3-EGII-CelE-BGL1 HZ1883b + HZ1893b pYD1-CipA3-EGII & pRS425-CelE-BGL1 
CBHII-ctrl HZ1849b pRS425-CBHII 
BGL1-ctrl HZ1896 pRS425-BGL1 
a
  For the purpose of clarity, the strains in this chapter are referred by the names listed in the first column. 
b
 The plasmid needs to be minipreped from the numbered DH5α strain and (co)transformed into yeast 
strain EBY100. 
Of note, with a ~3-fold improvement in the BGL1 display level, strain 415-CipA3-EGII-
CBHII-BGL1 grew much faster and to a much higher saturation density than strain CipA3-EGII-
CBHII-BGL1 using cellobiose as the sole carbon source (Figure 5.3). In addition, it showed an 
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almost identical growth profile in cellobiose as that in glucose with a doubling time of ~3.5 
hours. 
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Figure 5.3 Growth curves of strain CipA3-EGII-CBHII-BGL1 and 415-CipA3-EGII-CBHII-BGL1 using 
glucose or cellobiose as the only carbon source. 
To reduce the metabolic burden, the second strategy was to reduce the number of 
cellulosomal enzymes from three to two. Since BGL1 activity was essential for yeast cell growth, 
it was coexpressed with either EGII or CBHII (see strains CipA3-EGII-BGL1 and CipA3-
CBHII-BGL1 in Table 5.1). As shown in Figure 5.4, both strains showed improved total protein 
expression level, however, the increase was mainly from the improved expression of the 
miniscaffoldin CipA3 rather than that of the enzymes. Note that the CBHII expression level was 
much lower (~180-fold lower as shown in Figure 4.6) than CipA3, thus the 2-fold improvement 
of CBHII accounted for only a small fraction of the total protein expression level. Extending the 
protein induction time from 48 hours to 72 hours resulted in a further decrease in the BGL1 
expression level in both strains. These data indicated that reducing the number of coexpressed 
enzymes helped reducing the metabolic burden, but the cells channeled more resources into 
synthesizing the miniscaffoldin rather than the enzymes. 
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Figure 5.4 Relative surface display levels of minicellulosomal components of strain CipA3-EGII-BGL1 
and CipA3-CBHII-BGL1 to those of strain CipA3-EGII-CBHII-BGL1. The MFU of strain CipA3-EGII-
CBHII-BGL1 minicellulosomal components was normalized to 1.  
5.2.3. Alternative Endoglucanases and Exoglucanases 
In an effort to improve the minicellulosomal enzyme expression level, several different 
endoglucanases and exoglucanases were coexpressed in different combinations with BGL1 (no 
BGL1 alternative was tested since it was highly active as shown in Figure 5.3). Four well-
characterized cellulases from Clostridium cellulolyticum, which have been shown to exhibit 
synergistic cellulose hydrolytic activity, were examined [11-15]: endoglucanase CelG or CelC 
was used to replace EGII and exoglucanase CelE or CelF was used to replace CBHII (Table 5.1). 
Unfortunately, all of these alternative enzymes showed much lower display levels than EGII and 
CBHII with ~80% and >95% decrease, respectively (Figure 5.5). Optimization of the induction 
temperature (20 °C vs. 30 °C) and time (24 hours vs. 48 hours) did not affect the expression 
levels significantly (data not shown, see Fei Wen Notebook 6, pp. 17-18). Of note, another two 
strains CipA3-EGII-CelF-BGL1 and CipA3-EGII-CelE-BGL1 (Table 5.1) were also tested, in 
which only the exoglucanase CBHII was replaced with CelF or CelE, respectively. They both 
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showed similar results (data not shown, see Fei Wen Notebook 6, pp. 26). Therefore, these four 
cellulases could not be used as alternatives to improve the enzyme display levels.  
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Figure 5.5 Relative surface display levels of minicellulosomal components of strain CipA1-CelG-CelF-
BGL1, CipA3-CelG-CelE-BGL1, CipA3-CelC-CelF-BGL1, and CipA3-CelC-CelE-BGL1 to those of 
strain CipA3-EGII-CBHII-BGL1. The MFU of strain CipA3-EGII-CBHII-BGL1 minicellulosomal 
components was normalized to 1. Endo=endoglucanase EGII, CelG, or CelC, Exo=exoglucanase CBHII, 
CelE, or CelF. 
5.2.4. In vitro Enzyme Loading onto the Yeast Surface Displayed Miniscaffoldin 
Since all of the attempts to improve the cellulosomal enzyme display levels through in 
vivo expression optimization failed, in vitro loading of free enzymes onto the miniscaffoldin 
displayed on yeast cell surface was tested next. Secretion strains CBHII-ctrl and BGL1-ctrl were 
constructed to obtain free soluble enzymes. The supernatant was concentrated by ~25-fold and 
mixed with CipA3-EGII-CBHII-BGL1 cells induced in 50 mL of YPG for 72 hours. After 
incubation at 4 °C overnight, the surface display levels of all four minicellulosomal components 
were measured by flow cytometry. As shown in Figure 5.6, the free CBHII enzyme was 
immobilized on yeast cell surface through cohesin-dockerin interaction and its display level was 
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significantly improved by ~100-fold. Interestingly, the display levels of CipA3 and EGII 
decreased after in vitro enzyme loading, probably due to their reduced accessibility by staining 
antibodies. The display level of BGL1 did not change significantly, probably due to the much 
better expression of CBHII than BGL1. Nevertheless, such low display level of BGL1 was 
enough to enable the cell growth on cellobiose (data not shown), thus not the limiting step in the 
following experiments. To further improve the total enzyme display capacity (i.e. the CipA3 
display level), protein induction in 3 mL volume for 72 hours was tested. As shown in Figure 
5.6, both CipA3 and EGII expressed twice as well and the resulting loaded cells also showed ~2-
fold improvement in the display levels of EGII and CBHII. 
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Figure 5.6 Surface display levels of minicellulosomal components of strain CipA3-EGII-CBHII-BGL1 
loaded with CBHII and BGL1. The CipA3-EGII-CBHII-BGL1 cells were induced in a volume of 50 mL 
or 3 mL YPG for 72 hours. 
With the success of improving minicellulosomal enzyme display levels through in vitro 
loading, the resulting cells were tested for their ability to grow using PASC as the sole carbon 
source. As shown in Figure 5.7, the 50mL-loaded cells showed very slow growth with ~40% 
increase in OD600 over a period of 8 days and stopped growing thereafter. With 2-fold higher 
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EGII and CBHII display levels, the 3mL-loaded cells showed a slightly more robust growth and 
doubled in ~8 days. Unfortunately, no sustained cell growth was observed. This result was not 
unexpected, since the expression of the minicellulosomal components was under the control of 
the galactose-inducible promoters (pGAL1 and pGAL10, Figure 4.2), thus the daughter yeast 
cells were not capable of producing new minicellulosomes to support continuous cell growth. 
Nevertheless, the cell growth on PASC observed with the in vitro enzyme-loaded CipA3-EGII-
CBHII-BGL1 indicated that it was feasible to engineer recombinant yeast strains with the ability 
to grow on and convert cellulose to ethanol. And the results presented in this section suggested 
that there are two key steps in achieving this goal: (1) establish a constitutive expression system 
for yeast surface display of minicellulosomes so that the miniscaffoldin and enzymes could be 
continuously synthesized, and (2) improve the enzyme expression to the levels that are high 
enough to support cell growth and cellulose fermentation. 
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Figure 5.7 Growth curves of strain CipA3-EGII-CBHII-BGL1 using PASC as the sole carbon source. 
The cells were induced in 50 mL or 3 mL of YPG and then loaded with free CBHII and BGL1 in vitro. 
The display levels of the minicellulosomal enzymes were shown in Figure 5.6. 
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5.2.5. Development of a Constitutive Yeast Surface Display System  
To develop a constitutive yeast surface display system, the initial strategy was to knock 
out galactokinase (Gal1p), the first enzyme of the Leloir pathway that catalyzes the formation of 
galactose-1-phosphate from galactose and ATP [16]. Studies have shown that the ∆gal1 strain 
cannot use galactose as a carbon source but only as a gratuitous inducer of pGAL in the presence 
of low glucose concentrations [17-19]. Given the low levels of glucose observed during cellulose 
hydrolysis (see Figure 4.9), such ∆gal1 strain should be able to utilize cellulose as the carbon 
source and galactose as the gratuitous inducer for continuous minicellulosome synthesis without 
glucose repression. Using a loxP–kanMX–loxP deletion cassette [20], a galactokinase null strain 
EBY100∆gal1 was created. Unfortunately, the EBY100∆gal1 strain did not show any 
miniscaffoldin display with three different carbon sources tested – glucose, ethanol, and glycerol 
(data not shown, see Fei Wen Notebook 6, pp. 45-46).  
The second strategy tested was to replace the galactose-inducible pGAL1 and pGAL10 to 
constitutive pTEF1 and pTEF2, respectively. To enable a constitutive display using yeast a-
agglutinin receptor, the pAGA1 in the genome of BJ5465, from which the EBY100 was created 
[21], was replaced with pTEF1 using the loxP–kanMX–loxP deletion cassette (this experiment 
was carried out by Jing Liang). The resulting strain BJ5465 pAGA1::kanMX-pTEF1 showed a 
very strong tendency to aggregate, maybe due to the constitutive expression of the mating 
receptor, the function of which was to promote cellular agglutination [22].  
Finally, the α-agglutinin receptor was employed to construct the constitutive 
minicellulosome display system. As shown in Figure 5.8, the DNA encoding the C-terminal 320 
amino acids of the α-agglutinin gene was fused to the end of the CipA3-encoding gene, and the 
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resulting chimeric protein was expressed under the control of pTEF1. The expression cassettes 
for the three cellulases were identical to those described in Figure 4.2 except that the pGAL1 
and pGAL10 were replaced with pTEF1 and pTEF2, respectively (Figure 5.8).  
CpRS425-EGII-BGL1
TEF1 TEF2
ss1 EGIIHisc-MycBGL1 ss2docA docS
TADH1TADH2
CpRS414-CipA3-CBHII
TEF2 TEF1
ss2 CαFLAGCBHII ss1docS V5
TADH1
CipA3
Tα
 
Figure 5.8 Plasmids used for constructing strain cCipA3-C2E2B1 (Table 5.2) constitutively expressing 
trifunctional minicellulosome CipA3-CBHII-EGII-BGL1. ss1 = synthetic prepro signal peptide [23], ss2 
= α-factor signal peptide with AG dipeptide spacer [24], Cα = C-terminal 320 amino acids of α-
agglutinin gene, T = terminator, Tα = terminator of α-agglutinin gene.  
To validate this constitutive display system, plasmid cpRS414-CipA3-CBHII was 
transformed into BJ5465 to obtain strain cCipA3-C2 (Table 5.2), which was then grew up using 
glucose as the sole carbon source and subjected to flow cytometry analysis. Of note, no 
transformants could be obtained when w303a was used as the host strain and no expression 
difference but only a slower cell growth rate was observed when EBY100 was used as the host 
strain. Therefore, the discussion hereafter focused on BJ5465 strain.  
Table 5.2 Recombinant S. cerevisiae BJ5465 yeast strains constructed in this study. 
Strain namea Database number Plasmid 
cdbØ HZ663b + HZ668b pRS414 & pRS425 
cCipA3-C2 HZ1925b cpRS414-CipA3-CBHII 
cCipA3-C2E2B1 HZ1925b + HZ1929b cpRS414-CipA3-CBHII & cpRS425-EGII-BGL1 
cCipA3-C2-pRS425 HZ1925b + HZ668b cpRS414-CipA3-CBHII & pRS425 
a
  For the purpose of clarity, the strains in this chapter are referred by the names listed in the first column. 
b
 The plasmid needs to be minipreped from the numbered DH5α strain and (co)transformed into yeast 
strain BJ5465. 
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As shown in Figure 5.9a, both CipA3 and CBHII were detected on the surface of strain 
cCipA3-C2, indicating a successful constitutive expression and assembly of the unifunctional 
minicellulosome CipA3-CBHII. Unfortunately but not unexpected, the use of constitutive 
promoters significantly reduced the expression levels of both CipA3 and CBHII by ~13- and ~6-
fold, respectively. And coexpression of additional two cellulases EGII and BGL1 further reduced 
the total enzyme display level on strain cCipA3-C2E2B1 (Figure 5.9b). Interestingly, 
maintaining an additional empty plasmid pRS425 also caused another ~9-fold decrease in the 
CBHII display level (compare cCipA3-C2 and cCipA3-C2-pRS425 in Figure 5.9b). 
Nevertheless, these data clearly suggested that a constitutive yeast display system has been 
successfully developed for surface assembly of trifunctional minicellulosomes. Although the 
resulting cCipA3-C2E2B1 strain did not show any growth on PASC due to the low expression 
levels of cellulases (data not shown), such constitutive expression system would be a useful 
platform for engineering cellulases with improved expression as stated in Section 5.2.4. 
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Figure 5.9 Display levels of the minicellulosomal components expressed under the control of constitutive 
promoters on yeast cell surface. (a) Compared to strain CipA3-CBHII (Table 4.1) that expressed the 
proteins under galactose-inducible promoters, strain cCipA3-C2 with the proteins expressed under 
constitutive promoters showed much lower display levels of both CipA3 and CBHII. (b) Evaluation of the 
constitutive system for yeast surface display of minicellulosomes. Note that the MFU in (a) is not 
comparable to that in (b), since the laser voltage settings used were different. 
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5.3. Conclusions and Outlook 
A cellulolytic yeast S. cerevisiae strain CipA3-EGII-CBHII-BGL1 has been created 
previously by displaying trifunctional minicellulosomes on the surface, however, its cellulose 
degradation capability was too low to support cell growth on PASC ([6] and Chapter 4). In an 
effort to improve the cellulolytic efficiency of this strain, various strategies have been employed 
with a focus of improving the minicellulosomal enzyme display levels. All of the attempts to 
improve the in vivo protein expression failed, including optimization of the protein induction 
conditions, reduction of the plasmid copy number, expression of fewer enzymes, and different 
combinations of alternative endoglucanases (CelG and CelC) and exoglucanases (CelE and 
CelF) isolated from C. cellulolyticum.  
In contrast, in vitro loading of cellulases onto the miniscaffoldin displayed on the yeast 
cell surface enabled a cell doubling over a period of ~8 days, confirming that the low enzyme 
expression level was the limiting step. This result also suggested that the minicellulosomes 
should be continuously synthesized to support a sustained cell culture for consolidated 
bioprocessing. By using the C-terminal half of the α-agglutinin as the cell anchor and pTEF1/2 
promoters, a yeast display system was developed to enable constitutive minicellulosome 
synthesis and assembly on the cell surface. Compared to the inducible system described in 
Chapter 4, the constitutive expression levels of all the minicellulosomal components 
significantly reduced, presenting us an even more challenging task to improve the enzyme 
expression to the desired level, which was estimated to be ~20 mg/L (data provided by Jing 
Liang). Nevertheless, these results clearly suggested the feasibility of engineering yeast cells 
with the ability to grow on and ferment cellulose to ethanol. 
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In a continuing effort to improve the minicellulosomal enzyme display level, the 
constitutive expression cassettes of EGII or CBHII are being integrated individually and in 
combination into the δ-sites of yeast genome using a modified δ-integration vector [25]. 
Approximately 60-120 copies of the expression cassette are expected to be integrated per cell 
and increase the expression of EGII and/or CBHII to the level high enough to support cell 
growth on PASC. If not successful, directed evolution could be carried out to select EGII and/or 
CBHII mutants with improved expression. Specifically, an EP-PCR library could be created and 
displayed on yeast cell surface using C-terminal half of the α-agglutinin as the anchor protein. 
The mutants with improved expression could then be selected in a high throughput manner using 
FACS and an antibody specific for a protein expression tag, such as V5, His, or FLAG. Once 
such mutants are identified, they could be integrated into the δ-sites to create a stable yeast strain 
capable of expressing enzymes at a high level in non-selective rich medium. If successful, the 
resulting strain could be used as a host for protein and metabolic engineering in a high 
throughput manner with aims to (1) further improve the expression of cellulases, (2) improve the 
cellulase hydrolytic activity, (3) select mutant yeast strains through adapted evolution, (4) 
improve the enzyme-enzyme synergy of different cellulases, and (5) create a cellulolytic and 
hemi-cellulolytic yeast strain that is capable of utilizing both cellulose and hemicellulose, which 
account for more than two-third of the lignocellulosic biomass [26]. 
With regard to #4, another cellobiohydrolase CBHI from T. reesei has been successfully 
cloned and displayed on yeast cell surface (Figure 5.10). CBHI is the most abundant cellulase 
produced in T. reesei, representing >60% of the total extracellular protein [27]. The 
incorporation of CBHI into the minicellulosome is essential for crystalline cellulose utilization, 
since it prefers the reducing ends of cellulose chains and exhibits synergy with CBHII that 
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prefers the non-reducing ends [3]. With regard to #5, three hemicellulases have been successfully 
displayed on yeast cell surface in the form of minixylanosomal enzymes (Figure 5.10): α-L-
arabinofuranosidase B (ABFB) and β-xylosidase D (XLND) from Aspergillus niger, and 
xylanase II (XYNII) from T. reesei [28, 29]. All three surface displayed unifunctional 
minixylanosomes showed activity toward their respective substrates: XYNII was active on water 
soluble arabinoxylan, XLND was active on xylobiose, xylotriose, and xylotetraose, and ABFB 
was active on 4-nitrophenyl α-L-arabinofuranoside (data not shown, the activity assays were 
carried out by Tong Si, Jie Sun, and Fei Wen). In summary, the results presented in this chapter 
have identified the key limiting step in realizing the potential of engineering yeast as a CBP 
platform organism, and the research progress has laid a solid foundation for future engineering 
work. 
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Figure 5.10 Yeast surface display of cellulase CBHI and hemicellulases XYNII, XLND, and ABFB as 
minicellulosomal and minixylanosomal enzymes, respectively. 
5.4. Materials and Methods 
5.4.1. Strains, Media, and Reagents 
S cerevisiae EBY100 (Invitrogen, Carlsbad, CA) and BJ5465 (American Type Culture 
Collection, Manassas, VA) were used for the yeast cell surface display, and the recombinant 
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yeast strains were summarized in Table 5.1 and Table 5.2. Escherichia coli DH5α (Cell media 
facility, University of Illinois at Urbana-Champaign, Urbana, IL) was used for recombinant 
DNA manipulation. Clostridium cellulolyticum (DSM5812) was purchased from DSMZ 
(Braunschweig, Germany). S. cerevisiae transformants were selected and maintained on SC-Leu 
or SC-Trp-Leu plates (0.167% yeast nitrogen base without amino acids and ammonium sulfate 
[Difco laboratories, Detroit, MI], 0.5% ammonium sulfate, 2% glucose, 1.5% agar, and 
appropriate supplements) and induced in YPG (1% yeast extract, 2% peptone, 2% galactose). E. 
coli was cultured in LB medium (Fisher, Pittsburgh, PA). C. cellulolyticum was cultured 
anaerobically in Reinforced Clostridial Medium (Difco) supplemented with 0.6% cellobiose. T 
reesei was grown on YPAD plates (1% yeast extract, 2% peptone, 2% glucose, 0.01% adenine 
hemisulphate, 1.5% agar). The anaerobic medium was prepared by dissolving the mixed powder 
in anaerobic ddH2O in an anaerobic chamber, followed by autoclave in rubber-stoppered serum 
bottles. All restriction enzymes were obtained from New England Biolabs (Ipswich, MA). 
Unless otherwise indicated, all chemicals were purchased from Sigma (St. Louis, MO).  
5.4.2. Plasmid Construction 
The sequences of all PCR primers used are listed in Table 5.3. Primers were synthesized 
by Integrated DNA Technologies (Coralville, IA). The PCR reaction condition used is described 
in the first paragraph of Section 2.4 unless otherwise specified. All plasmids were constructed 
using the DNA assembler method as described elsewhere [30]. Briefly, several DNA fragments 
with homologous ends were prepared by PCR and cotransformed with a linearized vector into 
yeast cells, generating an episomal plasmid through homologous recombination. The templates, 
primer pairs, and PCR products used for each plasmid assembly were summarized in Table 5.4. 
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Table 5.3 Primers used for cloning. 
Name Sequence 5’→3’ 
AmpFor CAGAAGTAAGTTGGCCGC 
LEU2Rev AGTTAAGAAAATCCTTGC 
9E-docStFor CCATGGGGATCTGGAGGAGGTGGGTCCTCTACTAAATTATACGGCGACGTC 
9E-docStRev GACTTGACCAAACCTCTGGCGAAGAAGTCCATTAGTTCTTGTACGGCAATGTA 
48CelFFor2 GCAGAAGGCTCTTTGGACAAGAGAGAAGCTCGGCCGGATTATAAAGATGACG
ATGACAAAGCTTCAAGTCCTGCAAACAAGGTGTACC 
48CelFRev2 GTAGAGGACCCACCTCCTCCAGATCCCCATGGACCTTGATCTGGGAAGAGTAT
TGCATAAAC 
9CelEFor2 GCAGAAGGCTCTTTGGACAAGAGAGAAGCTCGGCCGGATTATAAAGATGACG
ATGACAAATTTGCCCTTGTTGGGGCAGGAGATTTGATTCG 
9CelERev2 GTAGAGGACCCACCTCCTCCAGATCCCCATGGAGTCACTGACCCACCAATCTC
TGGCCCCTTTTC 
G1A2For1 GCGATTAGTTTTTTAGCCTTATTTCTGGGG 
G1A2Rev1 ACCTGCAGCTAATGCGGAGGATGCTGCGAATAAAACTGCAGTAAAAATTGAA
GGAAATCTCATGGTTTTTTCTCCTTGACGTTAAAGTATAGAGG 
G1A2For2 CCTCAGGTTGTTTACGGTGATGTAAATGGCGACG  
G1A2Rev2 GAGATCCGCTTATTTAGAAGTGTCGAATTCCTAATAAGGTAGGTGGGGTATGC
TCTTTATC 
G1A2For3 GAATTCGACACTTCTAAATAAGCGGATCTC  
G1A2Rev3 GTAATACGACTCACTATAGGGCGAATTGGGCTCGAGGGCATGCGAAGGAAAA
TG 
BGL1For3 GTTTTATTCGCAGCATCCTCCGCATTAGCTGCAGGTGAACAAAAACTCATCTCA
GAAGAGGATCTGGATGAACTGGCGTTCTCTCCTCCATTCTATCCC 
BGL1Rev3 CGTCGCCATTTACATCACCGTAAACAACCTGAGGAGAACCTCCACCGCCACTA
CCCCCGGGTTGCACCTTCGGGAGCGCTGCGTGAAGGGGC 
GACFor1 GTACAGATCCCGACCCATTTGC 
GACRev1 CGCTTAACTGCTCATTGCTATATTGAAGTACGGATTAGAAGCCGCCGAGCGGG
TGACAGC 
GACFor2 GTACTTCAATATAGCAATGAGCAGTTAAGCG 
GACRev2 ACCATGGTGATGGTGATGATGAGCTTCTCTCTTGTCCAAAGAGCC 
GACFor3 CCATGGGGATCTGGAGGAGGTGGG  
GACRev3 CTAAAGGGAACAAAAGCTGGCTAGTCATGCCGGTAGAGGTGTGGTC 
GACFor4 GACCACACCTCTACCGGCATGACTAGCCAGCTTTTGTTCCCTTTAG 
GACRev4 CCTGGTATCTTTATAGTCCTG 
RS-TEF2For GTTGCTCATATGGCATGCCCCGGGGCTAGCGGGGCCGTATACTTACATATAGTAGATGTC 
RS-TEF2Rev CAAGACAATCAAAACCTTCATGTTTAGTTAATTATAGTTCG 
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Table 5.3 continued 
Name Sequence 5’→3’ 
9CelGFor GAGAGAAGCTCATCATCACCATCACCATGGTGCAGGAACATATAACTATGGAG
AAGC 
9CelGRev GTAGAGGACCCACCTCCTCCAGATCCCCATGGATCAGGGTTTTCCGATCCACCT
GCGGG 
8CelCFor GAGAGAAGCTCATCATCACCATCACCATGGTGCTGATCAAATTCCTTTCCCATA
TGACGC 
8CelCRev GTAGAGGACCCACCTCCTCCAGATCCCCATGGGTTAAGCAGTTTAACTTTTAGC
TGAGC 
RS-TEF1For GCTAGCCCCGGGGCATGCCATATGAGCAACAGGCGCGTTGGACTTTTAATTTTCG 
RS-TEF1Rev GCAGTAAAAATTGAAGGAAATCTCATTTTGTAATTAAAACTTAGATTAGATTGCTATGC  
C-CipA3-HR2Rev CCGAGGAGAGGGTTAGGGATAGGCTTACCACCTGCAGCTAATGCGGAGGATGCTGCGAATAAAACTGCAGTAAAAATTGAAGGAAATCTCATTTTG 
C-CipA3-HR3For GGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGGTATCGGCGGCCACAATGACAGTCGAG 
C-CipA3-HR3Rev GGCGCTAGAACCTCCACCGCCACTACCGCCTCCACCATTCGAATCATCTGTCGGTGTTG 
C-CipA3-HR4For CGAATGGTGGAGGCGGTAGTGGCGGTGGAGGTTCTAGCGCCAAAAGCTCTTTTATCTCAACC 
C-CipA3-HR4Rev GGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCTATCTTCAGGCAAATGATGACG 
C-CBH2-HR6For CGAACTATAATTAACTAAACATGAAGGTTTTGATTGTCTTG  
C-CBH2-HR6Rev CGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCCATGCCGGTAGAGGTGTGGTCAATAAG 
C-BGL1-HR1FL CTCCCGAGTCCGAGTTGACG 
C-BGL1-HR1Rev GCAATCTAATCTAAGTTTTAATTACAAAATGAGATTTCCTTCAATTTTTACTGC  
C-TEF1-HR2For CATTTTGTAATTAAAACTTAGATTAGATTGC 
C-TEF2-HR3Rev CCAACAAGACAATCAAAACCTTCATGTTTAGTTAATTATAGTTCG  
C-EGII-HR4For CTAAACATGAAGGTTTTGATTGTCTTGTTGG 
C-EGII-HR4Rev CGAGCATAATTGTGGATGTCG  
Plasmid pRS415-CBHII-BGL1 was obtained by cotransforming CEN-ARS-HR and XbaI 
digested pRS425-CBHII-BGL1 into EBY100. The genomic DNA of C. cellulolyticum was 
isolated using the Wizard genomic DNA purification kit (Promega, Madison, WI) following the 
manufacturer’s protocol for Gram positive bacteria. PCR products FLAG-CelF(E) and docS 
were cotransformed with EagI/NdeI digested pRS425-NL-CelS, yielding plasmids pRS425-
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CelF(E), which were then digested with ApaI and cotransformed with PCR products G1A2-HR1, 
c-myc-BGL1, docAt, and ADH2 into EBY100, yielding plasmids pRS425-CelF(E)-BGL1. 
Plasmids pYD1-CipA1(3)-CelG(C) were obtained by cotransforming GAC-HR1, GAC-HR2, 
GAC-HR3, GAC-HR4, and HisG-CelG(C) with DrdI/NheI digested pYD1-CipA1(3). Plasmid 
cpRS414-CipA3-CBHII was obtained by cotransforming C-CipA3-HR1-6 with XhoI/SpeI 
digested pRS414 into BJ5464. Plasmid cpRS425-EGII-BGL1 was obtained by cotransforming 
C-pRS425-HR1L, C-pRS425-HR2-4 with BlpI digested pRS425-EGII-BGL1 into BJ5465. 
Plasmid pYD1-CipA3-CBHI was obtained by cotransforming CBHI-HR and SacI digested 
pYD1-CipA3-EGII into EBY100. See Fei Wen Notebook 6, pp. 8, 11, 13, 16, 25, 41-44, 48-50, 
and Notebook 7, pp. 1-2. 
Table 5.4 PCR fragment sets for plasmid construction using the DNA assembler method [30]. 
Template Primer pairs (forward/reverse) PCR product 
pRS415 AmpFor/ LEU2Rev CEN-ARS-HR 
C. thermocellum genomic DNA 9E-docStFor/9E-docStRev docS 
C. cellulolyticum genomic DNA 48CelFFor2/48CelFRev2 FLAG-CelF 
C. cellulolyticum genomic DNA 9CelEFor2/9CelERev2 FLAG-CelE 
pYD1 G1A2For1/G1A2Rev1 G1A2-HR1 
A. aculeatus cDNA BGL1For3/BGL1Rev3 c-myc-BGL1 
C. thermocellum  genomic DNA G1A2For2/G1A2Rev2 docAt 
Yeast  genomic DNA G1A2For3/G1A2Rev3 ADH2 
pYD1 GACFor1/ GACRev1 GAC-HR1  
pRS425- CelE GACFor2/ GACRev2 GAC-HR2 
pRS425- CelE GACFor3/ GACRev3 GAC-HR3 
pYD1 GACFor4/ GACRev4 GAC-HR4 
C. cellulolyticum genomic DNA 9CelGFor/9CelGRev HisG-CelG 
C. cellulolyticum genomic DNA 8CelCFor/8CelCRev HisG-CelC 
ySG50 genomic DNA RS-TEF1For/RS-TEF1Rev C-CipA3-HR1 
C-CipA3-HR1 RS-TEF1For/ C-CipA3-HR2Rev C-CipA3-HR2 
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5.4.3. In vitro Loading of Cellulases 
Strains CBHII-ctrl and BGL1-ctrl were grown up in SC-Leu medium overnight to 
OD600~5. The cells were then washed twice with YPG, resuspended in 50 mL of YPG to a final 
OD600~1 in a 250 mL flask, and shaken 250 rpm, 20 °C for 72 hours. The induced cells were 
spun down at 4000 rpm for 10 minutes and the supernatant was concentrated to ~2 mL using the 
Amicon Ultra-15 centrifugal filter unit (Millipore, Billerica, MA) at 4 °C. ~5×107 induced 
CipA3-EGII-CBHII-BGL1 cells were resuspended in 2 mL of the resulting concentrate mix (1 
mL from CBHII-ctrl and 1 mL from BGL1-ctrl) and incubated at 4 °C overnight. The loaded 
cells were subjected to flow cytometry analysis and growth assay using PASC as the sole carbon 
source. See Fei Wen Notebook 6, pp. 26. 
5.4.4. Cell Growth Analysis on PASC 
Cells displaying the minicellulosomes were washed three times with appropriate SC 
dropout media to prevent glucose/galactose carry-over. In the mean time, PASC was washed 
extensively (at least ten times) with the same SC dropout media to remove sodium azide and/or 
Table 5.4 continued 
Template Primer pairs (forward/reverse) PCR product 
pYD1-CipA3 C-CipA3-HR3For/ C-CipA3-HR3Rev C-CipA3-HR3 
ySG50 genomic DNA C-CipA3-HR4For/ C-CipA3-HR4Rev C-CipA3-HR4 
ySG50 genomic DNA RS-TEF2For/ RS-TEF2Rev C-CipA3-HR5 
pYD1-CipA3-CBH2 C-CBH2-HR6For/ C-CBH2-HR6Rev C-CipA3-HR6 
pRS425-EGII-BGL1 C-BGL1-HR1FL/ C-BGL1-HR1Rev C-pRS425-HR1L 
ySG50 gDNA C-TEF1-HR2For/RS-TEF1For C-pRS425-HR2 
ySG50 gDNA RS-TEF2For/C-TEF2-HR3Rev C-pRS425-HR3 
pRS425-EGII-BGL1 C-EGII-HR4For/C-EGII-HR4Rev C-pRS425-HR4 
T. reesei cDNA CBHIFor/CBHIRev CBHI-HR 
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soluble sugars. And then the cells and PASC were combined to desired OD600 (e.g. 0.2, 0.5, or 1) 
and sugar concentration (e.g. 0.1%, 0.5%, or 1%) in a glass culture tube. 200 µL of sample was 
drawn every 24 hours and the cell density was counted using a haemocytometer (Hausser 
Scientific , Horsham, PA). 
5.4.5. Other Assays 
Please refer to Section 2.4.2 for yeast transformation, Section 2.4.3 for DNA sequencing, 
Section 4.4.3 for yeast surface display and flow cytometry analysis, and Section 4.4.4 for sugar 
analysis.  
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